

INDIAN JOURNAL OF MALARIOLOGY

Volume 35

Number 2

June 1998

MALARIA RESEARCH CENTRE

Indian Council of Medical Research

22-Sham Nath Marg

Delhi-110 054

INDIAN J. MALARIOL.

Quarterly
© Malaria Research Centre 1998
Year of Revival: 1981

SUBSCRIPTION RATE

Annual	India	Rs. 150.00*
	Other countries	US \$ 40.00
	(including airmail postage)	

*25% discount would be admissible to individual subscribers on annual basis.

Subscription may be made by a **Demand Draft or Cheque** drawn in favour of the
Director, Malaria Research Centre, Delhi, payable at Delhi
and send to the *Editor, Indian Journal of Malariology,*
Malaria Research Centre, 20-Madhuvan, Delhi-110 092.

The 'Indian Journal of Malariology' is indexed by 'BIOSIS', 'Drugs and Pharmaceuticals Current Indian Titles', 'EMBASE/Excerpta Medica', 'Index Medicus', 'Indian Science Abstracts', 'Review of Applied Entomology', 'Protozoological Abstracts', 'Quarterly Bibliography of Major Tropical Diseases' and it is selectively abstracted by 'Tropical Diseases Bulletin'. This Journal is also accessible on the CAB Computer Database, ExtraMed CD-ROM, SourceOne UnCover and MEDLINE.

INDIAN JOURNAL OF MALARIOLOGY

Chairman
Prof. N.K. Ganguly

Editor-in-Chief
Dr. V.P. Sharma

Consultant Editors

Dr. Shiv Lal
Mr. N.L. Kalra

Editor
Dr. Aruna Srivastava

EDITORIAL BOARD

Prof. V.S. Chauhan
Director
International Centre for Genetic
Engineering and Biotechnology
Aruna Asaf Ali Marg
New Delhi-110 067.

Dr. B.S. Das
Head
Department of Biochemistry
Ispat General Hospital
Rourkela-769 005.

Dr. C.M. Gupta
Director
Central Drug Research Institute
Chattar Manzil
Lucknow-226 001.

Dr. R.C. Mahajan
Prof. and Head
Department of Parasitology
Postgraduate Institute of
Medical Education and Research
Chandigarh-160 012.

Dr. S. Pattanayak
Retd. Director, NMEP
B-91, Swasthya Vihar
Delhi-110 092.

Dr. Y.D. Sharma
Additional Prof. and Head
Department of Biotechnology
All India Institute of Medical
Sciences
Ansari Nagar
New Delhi-110 029.

Assistant Editor
Seema Vedantam

Associate Editor
Dr. B.N. Nagpal

DTP Operator
Kamini Verma

Publication Assistant
Jitender Kumar

Production
D.S. Sontiyal
Arti Sharma

Artist
Tarun Malhotra

INDIAN JOURNAL OF MALARIOLOGY

CONTENTS

Volume 35
Number 2
June 1998

Studies on Bionomics of <i>Anopheles fluviatilis</i> and its Sibling Species in Nainital District, U.P.	41
<i>R.P. Shukla, Nutan Nanda, A.C. Pandey, V.K. Kohli, Hema Joshi and S.K. Subbarao</i>	
A Longitudinal Study of Sero-reactivity to <i>Plasmodium falciparum</i> Antigen in Children and Adult Living in an Endemic Area of U.P.	48
<i>Arati Roy, M.A. Ansari and L. Kabilan</i>	
Plants Showing Antiplasmodial Activity — From Crude Extracts to Isolated Compounds	57
<i>Poonam Sharma and Jayashri Devi Sharma</i>	
Changing Scenario of Malaria : A Study at Calcutta	111
<i>B.R. Hazra, R. Sinha Chowdhury, S.K. Saha, M.B. Ghosh and A.K. Mazumder</i>	
Short Note	
Factors Influencing the Larvicidal Activity of Bacterial Toxin	117
<i>Laojana Chowanadisai</i>	

Note: The editor assumes no responsibility for the statements and opinions expressed by the contributors.
This issue is delayed due to unavoidable circumstances.

Studies on Bionomics of *Anopheles fluviatilis* and its Sibling Species in Nainital District, U.P.

R.P. SHUKLA, NUTAN NANDA^a, A.C. PANDEY^b, V.K. KOHLI, HEMA JOSHI^a
and S.K. SUBBARAO^a

A study on the bionomics of *Anopheles fluviatilis sensu lato* was carried out in two physiographic regions, viz. Bhabar and Terai of District Nainital, Uttar Pradesh. In both areas, *An. fluviatilis* was found resting indoors predominantly in cattlesheds. Cytological examination of *An. fluviatilis* revealed that species T and U were sympatric in Bhabar and Terai villages with predominance of species T. These two sibling species appear to be poor vectors of malaria.

Keywords: *An. fluviatilis*, Bionomics, Malaria vector, Sibling species

INTRODUCTION

An. fluviatilis James is widely distributed in India, and variations in the feeding preference and infection rates have been reported i.e. low densities with high anthropophagy and high infection rate in hills and foothills; and high densities, high zoophagy and low infection rates in plains¹. In Nainital district, which was hyperendemic for malaria^{2,3}, *An. culicifacies* *sensu lato* and *An. fluviatilis*

sensu lato were the only vectors of malaria⁴ and *An. fluviatilis* was repeatedly found as an efficient vector^{5,6}. Cytotaxonomic studies have shown that the above mentioned vectors are species complexes. *An. culicifacies* is a complex of four sibling species⁷ and *An. fluviatilis* is a complex of three sibling species provisionally designated as species S, T and U⁸. These sibling species vary in their biological characteristics⁹⁻¹¹. This paper reports the results of the study

Malaria Research Centre (Field Station), Inderjeet Garden, Bhotia Parao, Haldwani-263 141, India.

^aMalaria Research Centre, 22-Sham Nath Marg, Delhi-110 054, India.

^bMalaria Research Centre (Field Station), BHEL Complex, Ranipur, Hardwar-249 403, India.

carried out during 1991-94 on the bionomics of *An. fluviatilis s.l.* and its sibling species composition in Bhabar and Terai villages of District Nainital.

MATERIALS AND METHODS

Study area

In District Nainital, there are two long narrow belts of land with markedly different physical features in the foothills of the Himalayas. Immediately skirting the foothills is a waterless belt of porous and sandy soil with a width ranging from 10-15 km, known as the Bhabar area. Adjoining to Bhabar belt towards south is a wet belt of loamy, clay like soil about 13-16 km wide, known as the Terai. In Bhabar, two villages, viz. Pachaunia and Nai Avadi with a human population of 286 and 225 respectively were selected. These villages are located near a forest where the main source of water for irrigation is a perennial stream. In Terai, the selected villages, viz. Matkota and Tilpuri comprising of a population of 314 and 525 respectively, are located near a forest and the Haripura reservoir. The main source of water for irrigation and drinking in these villages are artesian wells and reservoir.

In the selected villages of both regions, larval surveys in peri-domestic and intra-domestic breeding habitats were carried out at fortnightly intervals using standard dipper. Larval samples from various breeding habitats were brought to laboratory and reared up to emergence of adults for species identifi-

cation. Adult indoor resting densities were monitored by hand catch using suction tube method in the morning between 0600 to 0800 hrs from human dwellings and cattlesheds, and per man hour densities were calculated. All night biting collections were made in study villages of Terai from 1800 to 0600 hrs on man and cattle in human dwellings and cattlesheds respectively.

Head and thorax of *An. fluviatilis s.l.* specimens and of those which were cytologically identified as sibling species ($n = 489$)⁹ were stored dry and processed for the detection of *Plasmodium* infection using two-site immunoradiometric assay (IRMA)¹². Identification of sibling species was done by using diagnostic paracentric inversions on the ovarian polytene chromosomes⁷.

Fortnightly surveys were carried out for fever in the study villages and the blood smears collected were stained with JSB stain and examined for malaria parasite. Radical treatment to the malaria positive cases was given as per National Malaria Eradication Programme (NMEP) drug policy.

RESULTS AND DISCUSSION

An. fluviatilis breeding was mainly observed in artesian (irrigation) drains, and streams in Terai (larval density per dip ranging from 0.11-0.78) and small ponds in Bhabar (up to 0.82/dip); whereas very few larvae were recorded from cemented tanks and shallow wells of Bhabar and Terai areas respectively with larval density per dip ranging 0 to 0.16.

During the study period a total of eight anopheline species, viz. *An. culicifacies*, *An. fluviatilis*, *An. annularis*, *An. subpictus*, *An. splendidus*, *An. stephensi*, *An. vagus* and *An. barbirostris* were recorded from selected villages in Bhabar whereas in Terai villages, in addition to the above mentioned anophelines, *An. nigerrimus*, *An. varuna* and *An. aconitus* were also found.

Per man hour densities (MHD) of vector anophelines (*An. fluviatilis* and *An. culicifacies*) and total anophelines for two calendar years in Terai and Bhabar villages are shown in Figs. 1 and 2. Adult *An. fluviatilis* densities were low from May to August in Terai (range 0 to 10.5) and Bhabar (range 0.5 to 9.5). The densities started building up after monsoon and high densities of *An. fluviatilis* were observed from September to April, the peak in February (229.0) and October (52.0) in Terai and Bhabar areas respectively. Prevalence ratio of *An. fluviatilis* in cattlesheds and human dwellings was 9:1 in Bhabar and 21:1 in Terai showing high preference for resting in cattlesheds. Indoor collections of *An. fluviatilis* females showed 326 unfed, 1470 full-fed, 1580 semigravid and 747 gravid in Terai villages whereas examination of abdominal conditions in Bhabar collections revealed 78 unfed, 239 full-fed, 258 semigravid and 132 gravid. These data suggest that *An. fluviatilis* is an indoor resting species and spends most of the period of gonotrophic cycle indoors in both Bhabar and Terai regions.

Results of whole night biting of *An. fluviatilis*




Fig. 1: Man hour densities of vectors and total anopheline in Terai villages




Fig. 2: Man hour densities of vectors and total anopheline in Bhabar villages

on cattle and human baits during summer and post-monsoon months in Terai area are given in Tables 1 and 2. Biting of *An. fluviatilis* on cattle baits was observed throughout the night, the peak biting occurred during second quarter of night in both the seasons. Biting on human baits was very low ranging from 0.08 to 0.33 bites/bait/night, which suggests that *An. fluviatilis* in

Terai area has very little preference for human blood and is almost zoophagic. Our earlier report⁹ on feeding preferences of sibling species of *An. fluviatilis* complex revealed that species T and U were found sympatric in Bhabar and Terai areas. Out of 138 specimens cytologically identified from Bhabar area, 132 (95.7%) were species T and only 6 (4.3%) were species U. In Terai out of 599 samples, 435 (72.6%) were species T and 164 (27.4%) were species U. In both the areas species U were exclusively zoophagic and species T were occasionally

found feeding on human blood with an HBI of 0.01.

An. fluviatilis specimens collected from study villages in Bhabar and Terai areas during October 1991 and February 1992 when it was a predominant species, were examined for the presence of *P. vivax* and *P. falciparum* sporozoite antigens by two-site immuno-radiometric assay using species specific monoclonal antibodies. None out of 248 *An. fluviatilis* s.l. and 241 cytologically identified specimens (163 species T and 78 spe-

Table 1. Results of all night biting collections of *An. fluviatilis* s.l. on cattle and human baits in Terai during summer

Time (hrs)	Numbers biting on			
	Cattle*		Human**	
	Nos.	Biting nos./bait/ night	Nos.	Biting nos./bait/ night
1800-1900	0	0	0	0
1900-2000	28	3.50	0	0
2000-2100	117	14.62	0	0
2100-2200	184	23.00	0	0
2200-2300	215	26.87	1	0.16
2300-2400	139	17.37	2	0.33
0000-0100	123	15.37	0	0
0100-0200	116	14.50	0	0
0200-0300	120	15.00	1	0.16
0300-0400	64	8.00	0	0
0400-0500	52	6.50	0	0
0500-0600	65	8.12	0	0
Total	1223	152.87	4	0.66

*Total of eight night collections of April 1993; **Total of six night collections of April 1993.

Table 2. Results of all night biting collections of *An. fluviatilis s.l.* on cattle and human baits in Terai during winter

Time (hrs)	Number biting on			
	Cattle*		Human**	
	Nos.	Biting nos./bait/ night	Nos.	Biting nos./bait/ night
1800-1900	4	1.00	0	0
1900-2000	7	1.75	1	0.08
2000-2100	6	1.50	0	0
2100-2200	8	2.00	1	0.08
2200-2300	5	1.25	1	0.08
2300-2400	6	1.50	0	0
0000-0100	3	0.75	0	0
0100-0200	4	1.00	0	0
0200-0300	2	0.50	0	0
0300-0400	7	1.75	4	0.33
0400-0500	2	0.50	0	0
0500-0600	0	0.0	1	0.08
Total	54	13.50	8	0.67

*Total of four night collections of November 1993; **Total of twelve night collections between September and October 1993.

cies U) had sporozoite antigens of above mentioned species of human malaria parasites. These observations suggest poor vectorial potential of *An. fluviatilis* sibling species prevalent in the study villages. Results from night biting collections and blood meal analysis data⁹ suggest that the preference of species T and U to feed on cattle could be one of the major factors for their poor vectorial potential.

Malaria incidence in Bhabar and Terai villages was also monitored for two calendar years (Table 3). The slide positivity rate

(SPR) in 1992 and 1993 was 29.7 and 12.5 per cent in Terai and 5.2 and 1.3 per cent in Bhabar villages respectively. Majority of cases in Terai were recorded from May to September (21 of the total 32 malaria positive cases during 1992-93) when *An. fluviatilis* densities were low (MHD ranging from 0-24.5) and *An. culicifacies* were encountered in high numbers (MHD ranging from 13.5-117.5, Fig. 1). Similar situation existed in Bhabar where *An. culicifacies* adult prevalence was recorded high from May to September and *An. fluviatilis* from October to April (no malaria case was found during

Table 3. Malaria cases in the study villages for two calendar years

Year	Area	No. (+ve)												Total B.S. exam.	Total	<i>Pv</i>	<i>Pf</i>	SPR
		Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec					
1992	Bhabar	-	-	-	0	0	0	1	0	1	0	0	0	2	38	2	0	5.2
	Terai	-	-	-	2	1	7	2	4	2	4	0	0	22	74	20	2	29.7
1993	Bhabar	0	0	0	0	0	0	0	1	0	0	0	0	1	74	1	0	1.3
	Terai	0	1	0	2	0	2	0	1	2	2	0	0	10	80	6	4	12.5
1994	Bhabar	0	0	0	-	-	-	-	-	-	-	-	-	0	6	0	0	0.0
	Terai	0	0	0	-	-	-	-	-	-	-	-	-	0	10	0	0	0.0

(-) Fever survey not done; Bhabar population (511); Terai population (839).

these months). Since majority of malaria cases found were of *P. vivax* which caused relapses, therefore, it needs to be ascertained whether these cases were due to active transmission by *An. culicifacies*. Studies are indicated on the bionomics of *An. culicifacies* sibling species in these areas in order to establish their role in malaria transmission.

Earlier workers have reported preference of *An. fluviatilis* to rest predominantly in human dwellings^{1,6} with high human blood index^{1,13}. In Terai this species was reported to have high anthropophilic index (47%) and sporozoite rate (11.1%)^{6,14} but subsequently due to its low preference for human blood and resting behaviour, *An. fluviatilis* was reported as a secondary vector⁹. Results of the present investigation also revealed that *An. fluviatilis* sibling species T and U prevalent in the study villages prefer to rest in cattlesheds and are almost zoophagic thereby playing a minor role in malaria transmission. These results are further supported by the

similar observations recorded in Districts Dehradun and Hardwar (Uttar Pradesh) where species T and U are prevalent¹⁵.

ACKNOWLEDGEMENTS

Authors gratefully acknowledge the excellent assistance of the staff members of Malaria Research Centre (Field Station) at Haldwani and Genetics Division, Delhi for collection and processing the mosquitoes for various studies.

REFERENCES

1. Rao, T.R. (1984). *The Anophelines of India*. Rev. ed. (Malaria Research centre, ICMR, Delhi): 518.
2. Clyd, D. (1931). Report on the control of malaria during the Sarda Canal construction (1920-1929). *Rec. Mal. Surv. India*, 2: 49-110.
3. Hehir, P. (1927). *Malaria in India* (Oxford University Press): 16.
4. Choudhury, D.S., M.S. Malhotra, R.P. Shukla, S.K. Ghosh and V.P. Sharma (1983). Resurgence

- of malaria in Gadarpur PHC, District Nainital, Uttar Pradesh. *Indian J. Malariaol.*, **20**: 49-58.
5. Issaris, P.C., S.N. Rastogi and V. Ramakrishna (1953). The malaria transmission in the Terai, Nainital district, Uttar Pradesh, India. *Bull. WHO*, **9**: 311-333.
 6. Srivastava, R.S. and A.K. Chakrabarti (1952). Malaria control measures in the Terai area under the Terai colonization scheme, Kichha, District Nainital: 1949-1951 (Ind Report). *Indian J. Malariaol.*, **6**: 381-394.
 7. Subbarao, S.K., K. Vasantha and V.P. Sharma (1988). Cytotaxonomy of certain malaria vectors of India. In *Biosystematics of Haemato-phagous Insects*. Ed. M.W. Service (Clarendon Press, Oxford): 25-37.
 8. Subbarao, S.K., N. Nanda, K. Vasantha, V.K. Dua, M.S. Malhotra, R.S. Yadav and V.P. Sharma (1994). Population cytogenetic evidence for three sibling species in *An. fluviatilis* (Diptera : Culicidae). *Ann. Entomol. Soc. Amer.*, **87**: 116-121.
 9. Nanda, N., H. Joshi, S.K. Subbarao, R.S. Yadav, R.P. Shukla, V.K. Dua and V.P. Sharma (1996). *Anopheles fluviatilis* complex: Host feeding patterns of species S, T and U. *J. Amer. Mosq. Contr. Assoc.*, **12**: 147-149.
 10. Subbarao, S.K., T. Adak, K. Vasantha, H. Joshi, K. Raghavendra, A.H. Cochrane, R.S. Nussenzweig and V.P. Sharma (1988). Susceptibility of *Anopheles culicifacies* species A and B to *Plasmodium vivax* and *Plasmodium falciparum* as determined by immunoradiometric assay. *Trans. R. Soc. Trop. Med. Hyg.*, **82**: 394-397.
 11. Subbarao, Sarala K. (1991). The *Anopheles culicifacies* complex and control of malaria. *ICMR, Bull.*, **21**: 61-65.
 12. Zavala, F., R.W. Gwadz, F.H. Collins, R.S. Nussenzweig and V. Nussenzweig (1982). Monoclonal antibodies to circumsporozoite proteins identify the species of malaria parasite in infected mosquitoes. *Nature*, **299**: 737-738.
 13. Senior-White, R. (1947). On the anthropophilic indices of some *Anopheles* found in East-Central India. *Indian J. Malariaol.*, **1**: 111-112.
 14. Ramakrishna, S.P. and Satya Prakash (1953). Host predilection of *An. fluviatilis* in Terai region of Uttar Pradesh, India. *Indian J. Malariaol.*, **7**: 107-112.
 15. Sharma, S.K., N. Nanda, V.K. Dua, H. Joshi, S.K. Subbarao and V.P. Sharma (1995). Studies on the bionomics of *An. fluviatilis sensu lato* and the sibling species composition in the foothills of Shivalik range (Uttar Pradesh), India. *Southeast Asian J. Trop. Med. Pub. Hlth.*, **26**: 566-572.

A Longitudinal Study of Sero-reactivity to *Plasmodium falciparum* Antigen in Children and Adult Living in an Endemic Area of U.P.

ARATI ROY, M.A. ANSARI^a and L. KABILAN^b

Antibody levels to *Pf* RESA derived peptide R1 (EENVEHDA-C) from individuals living in malaria endemic areas correlated well with levels of endemicity. Serological and parasitological investigations were done in 32 adults (>20 yrs) and 35 children (2-5 yrs) for three years; i.e. from 1992-95 periodically in village Piyawoli, U.P. Antibody levels against R1 peptide was estimated by ELISA, and blood smear for *P. falciparum* and *P. vivax* were screened using Jaswant Singh-Bhattacharya (JSB) staining. It appeared from our investigations that anti-R1 antibodies had a short span of life, i.e. 6-9 months. The longevity of these antibodies do not differ much in adults and children. The studies do not indicate any protective role for these antibodies. However, the levels of anti-R1 antibodies in a population living under malariogenic condition are related to *Pf* malaria endemicity.

Keywords: Longitudinal study, Malaria endemic area, Octapeptide of *Pf*155/RESA, Peptide ELISA, Serology, Slide positivity rate

INTRODUCTION

Due to poor malaria surveillance¹ resurgence of malaria took place in late 1960's. Tedious and inadequate analysis of blood slide examination needed an efficient surveillance

system. As peptide ELISA gives period prevalence it has been considered as a method for malaria epidemiology.

The *Pf* antigen (*Pf*155/RESA)² has been considered as one of the malaria vaccine candi-

^aMalaria Research Centre, 22-Sham Nath Marg, Delhi-110 054, India.

^bMalaria Research Centre, 20-Madhuvan, Delhi-110 092, India.

^bCentre for Research in Medical Entomology, 4-Sarojini Street, Chinnachokkulam, Madurai - 625 002, India.

date antigens^{3,4}. The C-terminal repeat region of *Pf*155/RESA which is conserved in different *Pf* strains⁴ consists of repeats of 4-amino acids (EENV) and 8-amino acids (EENVEHDA). Humoral immune responses against these peptides related only anti-EENV antibodies in protection against *Pf*malaria⁵. However, studies on antibody responses to EENVEHDA-Cys⁶⁻⁸ in population residing under malariogenic conditions suggested an association between the levels of anti-R1 antibodies and degrees of malaria priming. Lack of information on the longevity of anti-R1 antibody limits the possibilities of determining *Pf*malaria endemicity by estimating anti-R1 antibodies.

Therefore, we have made an attempt to investigate the life span and protective role of anti-R1 antibody in a longitudinal study in a *Pf* malaria endemic village, in U.P. Both serological (estimation of anti-R1-antibodies) and parasitological examinations were carried out periodically in subjects (adults and children) for three consecutive years.

MATERIALS AND METHODS

Antigen: A synthetic nonapeptide, EENVEHDA-C was purchased from Cambridge Research Biochemicals, U.K.

Negative control: Nonendemic Srinagar population were taken as negative control, Mean+2SD (0.35 O.D.) was taken as cut off value for determining seropositivity in healthy control of Piyawoli village.

Study area: The study area covered Piyawoli village of Dadri PHC, District Ghaziabad (U.P.). The village is surrounded by ponds, *kuccha* drain and many water bodies. Malaria is high and seasonal. Main vector is *An. culicifacies*, anthropophilic index (A.I.) was found to be 10.4 and a human cattle ratio was 5:2 in 1989 indicating a high malariogenic area⁹. The malaria transmission in this area occurs in July to November. During the rainy season, first *Pv*-cycle appears which followed by *Pf*-cycle. From our own study in 1988, 18 deaths were reported due to malaria (Table 1).

Study population: The entire population of the study village was 3000; most of the inhabitants were farmers but a sizable segment of the population consisted of migrant labourers. Survey was started in the month of September 1992, when malaria positive fever cases (32 adults and 35 children) were enrolled in the study population as active groups. A parallel group residing in the same area but with no symptom of fever and no history of malaria in recent past was taken as positive control.

Parasitological examination: Finger prick blood from malaria patients and healthy individuals were collected monthly from September 1992 and then from 1993 onwards periodically. Blood samples were collected in the months as shown in Figs. 1 and 2.

Each and every sample of finger prick blood collected during the longitudinal study period

Table 1. Epidemiological data of malaria in Piyawoli village during the year 1988

Time of sample collection	Mode of operation	Total slide exam.	Total (+ve)	<i>Pv</i>	<i>Pf</i>	Mix	SPR	SfR
28 Jul to 24 Nov	Reported death (18)	71	27	3	24	—	42.2	38
Dec	Mass survey	500	112	12	100	—	22.4	20
Jan to Oct	Slide examination	1761	904	211	691	2	51.3	39.2
2 Dec	Only NTPC employee residing in Piyawoli	35	8	0	8	—	22.8	22.8
Dec	Slide examination	196	55	6	48	1	28	25
Dec	Spleen examination	196	Spleen rate 33.6	Av. spleen enlargement 1.57	Av. spleen 0.52			

Pv—*Plasmodium vivax*; *Pf*—*Plasmodium falciparum*; SPR—Slide positivity rate; SfR—Slide falciparum rate.




Fig. 1: R1 ELISA OD with standard deviation in 35 malaria positive children during the years 1992-1995. Longitudinal study, vertical lines represent standard deviation




Fig. 2: R1 ELISA OD of 32 malaria positive adults from 1992-1995.
Vertical lines represent standard deviation

was examined for malaria parasite identification. All blood films thick and thin smears were stained with JSB and examined microscopically.

Serological examination: 50 µl finger prick blood samples were collected in 3 mm Whatman paper and kept at -20°C until used. Filter paper elution of blood sample was done at 1:100 dilution and was used for ELISA.

ELISA: Synthetic peptide at a conc. of 1 µg/ml was used for coating of ELISA plate. The procedure has been described in detail elsewhere⁷. Briefly, 96 well costar (USA) ELISA plates were coated with the peptide

and kept at 4°C overnight and then at 37°C for 1 h. Bovine serum albumin blocking and antibody incubation were done as described earlier. Bound antibodies were detected by rabbit antihuman horse radish peroxidase conjugated polyvalent Ig with orthophenylenediamine (OPD) as substrate. OD was taken at 490 nm in Sanofi, Pasteur (France) ELISA reader.

Statistical analysis: Statistical evaluation was done by student's *t*-test.

RESULTS

Table 1 describes malaria status of Piyawoli

village in 1988, four years before the present longitudinal study was undertaken. The village was highly endemic in malaria and 18 deaths were reported during August and November 1988 from our previous study. Slide positivity rate (SPR) was high (30.1) throughout the year. High endemicity was probably due to presence of numerous water bodies and migrant labourers as reservoir of malaria infection. Both *Pv* and *Pf* infections occurred in this area.

A total of 1843 blood samples from 1992 to 1995 were collected from all fever cases during the longitudinal study to assess the malaria situation. In the beginning all malaria smear positive cases were followed up. Subsequently there were a number of drop outs. At the end of the study, only 35 children and 32 adults remained in the completion list. We could complete serological investigations for the desired period only in these two groups.

There was a high incidence of malaria in 1992 (Table 2). Slide positivity for malaria parasite (MP) was higher in children than in

the adults. However, this data may not reflect the true malaria situation since the slides were collected from those individuals who had fever. The sample size was not large enough to look for significant differences between these groups. However, it appears that the malaria infectivity is more in children which is due to less protective immune responses against malaria in children.

Antibody to R1 peptide from the two groups were compared (Figs. 1 and 2). In the year 1992 following the transmission season the R1 antibody level remained high (ELISA OD values; Figs. 1 and 2) in both the groups showed a falling tendency in the later years. Parasitological examination (Table 3) showed that there was transmission of malaria in the village in the subsequent years. Though the longevity of the R1 antibody does not vary remarkably in both the groups there was more inconsistency in antibody levels in children groups. At the beginning of malaria infection in September and October 1992, the ELISA OD observed with R1 antigen was higher in children than in adult population compared to those in the latter part of the

Table 2. Study of malaria positive follow-up cases (Sep-Oct 1992)

Age group (yrs)	Mean age (yrs)	Total slides exam.	No. of active female patient		No. of active male patient		No. (+)'ve	SPR
			<i>Pv</i>	<i>Pf</i>	<i>Pv</i>	<i>Pf</i>		
2-5	3.1±1.4	104	8	7	10	11	30	34.6
>20	34.8±16.4	178	1	12	6	13	32	20.2

Pv—*Plasmodium vivax*; *Pf*—*Plasmodium falciparum*; SPR—Slide positivity rate.

Table 3. Parasitological information during study period

Year	Blood slide exam.	<i>Pv</i>	<i>Pf</i>	SPR	SfR	PI/1000 cases
1992	604	19	83	16.88	13.74	34
1993	383	22	8	7.8	2.0	10
1994	479	111	10	25.26	2.0	40
1995	377	19	3	5.3	0.7	7

SPR—Slide positivity rate; SfR—Slide falciparum rate; PI/1000—Parasite incidence per thousand cases.


longitudinal study (*t*-test, children $p < 0.001$, the difference is highly significant, for adult $p < 0.05$ difference is significant).

The results with a control group of normal children (0-5 yrs) and normal adults is given in Figs. 3a and b. In 1992, 150 children showed moderate ELISA OD and moderate per cent positivity where as in 81 adults, the ELISA OD and per cent positivity was higher. In December 1995 a different group of 42 normal children showed similar results as in

1992 where a control group of 41 adults showed little elevated values as seen in 1992. In a high endemic area like Piyawoli, control population also had high antibody titre whereas our previous study with nonendemic Srinagar population had low (Mean+2S.D.) 0.35 ELISA OD as cut off value.

DISCUSSION

Variation in the levels of anti-R1 antibody at different periods may reflect the intensity of



Figs. 3a and b: ELISA OD and percentage positivity of children and adult from control group in the years 1992 and 1995

transmission. The decline of R1 antibody levels in both the age groups in later part of the study period suggest that the intensity of malaria transmission is declining. It is shown that immune response gets boosted by repeated natural infection¹⁰.

It has also been shown in our previous studies that anti-R1 antibody levels are correlated well with levels of endemicity^{11,12}. However, the longevity of anti-R1 antibody has to be taken into consideration in such studies.

It appeared from our longitudinal study that anti-R1 antibody had a short life span (6-9 months). Antibodies to other *Pf* antigens like CSP and MSA-1 were also reported to be short-lived^{13,14}. There were no remarkable differences between the adults and children in the life span of anti-R1 antibody. Variability in antibody level indicated that children did not face many repeated exposure compared to the adults, since antibody increased with number of exposures and high level of antibodies were the cumulative effect of repeated infections.

At the beginning of the survey (1992) there was positive correlation between antibody and parasitological status in both the groups. Whereas, in 1994 such association was seen between these two parameters in both the groups which may probably reflect the immune status of individuals. However, an association was seen between anti-R1 antibody level and parasite positivity rate (SPR) in 1995 in individual analysis, raising a ques-

tion whether anti-R1 antibody contribute to protection against *Pf* malaria.

The protective value of anti-RESA antibodies have been described in detail¹⁵⁻¹⁹. It appears from our studies that anti-R1 antibodies do not confer protection against *Pf* malaria. Similar observations were found from earlier studies¹⁹. It has been established that parasites evade host-immune defense by immunomodulation, antigenic variation and parasite immuno suppressive factors^{20,21}. It is evident from the previous and the present study, that anti-R1 antibodies are produced in individuals living in malaria endemic areas and the protective capacity of these antibodies is marginal. The antibodies have a short life span (6-9 months) and relate to the degree of exposure. Thus, measuring anti-R1 antibody levels may function as one of the parameters in estimating the levels of malaria endemicity.

Longitudinal analysis of seroreactivity to *Pf* antigen in small children living in a holoendemic area of Liberia was studied and found to be not a reliable parameter for protective immunity^{22,23}. Our results with R1 confirms this observation.

ACKNOWLEDGEMENTS

Authors are grateful to Prof. Kunal B. Roy, Jawaharlal Nehru University for valuable suggestion. Thanks are also due to Ms. Kamla Negi and Mr. Ajit Singh for their technical help and Mr. Ovinder Sharma for collection of samples.

REFERENCES

1. Sharma, V.P. and K.N. Mehrotra (1980). Malaria resurgence in India: A critical study. *Soc. Sci. Med.*, **22**(8): 835-845.
2. Perlmann, H., K. Berzins, M. Wahlgren, J. Carlsson, A. Bjorkman and M.E. Patarroyo (1984). Antibodies in malaria sera to parasite antigens in the membrane of erythrocytes infected with early asexual stages of *Plasmodium falciparum*. *J. Exp. Med.*, **159**: 1686-1704.
3. Coppel, R.L., A.F. Cowman, R.F. Anders, A.E. Bianco, R.B. Saint and K.R. Hingelback (1984). Immune sera recognize on erythrocytes a *Plasmodium falciparum* antigen composed of repeated amino acid sequences. *Nature*, **310**: 789-792.
4. Perlmann, P., K. Berzins, H. Perlmann, M. Troye Blomberg, M. Wahlgren and B. Wahlin (1988). Malaria vaccines: Immunogens selection and epitope mapping. *Vaccine*, **6**: 183-187.
5. Perlmann, H., K. Berzins, B. Wahlin, R. Udomsangpetch, W. Ruangirachuporn and M. Wahlgren (1987). Absence of antigenic diversity in *Pf155*, a major parasite in membranes of erythrocytes infected with *Plasmodium falciparum*. *J. Clin. Microbiol.*, **25**: 2347-2354.
6. Berzins, K., H. Perlmann, B. Wahlin, H.P. Ekre, B. Hogh and E. Peterson (1991). Passive immunization of aotous monkeys with human antibodies to the *Pf* antigen *Pf155/RESA*. *Infect. Immune*, **59**(4): 1500-1506.
7. Roy, A., V.P. Sharma and V.S. Chauhan (1994). The use of peptide ELISA in determining malaria endemicity. *J. Immunol. Meth.*, **167**: 137-143.
8. Roy, A., S. Biswas, L. Kabilan and V.P. Sharma (1995). Application of simple peptide ELISA for stratification of malaria endemicity. *Indian J. Malariol.*, **32**: 164-173.
9. Roy, A., S. Biswas and N. Singh (1996). Application of peptide ELISA in tribal malaria of Madhya Pradesh. *Indian J. Malariol.*, **33**: 144-153.
10. Roy, A., M.A. Ansari and V.P. Sharma (1991). Feeding behaviour patterns of anophelines from Uttar Pradesh and Gujarat States of India. *J. Amer. Mosq. Contr. Assoc.*, **7**(1): 11-15.
11. Kabilan, L. (1997). T-cell immunity in malaria. *Indian J. Med. Res.*, **106**: 130-148.
12. Roy, A., S. Biswas, M.A. Ansari and L. Kabilan (1997). Comparison of parasitological and serological data in evaluating malaria. *J. Com. Dis.*, **29**(1): 63-65.
13. Roy, A., S. Biswas, R.P. Shukla and M.S. Malhotra (1996). Assessment of malaria transmission through seroepidemiology of children population. *J. Parasit. Dis.*, **20**: 53-56.
14. Deloron, P., G.H. Campbell, D. Branding-Bennet, M. Jacquelin, I. Schuartz and J.S. Odera (1989). Antibodies to the *Plasmodium falciparum* ring infected erythrocyte surface antigen and to the *P. falciparum* and *P. malariae* circumsporozoite proteins: Seasonal prevalence in Kanyan villages. *American J. Trop. Med. Hyg.*, **41**(4): 395-399.
15. Friih, K., O. Doumbo, H.M. Muller, O. Koita, J. McBride and A. Crisanti (1991). Human antibody response to the major merozoite surface antigen of *Pf* is strain-specific and short-lived. *Infect. Immune*, **59**(4): 1319-1324.
16. Wahlgren, M., A. Bjorkman, A. Perlmann, H. Perlmann, K. Berzins and P. Perlmann (1986). Anti-*Plasmodium falciparum* antibodies acquired by residents in a holoendemic area of Liberia during development of clinical immunity. *American J. Trop. Med. Hyg.*, **35**: 22-29.
17. Chizzolini, C., E. Delaporte, M.H. Kaufmann, J.P. Akue, A.S. Verdini and A. Pessi (1989). Age-related prevalence of antibody response against three different, defined *Plasmodium falciparum* antigens in children from the Haut-ogone province in Gabon. *Trans. R. Soc. Trop. Med. Hyg.*, **83**: 147-151.
18. Chumpitazzi, B., P. Deloron, F. Peyron, C. Boudin, S. Picot and P.A. Thomas (1991). Relationship between clinical protection and antibodies to *PfRESA* (Ring infected erythrocyte surface antigen) peptides. *Inter. J. Parasitol.*, **21**(2): 271-274.

19. Astagnean, P., J.P. Lepers, C. Chougnat, C. Gaudebout, M. Danielle and A. Rason (1991). Assessment of the protective value of antibodies to the *Pf* ring-infected erythrocyte surface antigen (RESA): An epidemiologic studies in Madagascar. *American J. Epidemiol.*, **133**(2): 177-184.
20. Perlmann, H., P. Perlmann, K. Berzins, B. Wahlin, M. Troyebloemberg and M. Hagstedt (1989). Dissection of the human antibody response to the malaria antigen *Pf*155/RESA into epitope specific components. *Immunol. Rev.*, **112**: 115-132.
21. Ander, S.R.F. (1986). Multiple cross-reactivities among antigen of *Pf* impair the development of protective immunity against malaria. *Parasit. Immunol.*, **8**: 529-539.
22. Srour, E.F., M. Segre and D. Segre (1989). Modulation of the host's immune response to *P. berghei* by a parasite-derived immunosuppressive factor. *J. Protozool.*, **36**: 341-344.
23. Bjorkman, A., M. Lebbad, P. Perlmann, T. Freeman, B. Hogh and E. Peterson (1991). Longitudinal study of seroreactivities to *Pf*155/RESA and its repetitive sequence in small children from a holoendemic area of Liberia. *Parasit. Immunol.*, **13**: 301-311.

Plants Showing Antiplasmodial Activity — From Crude Extracts to Isolated Compounds

POONAM SHARMA and JAYASHRI DEVI SHARMA

The derivation of important antimalarial compounds started with the discovery of *Cinchona* bark powder with wine. Subsequently, post World War-I was a period of intensive work in maintaining such ethnobotanical records, in which the use of quinine has remained the drug of choice in malaria. After World War-II new chemical techniques were used to fractionate and isolate, and also for structure determinations, which led to an ever increasing number of potential antiplasmodial compounds. Recently experimental studies in animals and in clinical trials, showed the emergence of CQ-sensitive and CQ-resistant strains of *Plasmodium*. This paper is an attempt to update a historical list of antimalarial plants and their natural products as studied by pharmacognostic extraction methods of crude drug research of those times. Further an attempt has been undertaken to list the compounds as classified into three major groups, namely alkaloids, terpenes and quassinoids and aromatic and miscellaneous compounds. The most promising is a quassinoid, artemisinin derived from *Artemisia annua* which has caused a resurgence for the quest of newer antimalarial compounds.

Keywords: Alkaloids, Antimalarial, Chloroquine resistance, Crude extracts, Ethnobotany, Natural products, *Plasmodium*, Quassinoids and aromatic compounds

INTRODUCTION

Natural products are important source of biologically active compounds and have potential for the development of novel antimalarial drugs¹. First time a natural product gained

wide acceptance as a treatment for malaria was in the 16th century when the therapeutic action of the bark of *Cinchona* tree was disclosed by the natives of Peru to Jesuit missionaries², who, in turn brought its utility to Europe in the 17th century³. Prior to 1820,

ague was treated with suspension of finely powdered *Cinchona* bark in wine⁴. In the beginning of the nineteenth century, new chemical techniques were developed that made possible the isolation of vegetable alkaloids. Among the first to be studied were Opium and *Cinchona* because of their medicinal value⁵. Isolation of the major alkaloids of *Cinchona* bark, including quinine itself, was achieved by Pelletier and Caventou in Paris in 1820⁶. The second most important plant from ethnobotanical origin, emerged 150 years later, when the plant *Artemisia annua* was recovered as a Chinese traditional remedy, along with its chemical characterizations, studied to isolate Quinghaosu⁷. Ethnobotanical records afforded the discovery of a succession of synthetic drugs that exhibited potent antimalarial activity in a 30-year period between 1925 and 1955⁸.

The prevalence of multidrug-resistant strains and the cases of adverse reactions of available antimalarial drug have necessitated a search for newer and more efficient antimalarial drugs^{9,10}. The first recorded instance of drug-resistant malaria occurred in Brazil early in this century with the discovery of quinine-resistant *Plasmodium falciparum*¹¹. While *Plasmodium falciparum* resistant to chloroquine was first reported in the late 1950's in South America and Thailand¹². Quinghaosu (Artemisinin, QHS) is a novel antimalarial drug developed from the traditional Chinese remedy whose plasmodicidal effects have been confirmed in experimental studies in animals and in clinical trials against both CQ-sensi-

tive and CQ-resistant strains of *P. falciparum*^{13,14}.

Malaria still remains one of the greatest causes of illness and death in the world¹⁵. Each year this disease infects up to half a billion people and exacts a toll of roughly two million deaths¹⁶. The eradication of the disease has been hampered by the emergence and spread of multidrug resistant malarial parasites, especially *P. falciparum* strains resistant to many antimalarial drugs¹⁷. WHO experts say that the number of people worldwide infected with malaria is still increasing at the rate of about five per cent annually¹⁸ despite the extensive programme by the drug control and eradication by the WHO. The prevalence of multidrug-resistant strains and the cases of adverse reactions of available antimalarial drugs have necessitated a search for newer and more efficient antimalarials from plants.

This paper is an attempt, both to update a list of plants found to combat malaria and to summarize published data regarding the active fractions/extracts by bringing together the scattered information of innumerable studies (Table 1). Further the isolated compounds have been classified into three major groups — alkaloids (Table 2); terpenes and quassinooids (Table 3); and aromatic and miscellaneous compounds (Table 4).

DISCUSSION

The results of above studies indicate that these taxonomically different plants possess

Table 1. A composite table of different crude extracts derived from various parts of plants showing their *in vitro* and *in vivo* antiplasmodial activities against different species and strains of *Plasmodia*

Plant species	Family	Part used	Extract/Fraction	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
<i>Abutilon grandiflorum</i>	Malvaceae	Roots ¹⁹	Ethylacetate	IC ₅₀ (µg/ml)	10.0	<i>P. berghei</i> Anka
<i>Abutilon grandiflorum</i>	Malvaceae	Leaves ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (µg/ml)	180 105 230 27	<i>P. falciparum</i> K1
		Roots	Ethanol Petroleum ether Ethylacetate Water		27 10 >500 >500	
<i>Acacia clavigera</i>	Leguminosae	Stem bark ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (µg/ml)	100-499 100-499 >499	<i>P. falciparum</i> K1
<i>Acacia polyacantha</i>	Mimosaceae	Root bark ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (µg/ml)	93 27 13 >500	<i>P. falciparum</i> K1
<i>Acampe pachyglossa</i>	Orchidaceae	Leaves ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (µg/ml)	68 160 11 50	<i>P. falciparum</i> K1
<i>Achyranthesa spera</i>	Amaranthaceae	Root bark ¹⁹	Ethylacetate	IC ₅₀ (µg/ml)	3.0	<i>P. berghei</i> Anka
<i>Achyranthesa spera</i>	Amaranthaceae	Root bark ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (µg/ml)	78 72 3.0 >500	<i>P. falciparum</i> K1
<i>Adansonia digitata</i>	Bombacaceae	Stem bark ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (µg/ml)	42 38 8.2 280	<i>P. falciparum</i> K1
<i>Aegle marmelos*</i>	Rutaceae	Seed ²²	Ethanol	% inhibition	60.45 & 54.06	<i>P. berghei</i> NK65 <i>in vivo</i> and <i>in vitro</i>
<i>Aerva lannata</i>	Amaranthaceae	Whole plant ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (µg/ml)	48 86 8.6 >500	<i>P. falciparum</i> K1

contd...

Table 1. (contd.)

Plant species	Family	Part used	Extract/ Fraction	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
<i>Alacia madagascariensis</i>	Celastraceae	Roots ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (μ g/ml)	1.9 0.8 1.6 36	<i>P. falciparum</i> K1
<i>Albizia anthelmintica</i>	Leguminosae	Stem bark ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (μ g/ml)	>499 >499 >499	<i>P. falciparum</i> K1
<i>Albizia chinensis</i>	Fabaceae	Bark ²³	Aqueous ethanol	IC ₅₀ (μ g/ml)	>20000 & 9600	<i>P. falciparum</i> D6 and W2
<i>Albizia gummifera</i>	Mimosaceæ	Stem bark ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (ng/ml)	90 24 15 150	<i>P. falciparum</i> K1
<i>Alnus incana</i>	Betulaceae	Stipes ²⁴	Ethylacetate	ED ₅₀ (μ g/ml)	8.7 & 7.3	<i>P. falciparum</i> D6 and W2
<i>Ampelocissus africana</i>	Ampelideaceae	Leaves ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (μ g/ml)	32 80 90 42	<i>P. falciparum</i> K1
<i>Ancistrocladus barteri</i>	Ancistrocladaceae	Root ²⁵	Ethanol	IC ₅₀ (μ g/ml)	4.933 & N.T.	<i>P. falciparum</i> NF 54 and <i>P.</i> <i>berghei</i> Anka
		Leaf	Petroleum ether Dichloroethane Ethanol		>50 N.T. 12.293 & N.T. 0.658 & 7.344	
<i>Ancistrocladus heyneanus</i>	Ancistrocladaceae	Root ²⁵	Dichloro-methane/M Ethanol (1:1) Aqueous Petroleum ether	IC ₅₀ (μ g/ml)	3.11 & N.T. 41.92 & N.T. >50 & N.T. 12.36 & N.T.	<i>P. falciparum</i> NF 54 and <i>P.</i> <i>berghei</i> Anka
<i>Ancistrocladus robertsoniorum</i>	Ancistrocladaceae	Leaf	Ethylalcohol	IC ₅₀ (μ g/ml)	>50 & N.T.	<i>P. falciparum</i> NF 54 and <i>P.</i> <i>berghei</i> Anka
		Bark	Ethylalcohol		>50 & N.T.	
		Branch	Dichloromethane/ ammonia		>50 & N.T.	

contd..

Table 1. (contd.)

Plant species	Family	Part used	Extract/ Fraction	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
<i>Ancistrocladus tectorius</i>	Ancistrocladaceae	Leaf ²⁵	Dichloromethane	IC ₅₀ (µg/ml)	0.709 & 9.616	<i>P. falciparum</i> NF 54 <i>P. berghei</i> Anka
		Bark	Dichloromethane/ammonia		0.798 & 0.648	
<i>Andrographis paniculata*</i>	Acanthaceae	Whole plant ²²	Ethanol	% inhibition	39.26 & 46.23	<i>P. berghei</i> NK 65 <i>in vivo</i> and <i>in vitro</i>
<i>Annona muricata</i>	Annonaceae	Leaves ²⁶	Ethanol	IC ₅₀ (ng/ml)	39.9	<i>P. falciparum</i>
<i>Ansellia africana</i>	Orchidaceae	Leaves ²⁰	Ethanol	IC ₅₀ (µg/ml)	55	<i>P. falciparum</i>
			Petroleum ether		80	K1
			Ethylacetate		10	
			Water		380	
<i>Artemisia absinthium*</i>	Asteraceae	Leaves ²⁷	Ethanol	Parasitaemia suppression	96% at 74 mg/kg	<i>P. berghei</i>
			Water		66% at 25 mg/kg	
<i>Artemisia afra</i>	Asteraceae	Root bark ²¹	Petroleum ether	IC ₅₀ (µg/ml)	50-99	<i>P. falciparum</i>
			Dichloromethane		10-49	K1
		Aerial	Methanol		10-49	
			Petroleum ether		100-499	
<i>Artemisia japonica*</i>	Asteraceae	Aerial parts of roots ²⁸	Dichloromethane		100-499	
			Methanol			
<i>Artemisia maritima*</i>	Asteraceae	Aerial parts of roots ²⁸	Petroleum ether, ethanol	Complete cure	Petroleum ether produced at 320 mg/kg	<i>P. falciparum</i> FDL-R1
<i>Artemisia nilegarica*</i>	Asteraceae	Roots ²⁸	Ethanol	% schizont maturation inhibition	100% at 40 (µg/ml)	<i>P. falciparum</i> FDL-R1
<i>Artemisia parviflora*</i>	Asteraceae	Aerial parts ²⁹	Ethanol	% schizont maturation inhibition	100% at 40 (µg/ml)	<i>P. falciparum</i> FDL-R1
<i>Artemisia scoparia*</i>	Asteraceae	Whole plant excluding root ²²	Ethanol	IC ₅₀ (µg/ml)	250, 100, 200, 150 & 200	<i>P. falciparum</i> FAN-5, FMN-13, FMN-17, MP-11 and S0
<i>Aspidosperma oblongum</i>	N.a.	N.a. ³⁰	Ethanol	% inhibition	70.28 & 62.38	<i>P. berghei</i> NK 65 <i>in vivo</i> and <i>in vitro</i>

contd...

Table 1. (contd.)

Plant species	Family	Part used	Extract/ Fraction	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
<i>Aspilia mossambicensis</i>	Asteraceae	Leaves ³¹	Aqueous	IC ₅₀ ($\mu\text{g/ml}$)	406, 730 & 720	<i>P. falciparum</i> M24, K67 and ENT-7
<i>Atlantia monophyla*</i>	Rutaceae	Aerial parts ²⁹	Ethanol	MED ₅₀ ($\mu\text{g/ml}$)	50, 50 50, 50 & 50	<i>P. falciparum</i> FAN-5 FMN-13, FMN-17, MP-11 and SO
<i>Azadirachta indica*</i>	Meliaceae	Leaves ³²	Ethanol Ether acetone	MED ₅₀ ($\mu\text{g/ml}$)	25-75 750-1000	<i>P. falciparum</i> FAN-5, FCK-2 FCK-3,
		Seeds	Ethanol Water		200 700	FMN-33 and MP-11
<i>Azadirachta indica*</i>	Meliaceae	Leaves ³³	Water	Significant activity	at 125-500 mg/kg	<i>P. berghei</i>
<i>Azadirachta indica*</i>	Meliaceae	Leaves ³⁴	Water	% parasitaemia suppression	41.2%	<i>P. berghei</i>
<i>Azadirachta indica*</i>	Meliaceae	Stem bark ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ ($\mu\text{g/ml}$)	N.T. 100-499 N.T.	<i>P. falciparum</i> K1
		Leaves	Petroleum ether Dichloromethane Methanol		50-99 >499 >499	
<i>Balanites aegyptica</i>	Zygophylaceae	Stem bark ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ ($\mu\text{g/ml}$)	>499 10-49 50-99	<i>P. falciparum</i> K1
<i>Bidens pilosa</i>	Asteraceae	Whole plant ³⁵	Ethanol Butanol	% inhibition	90 N.T.	<i>P. falciparum</i> BH26/86
		Stem	Chloroform Butanol Ethanol		47 N.T. 90	
		Leaves	Chloroform Butanol Ethanol		94 79 90	
		Roots	Chloroform Butanol		86 68	
<i>Bombax rhodognaphalon</i>	Bombaceae	Root bark ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ ($\mu\text{g/ml}$)	80 26 34 230	<i>P. falciparum</i> K1

contd...

Table 1. (contd.)

Plant species	Family	Part used	Extract/ Fraction	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
<i>Bougainvillea spectabilis</i> *	Nyctaginaceae	Leaf ²²	Ethanol	% inhibition	Nil & 59.17	<i>P. berghei</i> NK 65 <i>in vivo</i> and <i>in vitro</i>
<i>Bridelia cathartica</i>	Euphorbiaceae	Root ³⁶	Ethanol Water	ID ₅₀ (μ g/ml)	0.05 0.05	<i>P. falciparum</i> FCK-3
		Stem	Ethanol		0.05	
<i>Bridelia cathartica</i>	Euphorbiaceae	Root bark ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (μ g/ml)	100-499 50-99 >499	<i>P. falciparum</i> K1
<i>Brucea javanica</i>	Simaroubaceae	Fruits ³⁷	Aqueous infusion Chloroform	IC ₅₀ (μ g/ml)	0.43 & 0.006	<i>P. falciparum</i>
			Aqueous infusion Chloroform	ED ₅₀ (mg/kg/day)	5000 & 7.4	<i>P. berghei</i>
<i>Caesalpinia bonducella</i>	Caesalpiniaceae	Whole plant ²¹	Petroleum ether Dichloromethane Metanol	IC ₅₀ (μ g/ml)	N.T. N.T. >499	<i>P. falciparum</i> K1
<i>Calotropis procera</i>	Asclepiadaceae	Whole plant excluding root ²²	Ethanol	% inhibition	Nil & 35.57	<i>P. berghei</i> NK 65 <i>in vivo</i> and <i>in vitro</i>
<i>Canthium phyllanthoideum</i>	Rubiaceae	Stem bark ³¹	Aqueous	IC ₅₀ (μ g/ml)	208, 360 & 540	<i>P. falciparum</i> M24, K67 and ENT-7
<i>Carapa guianensis</i>	N.a.	N.a. ³⁰	Ethanol	IC ₅₀ (μ g/ml)	32037.0 & 11640.0	<i>P. falciparum</i> W2 and D6
<i>Cassia abbreviata</i>	Caesalpiniaceae	Roots ³⁸	Methanol	IC ₅₀ (μ g/ml)	7.07	<i>P. falciparum</i>
<i>Cassia abbreviata</i>	Caesalpiniaceae	Root bark ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (μ g/ml)	50-99 100-499 100-499	<i>P. falciparum</i> K1
<i>Cassia abuscus</i> *	Leguminosae	Seed ²²	Ethanol	% inhibition	22.03 & Nil	<i>P. berghei</i> NK 65 <i>in vivo</i> and <i>in vitro</i>
<i>Cassia aff. abbreviata</i>	Caesalpiniaceae	Roots ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (μ g/ml)	85 160 39 400	<i>P. falciparum</i> K1
<i>Cassia occidentalis</i>	Caesalpiniaceae	Leaves ³⁹	Water	IC ₅₀ (μ g/ml)	0.66 & 0.5	<i>P. falciparum</i> FCC-2 and FZR

contd..

Table 1. (contd.)

Plant species	Family	Part used	Extract/Fraction	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
<i>Cassia occidentalis</i>	Caesalpinaeae	Whole plant ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (μ g/ml)	>499 >499 >499	<i>P. falciparum</i> K1
<i>Cassia siamea</i>	Caesalpinaeae	Leaves ⁴⁰	Water	IC ₅₀ (μ g/ml)	>7.5	<i>P. falciparum</i>
<i>Catha edulis</i>	Celastraceae	Aerial ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (μ g/ml)	N.T. N.T. >499	<i>P. falciparum</i> K1
<i>Chenopodium ambrosioides*</i>	Chenopodiaceae	Whole plant excluding root ²²	Ethanol	% inhibition	52.70 & 40.66	<i>P. berghei</i> NK 65 <i>in vivo</i> and <i>in vitro</i>
<i>Cichorium intybus*</i>	Asteraceae	Seed ²²	Ethanol	% inhibition	29.70 & 60.52	<i>P. berghei</i> NK 65 <i>in vivo</i> and <i>in vitro</i>
<i>Cinnamomum tamala*</i>	Lauraceae	Leaf ²²	Ethanol	% inhibition	62.69 & 67.82	<i>P. berghei</i> NK 65 <i>in vivo</i> and <i>in vitro</i>
<i>Cissampelos mucronata</i>	Menispermaceae	Roots ¹⁹	Ethylacetate	IC ₅₀ (μ g/ml)	0.38	<i>P. berghei</i> Anka
<i>Cissampelos mucronata</i>	Menispermaceae	Roots ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (μ g/ml)	1.3 8.0 0.38 1.2	<i>P. falciparum</i> K1
<i>Clausena anisata</i>	Rutaceae	Root bark ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (μ g/ml)	>499 >499 100-499	<i>P. falciparum</i> K1
		Stem bark	Petroleum ether Dichloromethane Methanol		100-499 50-99 50-99	
		Leaves	Petroleum ether Dichloromethane Methanol		>499 100-499 100-499	
<i>Cleome icosaandra*</i>	Capparidaceae	Whole plant excluding root ²²	Ethanol	% inhibition	Nil & 5.76	<i>P. berghei</i> NK 65 <i>in vivo</i> and <i>in vitro</i>
<i>Clerodendrum myricoides</i>	Verbanaceae	Root bark ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (μ g/ml)	300 47 11 300	<i>P. falciparum</i> K1

contd...

Table 1. (contd.)

Plant species	Family	Part used	Extract/ Fraction	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
<i>Clerodendrum pleiosciadium</i>	Verbanaceae	Leaves ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (µg/ml)	59 40 40 49	<i>P. falciparum</i> K1
<i>Clutia robusta</i>	Euphorbiaceae	Root bark ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (µg/ml)	>499 >499 >499	<i>P. falciparum</i> K1
<i>Cochlospermum angolense</i>	Cochlospermaceae	Roots ⁴¹	Ethanol	IC ₅₀ (µg/ml)	10	<i>P. falciparum</i>
<i>Cochlospermum tinctorim</i>	Cochlospermaceae	Tubercl ⁴²	Infusion in water Docoction in water	IC ₅₀ (ng/ml)	0.93 & 1.31 1.35 & 0.92	<i>P. falciparum</i> F32 and FCB1
<i>Combretum aff. psidiodoides</i> sub sp <i>psilophyllum</i>	Combretaceae	Root bark ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (µg/ml)	31 39 6.5 30	<i>P. falciparum</i> K1
<i>Conyza pyrrhopappa</i>	Asteraceae	Leaves ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (µg/ml)	100-499 10-49 50-99	<i>P. falciparum</i> K1
<i>Coptis teeta</i> *	Ranunculaceae	Rhizome ⁴³	Water	IC ₅₀ (µg/ml)	8.8 & N.A.	<i>P. falciparum</i> and <i>P. berghei</i>
<i>Coutarea latifolia</i>	Rubiaceae	Stem bark ⁴⁴	Aq. Ethanol Diethyl ether Ethylacetate Hydrolysed ethylacetate	IC ₅₀ (µg/ml)	69.5 31.3 9.2 7.3	<i>P. falciparum</i> FCM-5
<i>Crassocephalum bojeri</i>	Asteraceae	Aerial ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (µg/ml)	100-499 10-49 50-99	<i>P. falciparum</i> K1
<i>Crinum portifolium</i>	Amaryllidaceae	Whole plant ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (µg/ml)	N.T. N.T. >499	<i>P. falciparum</i> K1
<i>Crinum stuhlmanni</i>	Amaryllidaceae	Whole plant ²¹	Petroleum ether Dichloromethane Methol	IC ₅₀ (µg/ml)	N.T. N.T. 50-99	<i>P. falciparum</i> K1
<i>Crinum papulosum</i>	Amaryllidaceae	Whole plant ²¹	Petroleum ether Dichloromethane Methol	IC ₅₀ (µg/ml)	N.T. N.T. 10-49	<i>P. falciparum</i> K1
<i>Crossopterix febrifuga</i>	Rubiaceae	Stem bark ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (µg/ml)	100-499 100-499 100-499	<i>P. falciparum</i> K1

contd..

Table 1. (contd.)

Plant species	Family	Part used	Extract/ Fraction	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
<i>Croton guatemalensis</i>	Euphorbiaceae	Cortex ⁴⁵	Dichloromethane	IC ₅₀	27.8 & 23.1	<i>P. falciparum</i> NF 54 and K1
		Leaves	Dichloromethane	(μg/ml)	19.8 & 22.1	
<i>Cucumis aculeatus</i>	Cucurbitaceae	Whole fruit ³¹	Aqueous	IC ₅₀ (μg/ml)	60,30 & 30	<i>P. falciparum</i> M24, K67 and ENT-7
<i>Cussonia arborea</i>	Araliaceae	Root bark ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (μg/ml)	10-49 10-49 >499	<i>P. falciparum</i> K1
<i>Cussonia zimmermanni</i>	Araliaceae	Root bark ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (μg/ml)	90 3.3 20 400	<i>P. falciparum</i> K1
<i>Cussonia zimmermanni</i>	Araliaceae	Root bark ¹⁹	Petroleum ether	IC ₅₀ (μg/ml)	3.3	<i>P. berghei</i> Anka
<i>Cyperus rotundus*</i>	Cyperaceae	Whole plant excluding root ²²	Ethanol	% inhibition	49.65 & Nil	<i>P. berghei</i> NK 65 <i>in vivo</i> and <i>in vitro</i>
<i>Cyperus rotundus</i>	Cyperaceae	Tubers ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (μg/ml)	10-49 N.T. 5-9	<i>P. falciparum</i> K1
		Aerial	Petroleum ether Dichloromethane Methanol		100-499 10-49 N.T.	
<i>Cyperus scariosus*</i>	Cyperaceae	Whole plant excluding root ²²	Ethanol	% inhibition	Nil & 54.34	<i>P. berghei</i> NK 65 <i>in vivo</i> and <i>in vitro</i>
<i>Dialium guineense</i>	Caesalpinaeae	Twigs and leaves ⁴⁰	Water	IC ₅₀ (equiv. μg)	15 <IC ₅₀ <22.5	<i>P. falciparum</i>
<i>Dichapetalum guineense</i>	Chailletiaceae	All parts ⁴⁰	Water	IC ₅₀ (equiv. μg)	15 <IC ₅₀ <22.5	<i>P. falciparum</i>
<i>Diospyros zembensis</i>	Ebenaceae	Leaves ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (μg/ml)	110 190 35 300	<i>P. falciparum</i> K1
<i>Dissotis brazzae</i>	Melastomataceae	Roots ⁴⁶	Aqueous	IC ₅₀ (μg/ml)	218.1 & 131.7	<i>P. falciparum</i> ENT-36 and K 67
		Roots	Methanol		40.8 & 42.9	

contd...

Table 1. (contd.)

Plant species	Family	Part used	Extract/ Fraction	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
<i>Doliocarpus dentatum</i>	N.a.	N.a. ³⁰	Leaves	Aqueous	14.7 & 28.2	
			Stem	Aqueous	6.1 & >468.4	
			Stem	Methanol	14.5* & >377.9	
			Aerial	Aqueous	38.0 & 393.0	
			Aerial	Methanol	25.0 & 432.2	
<i>Dombeya shupangae</i>	Sterculiaceae	Leaves ²⁰	Ethanol	IC_{50} (ng/ml)	11641 & 15,2273	<i>P. falciparum</i> W2 and D6
<i>Echinops echinatus*</i>	Asteraceae	Root bark	Ethanol	IC_{50} (μ g/ml)	290	<i>P. falciparum</i> K1
			Petroleum ether	IC_{50} (μ g/ml)	85	
			Ethylacetate		110	
			Water		8.2	
		Aerial parts ²⁹	Ethanol		22	
			Petroleum ether		7.5	
			Ethylacetate		290	
			Water		230	
<i>Enantia chlorantha</i>	Annonaceae	Bark ⁴⁷	Aqueous	ED_{50} (mg/ml)	>2000	<i>P. falciparum</i>
			Ethanol		>2000	FAN-5
<i>Enicostema hyssopifolium*</i>	Gentianaceae	Root ²²	Ethanol	% inhibition	>2000	FMN-13,
					N.A. & N.A.	FMN-17,
						MP-11 and SO
<i>Entandrophragma bussei</i>	Meliaceae	Stem bark ²¹	Petroleum ether	IC_{50} (μ g/ml)	10-49	<i>P. falciparum</i>
			Dichloromethane		10-49	K1
			Methanol		100-499	
<i>Erythrina saculexii</i>	Fabaceae	Root bark ¹⁹	Ethylacetate	IC_{50} (μ g/ml)	3.3	<i>P. berghei</i>
<i>Erythrina saculexii</i>	Fabaceae	Leaves ²⁰	Ethanol	IC_{50} (μ g/ml)	140	<i>P. falciparum</i>
			Petroleum ether		10	K1
			Ethylacetate		120	
		Root bark	Water		3.6	
			Ethanol		20	
			Petroleum ether		3.0	
			Ethylacetate		200	
			Water		80	
<i>Etilingera elatior</i>	Zingiberaceae	Fruit ²³	Aqueous	IC_{50} (ng/ml)	>20000 & 9610	<i>P. falciparum</i>
		Stalk	Ethanol		>20000 & 8820	D6 and W2

contd...

Table 1. (contd.)

Plant species	Family	Part used	Extract/ Fraction	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
<i>Etlingera</i> sp	Zingiberaceae	Stalk ²³	Aqueous ethanol	IC ₅₀ (ng/ml)	>20000 & 15890	<i>P. falciparum</i> D6 and W2
<i>Eucalyptus globulus*</i>	Myrtaceae	Aerial parts ²⁹	Ethanol	MED ₅₀ (μg/ml)	150, 75, 100, 100 & 100	<i>P. falciparum</i> FAN-5, MN-13, FMN-17, MP-11 and SO
<i>Euphorbia thymifolia*</i>	Euphorbiaceae	Whole plant excluding root ²²	Ethanol	% inhibition	41.14 & 65.70	<i>P. berghei</i> NK 65 <i>in vivo</i> and <i>in vitro</i>
<i>Evodia fatraina</i>	Rutaceae	Stem bark ⁴⁸	Ethylacetate	IC ₅₀ (μg/ml)	8.5	<i>P. falciparum</i> FCM-29
			Butanol		16	FCM-29C1
			Ethanol		16	FCM-29C1
			Ethanol		20	FCM-29C3
			Ethanol		12.5	FCM-22
<i>Ficus polita</i>	Moraceae	Leaves ²⁶	Ethanol	IC ₅₀ (μg/ml)	20.8	<i>P. falciparum</i>
<i>Garcinia gummigutta</i>	N.a.	N.a. ⁴⁹	N.a.	% inhibition	97.5	<i>P. falciparum</i> K1
<i>Gardenia-jovis tonantis</i>	Rubiaceae	Root bark ³¹	Aqueous	IC ₅₀ (μg/ml)	820, 880 & 1750	<i>P. falciparum</i> M24, K67 and ENT-7
<i>Gardenia-jovis tonantis</i>	Rubiaceae	Stem bark ²¹	Petroleum ether Dichloromethane	IC ₅₀ (μg/ml)	N.T. N.T.	<i>P. falciparum</i> K1
<i>Geissospermum sericeum</i>	N.a.	N.a. ³⁰	Ethanol	IC ₅₀ (ng/ml)	5632.6 & 2156.2	<i>P. falciparum</i> W2 and D6
<i>Glycirrhiza glabra*</i>	Leguminosae	Root ²²	Ethanol	% inhibition	Nil & 63.54	<i>P. berghei</i> NK 65 <i>in vivo</i> and <i>in vitro</i>
<i>Gomphrena celosioides</i>	Amaranthaceae	Leaves ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (μg/ml)	230 45 15 >500	<i>P. falciparum</i> K1
<i>Gomphrena celosioides</i>	Amaranthaceae	All parts ⁴⁰	Water	IC ₅₀ (equiv. μg)	7.5 < IC ₅₀ < 15 μg	<i>P. falciparum</i>
<i>Grewia eggingii</i>	Tiliaceae	Stem bark ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (μg/ml)	50-99 N.T. N.T.	<i>P. falciparum</i> K1
<i>Grewia forbesii</i>	Tiliaceae	Leaves ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (μg/ml)	>499 100-499 100-499	<i>P. falciparum</i> K1

contd...

Table 1. (contd.)

Plant species	Family	Part used	Extract/ Fraction	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
<i>Gynandropsis gynandra</i>	Capparidaceae	Roots ²¹	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (μ g/ml)	300 87 14 >500	<i>P. falciparum</i> K1
<i>Harungana madagascariensis</i>	Guttiferae	Roots ¹⁹	Ethylacetate Petroleum ether	IC ₅₀ (μ g/ml)	4.0 6.0	<i>P. berghei</i> Anka
		Stem bark	Ethylacetate Petroleum ether		10.0 10.0	
<i>Harungana madagascariensis</i>	Guttiferae	Leaves ²⁰	Ethanol	IC ₅₀ (μ g/ml)	65	<i>P. falciparum</i> K1
		Stem bark			29	
		Roots			34	
		Leaves	Petroleum ether		11	
		Stem bark			10	
		Roots			6.0	
		Leaves	Ethylacetate		21	
		Stem bark			10	
		Roots			4.0	
		Leaves	Water		150	
		Stem bark			88	
		Roots			150	
<i>Hedychium spicatum*</i>	Zingiberaceae	Root ²²	Ethanol	% inhibition	Nil & 64.76	<i>P. berghei</i> NK65 <i>in vivo</i> and <i>in vitro</i>
<i>Henisia crinita</i> sub sp <i>parviflora</i>	Rubiaceae	Leaves ²⁰	Ethanol Petroleum ether	IC ₅₀ (μ g/ml)	95	<i>P. falciparum</i> K1
		Stem bark	Ethylacetate		30	
		Roots	Water		29	
					>300	
<i>Hernandia voyronii</i>	Hernandiaceae	Stem ⁵⁰ bark	Ethanol	IC ₅₀ (μ g/ml)	3.53	<i>P. falciparum</i> FCM-29C1
<i>Heteromorpha trifolia</i>	Apiaceae	Stem bark	Aqueous	IC ₅₀ (μ g/ml)	475,370 & 580	<i>P. falciparum</i> M24,K67 and ENT-7
<i>Hostlundia opposita</i>	Lamiaceae	Root bark ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (μ g/ml)	5-9 10-49 100-499	<i>P. falciparum</i> K1
		Stem bark	Petroleum ether Dichloromethane Methanol		50-99 >499 >499	

contd...

Table 1. (contd.)

Plant species	Family	Part used	Extract/Fraction	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
<i>Hoslundia opposita</i>	Lamiaceae	Roots ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (μ g/ml)	33 10 18 >100	<i>P. falciparum</i> K1
<i>Jacaranda copaia</i>	N.a.	N.a. ³⁰	Ethanol	IC ₅₀ (ng/ml)	11641 & 15273	<i>P. falciparum</i> W2 and D6
<i>Jatropha gossypiifolia</i>	Euphorbiaceae	Leaves ⁴⁰	Water	IC ₅₀ (equiv. μ g)	15 <IC ₅₀ <22.5	<i>P. falciparum</i>
<i>Jurinea macrocephala</i> *	Asteraceae	Root ²²	Ethanol	% inhibition	49.27 & 65.39	<i>P. berghei</i> NK 65 <i>in vivo</i> and <i>in vitro</i>
<i>Keetia zangibarica</i>	Rubiaceae	Leaves ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (μ g/ml)	92 140 32 190	<i>P. falciparum</i> K1
		Stem bark	Ethanol Petroleum ether Ethylacetate Water		>250 90 35 >310	
		Root	Ethanol Petroleum ether Ethylacetate Water		98 12 4.0 >450	
<i>Keetia zangibarica</i>	Rubiaceae	Roots ¹⁹	Ethylacetate	IC ₅₀ (μ g/ml)	4.0	<i>P. berghei</i> Anka
<i>Kigelia africana</i>	Bignoniaceae	Stem bark ²⁰	Petroleum ether Dichloromethane	IC ₅₀ (μ g/ml)	>499 >499	<i>P. falciparum</i> K1
		Leaves	Methanol Petroleum ether Dichloromethane Methanol		10-49 >499 >499 100-499	
<i>Lagenaria sphaerica</i>	Cucurbitaceae	Leaves ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (μ g/ml)	220 120 40 450	<i>P. falciparum</i> K1
<i>Lannea edulis</i>	Anacardeaceae	Roots ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (μ g/ml)	40 18 17 400	<i>P. falciparum</i> K1

contd...

Table 1. (contd.)

Plant species	Family	Part used	Extract/ Fraction	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
<i>Lansium domesticum</i>	Meliaceae	Bark ²³	Aqueous ethanol	IC ₅₀ (ng/ml)	9364 & 3105	<i>P. falciparum</i>
<i>Lantana camara</i>	Verbanaceae	Root bark ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (μg/ml)	5-9 10-49 100-499	<i>P. falciparum</i> K1
<i>Launaca nudicaulis*</i>	Asteraceae	Whole plant excluding root ²²	Ethanol	% inhibition	49.26 & Nil	<i>P. berghei</i> NK 65 <i>in vivo</i> and <i>in vitro</i>
<i>Leonotis mollissima</i>	Lamiaceae	Leaves ²⁰	Ethanol	IC ₅₀ (μg/ml)	30	<i>P. falciparum</i> K1
		Roots	Petroleum ether Ethylacetate Water		190 26 80	
		Roots	Ethanol Petroleum ether Ethylacetate Water		9.0 28 95 >500	
<i>Lippia cheralieri</i>	Verbanaceae	Leaves ³⁹	Water	IC ₅₀ (mg/ml)	0.30 & 0.38	<i>P. falciparum</i> FCC-2 and FZR
<i>Luffa aegyptiaca</i>	Cucurbitaceae	Leaves ²⁶	Ethanol	IC ₅₀ (μg/ml)	30.0	<i>P. falciparum</i> K1
<i>Luffa cylindrica</i>	Cucurbitaceae	Leaves ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (μg/ml)	100 300 30 >500	<i>P. falciparum</i> K1
<i>Mammea longifolia</i>	N.a.	N.a. ⁴⁹	N.A.	% inhibition	86	<i>P. falciparum</i> FCM-29 C1
<i>Margaritaria discoidea</i>	Euphorbiaceae	Root bark ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (μg/ml)	10-49 10-49 100-499	<i>P. falciparum</i> K1
<i>Maytenus senegalensis</i>	Celastraceae	Stem bark ¹⁹	Ethylacetate	IC ₅₀ (μg/ml)	0.16	<i>P. berghei</i> Anka
<i>Maytenus senegalensis</i> (Morogoro region)	Celastraceae	Stem bark ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (μg/ml)	1.9 4.5 12 7.5	<i>P. falciparum</i> K1
		Root bark	Ethanol Petroleum ether Ethylacetate Water		2.0 8.0 0.16 0.62	

contd...

Table 1. (contd.)

Plant species	Family	Part used	Extract/Fraction	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
<i>Maytenus senegalensis</i> (Kagera region)		Stem bark	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ ($\mu\text{g/ml}$)	3.0 80 85 205	<i>P. falciparum</i> K1
<i>Mikania cordata</i>	Asteraceae	Leaves ²¹	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ ($\mu\text{g/ml}$)	130 160 14 240	<i>P. falciparum</i> K1
<i>Momordica charantia</i>	Cucurbitaceae	Leaves ²⁶	Ethanol	IC ₅₀ ($\mu\text{g/ml}$)	68.4	<i>P. falciparum</i>
<i>Momordica dioica*</i>	Cucurbitaceae	Whole plant ²²	Ethanol	% inhibition	87.65 & Toxic	<i>P. berghei</i> NK65 <i>in vivo</i> and <i>in vitro</i>
<i>Momordica foetida</i>	Cucurbitaceae	Leaves ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ ($\mu\text{g/ml}$)	80 50 29 170	<i>P. falciparum</i> K1
<i>Morinda lucida</i>	Rubiaceae	Leaves ⁵¹	Petroleum ether	% suppression	51.6% at 600 mg/kg & 96.4% at 900 mg/kg	<i>P. berghei</i>
		Stem bark	Chloroform (Fraction B)			
<i>Morinda lucida</i>	Rubiaceae	Leaves ⁵²	Petrol	% chemosuppression	16-68% at 6.25-50 mg/kg/day	<i>P. berghei</i>
<i>Moringa pterygosperma</i>	Moringaceae	Twigs and leaves ²⁶	Ethanol	IC ₅₀ ($\mu\text{g/ml}$)	60.0	<i>P. falciparum</i>
<i>Nauclea latifolia</i>	Rubiaceae	Roots ⁴⁰	Water	IC ₅₀ ($\sim \mu\text{g}$)	15 $\mu\text{g} < \text{IC}_{50} < 22.5 \mu\text{g}$	<i>P. falciparum</i>
<i>Neuroleena lobata</i>	Asteraceae	Leaves ⁴⁵	Dichloromethane	IC ₅₀ ($\mu\text{g/ml}$)	8.6 & 10.6	<i>P. falciparum</i> NF54 and K1
<i>Newbouldia laevis</i>	Bignoniaceae	Leaves ²⁶	Ethanol	IC ₅₀ ($\mu\text{g/ml}$)	12.6	<i>P. falciparum</i>
<i>Nyctanthes arbortristis*</i>	Oleaceae	Stem bark ²²	Ethanol	% inhibition	Nil & 21.33	<i>P. berghei</i> NK 65 <i>in vivo</i> and <i>in vitro</i>
		Leaf			64.70 & 69.47	
		Root			21.46 & 55.38	
		Seed			Nil & 45.08	
		Flower			Nil & 20.54	

contd...

Table 1. (contd.)

Plant species	Family	Part used	Extract/ Fraction	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
<i>Nyctanthes arbor-tristis</i>	Nyctaginaceae	Aerial parts ²⁹	Ethanol	MED ₅₀ ($\mu\text{g/ml}$)	1000, 1200, 1000, N.A. & N.A.	<i>P. falciparum</i> FAN-5 FMN-17, MP-11 and SO
<i>Ocimum sanctum</i> *	Labiatae	Root ²²	Ethanol	% inhibition	24.11 & 11.62	<i>P. berghei</i> NK65
		Whole plant excluding root			Nil & 29.65	
<i>Oscimum sanctum</i> *	Lamiaceae	Aerial parts ²⁹	Ethanol	MED ₅₀ ($\mu\text{g/ml}$)	>2000, >2000, >2000, N.A. & N.A.	<i>P. falciparum</i> FAN-5, FMN-13, FMN-17, MP-11 and SO
<i>Ocotea usambarensis</i>	Lauraceae	Root bark ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ ($\mu\text{g/ml}$)	10-49 10-49 100-499	<i>P. falciparum</i> K1
<i>Olinia usambarensis</i>	Oliniaceae	Stem bark ³¹	Aqueous	IC ₅₀ ($\mu\text{g/ml}$)	204, 130 & 380	<i>P. falciparum</i> M24, K67 and ENT-7
<i>Oxyanthus pyriformis</i> sub sp <i>tangan</i> <i>yikensis</i>	Rubiaceae	Leaves ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ ($\mu\text{g/ml}$)	130 100 90 40	<i>P. falciparum</i> K1
		Roots	Ethanol Petroleum ether Ethylacetate Water		30 40 260 300	
<i>Ozoroa insignis</i>	Anacardiaceae	Root bark ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ ($\mu\text{g/ml}$)	10-49 10-49 >499	<i>P. falciparum</i> K1
<i>Pallinia pinnata</i>	Sapindaceae	Leaves ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ ($\mu\text{g/ml}$)	40 36 25 50	<i>P. falciparum</i> K1
<i>Parinari excelsa</i>	Chrysobalanaceae	Stem bark ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ ($\mu\text{g/ml}$)	41 12 10 92	<i>P. falciparum</i> K1
<i>Parinari excelsa sabin</i>	Rosaceae	Stem bark ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ ($\mu\text{g/ml}$)	10-49 10-49 >499	<i>P. falciparum</i> K1

contd...

Table 1. (contd.)

Plant species	Family	Part used	Extract/Fraction	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
<i>Parkia filicoidea</i>	Mimosaceae	Root bark ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (μ g/ml)	140 39 48 130	<i>P. falciparum</i> KI
<i>Paullinia pinnata</i>	Sapindaceae	All parts ⁴⁰	Water	IC ₅₀ (equiv. μ g)	<15 <IC ₅₀ <22.5	<i>P. falciparum</i>
<i>Pavetta crassipes</i>	Rubiaceae	All parts ⁴⁰	Water	IC ₅₀ (μ g/ml)	<7.5	<i>P. falciparum</i>
<i>Pavetta crassipes</i>	Rubiaceae	Leaves ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (μ g/ml)	170 95 33 >500	<i>P. falciparum</i> KI
<i>Pedalium murex</i> *	Pedaliaceae	Fruit ²²	Ethanol	% inhibition	Nil & 5.23	<i>P. berghei</i> NK 65 <i>in vivo</i> and <i>in vitro</i>
<i>Phyllanthus reticulatus</i>	Euphorbiaceae	Roots ⁴⁶	Aqueous	IC ₅₀ (μ g/ml)	159.8 & 165.1	<i>P. falciparum</i> ENT-36 and K 67
		Leaves	Aqueous		10.0 & 1.7	
		Stem	Aqueous		23.9 & 7.7	
		Stem	Methanol		21.5 & 52.2	
<i>Physalis minima</i> *	Solanaceae	Whole plant excluding root ²²	Ethanol	% inhibition	Nil & 57.5	<i>P. berghei</i> NK 65 <i>in vivo</i> and <i>in vitro</i>
<i>Picralima nitida</i>	Apocynaceae	Seeds ⁵³	Dichloromethane Methanol Water Petroleum ether	IC ₅₀ (μ g/ml)	5.15 & 5.03 7.35 & 12.99 17.40 & 12.15 20.81 & 25.87	<i>P. falciparum</i> W2 and D6
		Fruit rind	Dichloromethane Methanol		1.61 & 2.41 20.79 & 32.16	
		Stem bark	Dichloromethane Methanol		6.46 & 14.86 2.00 & 1.23	
<i>Picralima nitida</i>	Apocynaceae	Root ⁵⁴	Dichloromethane Methanol Water	IC ₅₀ (μ g/ml)	0.188 1.629 10.914	<i>P. falciparum</i> NF 54
		Stem bark	Dichloromethane Methanol Water		0.545 1.792 >50	

contd...

Table 1. (contd.)

Plant species	Family	Part used	Extract/ Fraction	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
<i>Piliostigma thonningii</i>	Leguminosae	Fruit rind	Dichloromethane	17.660		
			Methanol	41.342		
			Water	1.581		
		Leaves	Petroleum ether	>50		
			Dichloromethane	>50		
			Methanol	7.361		
		Seeds	Water	>50		
			Petroleum ether	>50		
		Stem bark ²¹	Dichloromethane	12.435		
			Methanol	>50		
			Water	>50		
<i>Pisum sativum</i> *	Fabaceae	Leaves ³³	Petroleum ether	IC ₅₀ (μg/ml)	100-499	<i>P. falciparum</i>
			Dichloromethane		100-499	K1
			Methanol		100-499	
<i>Pithecellobium acemosum</i>	N.A.	N.A. ³⁰	Petroleum ether	IC ₅₀ (ng/ml)	100-499	<i>P. falciparum</i>
			Dichloromethane		10-49	W2 and D6
			Methanol		10-49	
<i>Pittosporum viviflorum</i>	Pittosporaceae	Stem bark ³¹	Petroleum ether	IC ₅₀ (μg/ml)	80.30 & 170	<i>P. falciparum</i>
			Dichloromethane			M24, K67 and ENT-7
			Methanol			
<i>Plantago major</i>	Plantaginaceae	Whole plant ²¹	Petroleum ether	IC ₅₀ (μg/ml)	100-499	<i>P. falciparum</i>
			Dichloromethane		10-49	K1
			Methanol		>499	
<i>Pongamia pinnata</i> *	Leguminosae	Seed ²²	Ethanol	% inhibition	38.91 & 39.92	<i>P. berghei</i>
						NK 65 in vivo and in vitro
<i>Potomorphe peltata</i>	N.a.	N.a. ³⁰	Ethanol	IC ₅₀ (μg/ml)	9078.8 & partially active	<i>P. falciparum</i>
						W2 and D6
<i>Potomorphe umbellata</i>	Piperaceae	Leaves ⁵⁵	Ethanol	Reduction in parasitaemia	60% at 500 mg/kg	<i>P. berghei</i>
<i>Prunella amygdalus</i> *	Labiate	Fruit ²²	Ethanol	% inhibition	Nil & 10.27	<i>P. berghei</i>
						NK 65 in vivo and in vitro

contd..

Table 1. (contd.)

Plant species	Family	Part used	Extract/ Fraction	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
<i>Prunus persica*</i>	Rosaceae	Seed ²²	Ethanol	% inhibition	62.23 & 70.90	<i>P. berghei</i> NK65
		Leaf			Toxic & 3.06	
<i>Psidium guajava</i>	Myrtaceae	Leaves ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (µg/ml)	10-49 100-499 50-99	<i>P. falciparum</i> K1
<i>Psidium guajava</i>	Myrtaceae	Leaves ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (µg/ml)	36 13 10 80	<i>P. falciparum</i> K1
<i>Rauwolfia mombasiana</i>	Apocynaceae	Root bark ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (µg/ml)	100-499 N.T. 100-499	<i>P. falciparum</i> K1
		Stem bark	Petroleum ether Dichloromethane Methanol		N.T. 10-49 >499	
<i>Rhamnus staddo</i>	Rhamnaceae	Root bark ³¹	Aqueous	IC ₅₀ (µg/ml)	520,490 & 740	<i>P. falciparum</i> M24, K67 and ENT-
<i>Rhiocissus tridentata</i>	Vitaceae	Whole tuber ³¹	Aqueous	IC ₅₀ (µg/ml)	100,40 & 70	<i>P. falciparum</i> M24, K67 and ENT-7
<i>Salacia madagascariensis</i>	Celastraceae	Roots ¹⁹	Petroleum ether	IC ₅₀ (µg/ml)	0.80	<i>P. berghei</i> Anka
<i>Sansevieria guineensis</i>	Agavaceae	Roots ⁴⁵	Dichloromethane	IC ₅₀ (µg/ml)	17.0 & 15.8	<i>P. falciparum</i> NF54 and K1
		Leaves	Dichloromethane		38.5 & 39.5	
<i>Scadoxus multiflorus</i>	Amaryllidaceae	Whole plant ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (µg/ml)	N.T. N.T. 50-99	<i>P. falciparum</i> K1
<i>Sclerocarya caffra</i>	Anacardiaceae	Stem bark ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (µg/ml)	> 499 > 499 > 499	<i>P. falciparum</i> K1
<i>Scutia myrtina</i>	Rhamnaceae	Root bark ³¹	Aqueous	IC ₅₀ (µg/ml)	40,240 & 320	<i>P. falciparum</i> M24, K67 and ENT-7
<i>Senna petersiana</i>	Caesalpinea-ceae	Root ³⁸	Methanol Water Dichloromethane	IC ₅₀ (µg/ml)	>30 >100 13.26	<i>P. falciparum</i> V/S

contd...

Table 1. (contd.)

Plant species	Family	Part used	Extract/ Fraction	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
<i>Shrebera alata</i>	Oleaceae	Leaves	Methanol	2.67 3.97 6.94	627, 160 & 380	<i>P. falciparum</i> M24, K67 and ENT-7
			Water			
			Dichloromethane			
<i>Sida rambifolia</i> *	Malvaceae	Stem bark ³¹	Aqueous	IC ₅₀ (µg/ml)	627, 160 & 380	<i>P. falciparum</i> M24, K67 and ENT-7
<i>Simarouba amara</i>	Simarouba- ceae	Fruit ²²	Ethanol	% inhibition	Nil & 8.11	<i>P. berghei</i> NK 65 <i>in vivo</i> and <i>in vitro</i>
			Root		Nil & 56.05	
<i>Solanum nigrum</i> *	Solanaceae	Cortex ⁴⁵	Dichloromethane	IC ₅₀ (µg/ml)	0.195 & 0.184	<i>P. falciparum</i> NF 54 and K1
<i>Sorindeia madagascariensis</i>	Anacardiaceae	Root bark ²¹	Ethanol	% inhibition	Nil & 51.95	<i>P. falciparum</i> K1
			Petroleum ether Dichloromethane Methanol		100-499 100-499 >499	
<i>Spathodea campanulata</i>	Bignoniaceae	Leaves ⁵⁶	Hexane	ED ₅₀ (mg/kg/day)	Infective	<i>P. berghei</i>
			Water		100-400	
<i>Spilanthes oleracea</i>	Asteraceae	Flowers ³⁹	Water	IC ₅₀ (mg/ml)	0.18 & 0.20	<i>P. falciparum</i> FCC2 and FZR
<i>Spinacia oleracea</i> *	Chenopodi- ceae	Seed ²²	Ethanol	% inhibition	28.67 & 59.43	<i>P. berghei</i> NK 65 <i>in vivo</i> and <i>in vitro</i>
<i>Spirostachys africana</i>	Euphorbiaceae	Root ³⁶	Ethanol	ID ₅₀ (µg/ml)	5	<i>P. falciparum</i> FUP
		Leaves	Water		5	
<i>Stryphnodendron guyanense</i>		N.a. ³⁰	Petroleum ether	IC ₅₀ (ng/ml)	5	<i>P. falciparum</i> W2 and D6
			Ethanol		38903 & partially active	
<i>Suregada zanzibariensis</i>	Euphorbiaceae	Roots ⁴⁶	Aqueous	IC ₅₀ (µg/ml)	291.4 & 378.8	<i>P. falciparum</i> ENT-36 and K67
		Leaves	Aqueous		1.5 & 1.5	
		Stem	Aqueous		95.5 & >412.8	
<i>Tamarindus indica</i>	Caesalpinea- ceae	Fruits ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (µg/ml)	N.T. N.T. >499	<i>P. falciparum</i> K1

contd...

Table 1. (contd.)

Plant species	Family	Part used	Extract/ Fraction	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
<i>Tamarandus indica</i>	Caesalpinae- ceae	Leaves ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (µg/ml)	100 90 70 270	<i>P. falciparum</i> K1
<i>Tamarix gallica*</i>	Tamariaceae	Whole plant excluding root ²²	Ethanol	% inhibition	Nil & 28.03	<i>P. berghei</i> NK 65 <i>in vivo</i> and <i>in vitro</i>
<i>Terminalia spinosa</i>	Combretaceae	Stem bark ⁴⁶	Aqueous	IC ₅₀ (µg/ml)	29.5 & 9.9	<i>P. falciparum</i> ENT-36 and K67
		Stem wood	Aqueous		49.2 & 35.9	
<i>Thylachium africanum</i>	Capparidaceae	Leaves ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (µg/ml)	290 88 30 >500	<i>P. falciparum</i> K1
<i>Tinospora cordifolia*</i>	Menispermaceae	Whole plant ²²	Ethanol	% inhibition	40.58 & 65.29	<i>P. berghei</i> NK 65 <i>in vivo</i> and <i>in vitro</i>
<i>Todalia asiatica</i>	Rutaceae	Root bark ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (µg/ml)	50-99 10-49 >499	<i>P. falciparum</i> K1
		Stem bark	Petroleum ether Dichloromethane Methanol		100-499 10-49 50-99	
<i>Tribulus terrestris*</i>	Zygophyllaceae	Fruit ²²	Ethanol	% inhibition	6.66 & 15.68	<i>P. berghei</i> NK 65 <i>in vivo</i> and <i>in vitro</i>
<i>Tridax procumbans</i>	Asteraceae	Whole plant ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (µg/ml)	100-499 100-499 >499	<i>P. falciparum</i> K1
<i>Triphophyllum peltatum</i>	Dioncophyllaceae	Leaf ²⁵	Petroleum ether Dichloromethane Dichloromethane/ammonia Ethylalcohol Dichloromethane/ammonia	IC ₅₀ (µg/ml)	35.433 & N.T. 0.815 & 3.313 2.925 & N.T.	<i>P. falciparum</i> NF 54 and <i>P. berghei</i> Anka
		Bark			10.692 & N.T. 0.014 & 0.081	
<i>Turraea mombassana</i>	Meliaceae	Whole root ³¹	Aqueous	IC ₅₀ (µg/ml)	150, 90 & 100	<i>P. falciparum</i> M24, K67 and ENT-7

contd...

Table 1. (contd.)

Plant species	Family	Part used	Extract/ Fraction	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
<i>Tynanthus elegans</i>	N.a.	N.a. ³⁰	Ethanol	IC_{50} (ng/ml)	807030.0 & inactive	<i>P. falciparum</i> W2 and D6
<i>Uapaca nitida</i>	Euphorbiaceae	Root bark ⁵⁷	Ethanol Hexane Acetone Chloroform	IC_{50}	45 ng/ml 1.3 ng/ml 91 µg/ml 25 µg/ml	<i>P. falciparum</i> K1
		Leaves	Methanol Hexane		18 µg/ml 1.84 ng/ml	
<i>Urtica dioica</i>	Urticaceae	Rhizome ²⁴	Ethylacetate	ED_{50} (µg/ml)	3.9 & 3.8	<i>P. falciparum</i> D6 and W2
<i>Vangueria infausta</i>	Rubiaceae	Root bark ²¹	Petroleum ether Dichloromethane Methanol	IC_{50} (µg/ml)	>499 N.T. 10-49	<i>P. falciparum</i> K1
		Stem bark	Petroleum ether Dichloromethane Methanol		N.T. 10-49 100-499	
<i>Vepris lanceolata</i>	Rutaceae	Root bark ¹⁹	Ethylacetate Water	IC_{50} (µg/ml)	7.0 9.5	<i>P. berghei</i> Anka
<i>Vepris lanceolata</i>	Rutaceae	Leaves ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC_{50} (µg/ml)	10 15 26 12	<i>P. falciparum</i> K1
		Root bark	Ethanol Petroleum ether Ethylacetate Water		11 7.0 9.5 60	
<i>Vernonia amygdalina</i>	Asteraceae	Leaves ²¹	Petroleum ether Dichloromethane Methanol	IC_{50} (µg/ml)	N.T. N.T. >499	<i>P. falciparum</i> K1
<i>Vernonia colorata</i>	Asteraceae	Root bark ²¹	Petroleum ether Dichloromethane Methanol	IC_{50} (µg/ml)	100-499 >499 >499	<i>P. falciparum</i> K1
		Stem bark	Petroleum ether Dichloromethane Methanol		50-99 50-99 50-99	
		Leaves	Petroleum ether Dichloromethane Methanol		100-499 >499 >499	
<i>Viburnum opulus</i>	Caprifoliaceae	Stipes ²⁴	Ethylacetate	ED_{50} (µg/ml)	7.4 & 9.8	<i>P. falciparum</i> D6 and W2
<i>Vismia orientale</i>	Guttiferae	Stem bark ²¹	Petroleum ether Dichloromethane	IC_{50} (µg/ml)	N.T. N.T.	<i>P. falciparum</i> K1

contd..

Table 1. (contd.)

Plant species	Family	Part used	Extract/ Fraction	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
		Leaves	Methanol Petroleum ether Dichloromethane Methanol	IC ₅₀ (µg/ml)	N.T. N.T. >499 >499	
<i>Withania somnifera</i>	Solanaceae	Seed ²²	Ethanol	% inhibition	Nil & 47.76	<i>P. berghei</i> NK 65 <i>in vivo</i> and <i>in vitro</i>
<i>Xanthium strumarium</i>	Asteraceae	Arial parts ²⁹	Ethanol	MED ₅₀ (µg/ml)	25, 25, 25, 50 & 50	<i>P. falciparum</i> FAN-5, FMN-13, FMN-17, MP-11 and SO
<i>Ximenia cafra</i>	Olacaceae	Leaves ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (µg/ml)	>499 100-499 100-499	<i>P. falciparum</i> K1
<i>Zanthoxylum chalybeum</i> (Dares Salaam region)	Rutaceae	Stem bark ²⁰	Ethanol Petroleum ether Ethylacetate Water	IC ₅₀ (µg/ml)	31 22 7.0 0.7	<i>P. falciparum</i> K1
		Root bark	Ethanol Petroleum ether Ethylacetate Water		42 10 20 10	
<i>Zanthoxylum chalybeum</i> (Kagra region)		Stem bark	Ethanol Petroleum ether Ethylacetate Water		13 42 12 6.9	
		Root bark	Ethanol Petroleum ether Ethylacetate Water		23 12 7.0 0.43	
<i>Zanthoxylum chalybeum</i>	Rutaceae	Root bark ¹⁹	Water	IC ₅₀ (µg/ml)	0.43	<i>P. berghei</i> Anka
<i>Zanthoxylum gilletii</i>	Rutaceae	Root bark ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (µg/ml)	10-49 50-99 10-49	<i>P. falciparum</i> K1
		Stem bark	Petroleum ether Dichloromethane Methanol		50-99 50-99 10-49	
<i>Zanthoxylum xylosteum</i>	Rutaceae	Stem bark ²¹	Petroleum ether Dichloromethane Methanol	IC ₅₀ (µg/ml)	100-499 100-499 100-499	<i>P. falciparum</i> K1

N.A.—Tested but found to be not active; N.T.—Not tested; N.a.—Not available; Plants which have significantly high efficacies are in bold words; Plants frequently found in Indian subcontinent which have been scientifically studied are highlighted by (*).

Table 2. A composite table of alkaloids derived from plants showing their dose related effects *in vivo* for *P. bergeri* and *in vitro* for *P. falciparum*. Alkaloids from *Sychnos* and *Alstonia* species are reported to be many more times effective than those derived from *Cinchona*

Plant species	Family	Part used	Type of alkaloid	Compound	Toxicity	Dose efficiency	Plasmodium sp and strain
N.a.	Ancistrocladaceae	N.a.	Naphthiso-quinoline alkaloids ⁵⁸	Ancistrocladine Hamatine Ancistrobarterine A Ancistrobreve A	[IC ₅₀ (μg/ml)]	18.353 & N.A. 3.338 & N.A. 10.326 & N.A. 19.31 & N.A.	<i>P. falciparum</i> NF 54 and <i>P. bergeri</i> (Anka)
	Dioncophyllaceae			Dioncophylline C Dioncolactone A Dioncophyllacine A Dioncophylline A 7-epi-Dioncophylline A N-Methyldioncophylline A Dioncophylline A/4'-O-Demethyl-dioncophylline A 5'-O-Demethyl-8-O-methyl-7-epidioncophylline A		0.014 & 0.015 1.337 & 0.598 17.571 & N.A. 1.443 & 0.961 0.190 & 2.946 17.411 & 0.067 0.411 & 0.438 1.584 & 4.580	respectively
N.a.	Menispermaceae	N.a.	Bisbenzyliso-quinoline alkaloid ⁵⁹	Funiferine Tilagine Daphnoline Aromoline Homoaromoline Oxyacanthine HCl Thalispidine Phacanthine Tetrandrine Isotetrandrine Tetrandrine methiodide Pyrenamine Fangchinoline Berbamine Obamegine Dinklaconine Isochondrodendrine Trigillentimine	[IC ₅₀ (μM)]	0.63 6.32 0.96 1.36 3.46 1.06 0.09 1.46 0.57 0.16 >65.4 0.83 1.43 0.45 0.74 3.92 22.0 42.1	<i>P. falciparum</i> K1

contd..

Table 2. (*contd.*)

Plant species	Family	Part used	Type of alkaloid	Compound	Toxicity	Dose efficiency	Plasmodium sp and strain
N.a.	Rutaceae	N.a.	Acridone alkaloids ⁶⁰	Cochsoline Cocsuline Isotriobine Coculine methiodide Gilletine Insularine picrate	1.16 ~88.9 2.06 >17.8 1.81 2.07	>100 & >100 14.1 & 5.54 37.2 & 30.2 >100 & >100	<i>P.falciparum</i> HB3 and W2 respectively
				Normelicopidine Meliocopidine Melicopicine 1,3-Dihydroxy-N-methylacridone	IC_{50} ($\mu\text{g/ml}$)		
				Noracronycine N-Desmethyl acromycine Acromycine 2-Nitroacronycine 1,2-Dihydroxy-1,2-dihydroacronycine 1,2-Dihydroxy-1,2-dihydro-N-desmethyl-acromycine 2-Hydroxy-1,2-dehydroacronycine 2(-)-1,2-Dihydroacronycine-2 γ l (3-amino)-2,3,6-trideoxy- α -L-arabino hexapyranose	>100 & >100 10.4 & 2.35 7.03 & 1.44 2.78 & 1.93 10.9 & 9.14 7.92 & 6.05 13.7 & 3.26 4.86 & 0.60		
				2(S)(-)-1,2-Dihydroacronycine-2 γ l(4-O-acetyl)-3-bromo-2,3,6-trideoxy- α -L-arabino hexapyranose	6.94 & 1.46		
				1-Methoxy-3-(2-methyl-2-propanoatoxy)-9-acridanone-4-carbdehyde	16.8 & 10.8		
				Dimer AB-2	>100 & >100		
				Trimer AB-3	>100 & >100		
				Dimer Dieis-Alder adduct	>100 & >100		

Table 2. (contd.)

Plant species	Family	Part used	Type of alkaloid	Compound	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
				2(R)-1,2-Dihydroacronycine-2,3,6'-yl(4-O-acetyl-3-bromo)-2,3,6-trideoxy- α -1-arabinohexopyranose	3.45 & 1.78		
				Furoquinoline alkaloids	Haplopine Skimniamine Kokusaginine Acronycidine Acronyidine	ED ₅₀ (μ M)	P. falciparum K1
				Alkaloids ⁶¹	Alstonerine Alstophylline Macralstonine acetate Macrocarpanine 11-methoxyakuammicine Norfluorocuraine Pleiocarpamine Villastonine Vincamajine	8.90 & 8.34 15.7 & 14.1 23.1 & 7.70 19.9 & 5.72 12.1 & 2.18	8.90 & 8.34 15.7 & 14.1 23.1 & 7.70 19.9 & 5.72 12.1 & 2.18
<i>Alstonia angustifolia</i>	Apocynaceae	Roots	Alkaloids ⁶¹	Quinine type ⁶²	Coralstonine Coralstonidine Echitamine chloride	IC ₅₀ (μ M)	P. falciparum K1
				Indole alkaloids ⁶³	Dioncophylline A N-methylidioncophylline A	ED ₅₀ (μ g/kg)	P. berghei
<i>Alstonia coriacea</i>	Apocynaceae	Bark	Naphthylisoquinoline alkaloids ⁶⁴	Naphthylisoquinoline alkaloids ⁶⁴	IC ₅₀ (mg/ml)	961 & 1443 9207 & 13637	P. berghei (Anka) and P. falciparum NF-54 respectively
<i>Alstonia scholaris</i>	Apocynaceae	N.a.					
<i>Ancistrocladus abbreviatus</i>	Ancistrocladaceae	Stem bark					
<i>Ancistrocladus barteri</i>		Root	Naphthylisoquinoline alkaloids	Ancistrobrevine D Ancistrocladine		6069 & 12222 >50000 & 18353	
<i>Ancistrocladus heineanum</i>	Ancistrocladaceae	Root	Naphthylisoquinoline alkaloids ⁶⁵	Ancistroheynine	IC ₅₀ (μ g/ml)	2.1	P. falciparum

contd..

Table 2. (contd.)

Plant species	Family	Part used	Type of alkaloid	Compound	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
<i>Anisocycla cymosa</i>	Meliaceae	N.a.	Bisbenzyliso-quinoline alkaloid ⁶⁶	Coscoline	IC ₅₀ ($\mu\text{g/ml}$)	<0.2	<i>P. falciparum</i>
<i>Beilschmiedia madang</i>	Lauraceae	Wood	Bisbenzyliso-quinoline alkaloid ⁶⁷	Dehatrine	IC ₅₀ (μM)	0.17	<i>P. falciparum K1</i>
<i>Cinchona</i> sp	Rubiaceae	Bark	<i>Cinchona</i> alkaloid ⁶⁸	Quinine Dihydroquinine Quinidine	IC ₅₀ (nM)	29.3 & 103.2 21.3 & 151.7 13.4 & 43.7	<i>P. falciparum</i> D6 and W2 respectively
<i>Cinchona</i> sp	Rubiaceae	Bark	<i>Cinchona</i> alkaloid ⁶⁹	Dihydroquinidine 9-Epiquinine Quinine Quinidine Cinchonine	EC ₅₀ (ng/ml)	10.4 & 74.1 3471 & 1179 52.1 & 252.2 21.8 & 67.7 28.2 & 67.5	<i>P. falciparum</i> Quinine susceptible and Quinine resistant lines respectively
N.a.	Rutaceae (<i>Citrus*</i> <i>glycosmis</i> <i>severinia</i>)	Root bark	Acridone alkaloids ⁷⁰	Glandisine-II Glandisine-I Citpressine-I Citpressine-II O-Methylglycocitrine-II Glycocitrine-I Grandisine Citruamine-I N-Methylatalaphiline Glyfoline	% inhibition at 10 ($\mu\text{g/ml}$)	78 60 23 27 26 96 26 30 91 0 80	<i>P. yoelli</i> sub sp <i>nigeriensis</i>
				1,3-O-Methyl-N-methylacridone 1,3,5,6-O-Methyl-N-methylacridone Des-N-Methylnoracronycine Atalaphiline			
				Noracronycine 5-Hydroxynoracronycine Citracridone-I Atalaphiline	95 90 12 88 15 94		

contd..

Table 2. (contd.)

Plant species	Family	Part used	Type of alkaloid	Compound	Toxicity	Dose efficiency	Plasmodium sp and strain
<i>Cremato-sperma</i> sp				N-Methylseverifoline 5-Hydroxy-N-methylseverifoline		25	
<i>Crinum amabile</i>	Amaryllidaceae	Bulb	Alkaloid ⁷²	(-) Amabiline (-) Buphanisine (-) Augustine (-) Crinamine (-) Lycorine	ED ₅₀ (ng/ml)	>10000 & >10000 3500 & 5340 140 & 180 2180 & 2520	<i>P. falciparum</i> D6 and W2 respectively
<i>Cryptolepis sanguinolenta</i>	Asclepiadaceae	Root bark	Indolequinoline alkaloid ⁷³	Cryptolepine	IC ₅₀ (μM) IC ₅₀ (μM) chemo-suppression	0.031	<i>P. falciparum</i> K1
<i>Cryptolepis sanguinolenta</i>	Asclepiadaceae	Root	Indolequinoline alkaloid ⁷⁴	Cryptolepine hydrochloride	IC ₅₀ (μM) 80.5% at 50 mg/kg/day	0.114	<i>P. falciparum</i> K1 <i>P. berghei</i>
<i>Cryptolepis sanguinolenta</i>	Asclepiadaceae	Root	Indolequinoline alkaloid ⁷⁵	Cryptolepine hydrochloride Cryptolepine Isocryptolepine	IC ₅₀ (μM)	0.3, 0.43 & 0.44 0.19, 0.56 & N.T. N.T., 0.3 & N.T.	<i>P. falciparum</i> F32, FcB1 and FcR3 respectively
<i>Cyclea barbata</i>	Menispermaceae	Root	Bisbenzyliso-quinoline alkaloid ⁷⁶	Tetrandrine Limacine Thalrugosine Homoromoline Cycloepeltine	ED ₅₀ (ng/ml)	179 & 160 52.7 & 164 65.1 & 78.0 232 & 451 29.0 & 40.6	<i>P. falciparum</i> D6 and W2 respectively
<i>Enatia chlorantha</i>	Na.	Stem bark	Protobberine alkaloids ⁷⁷	Berberine Palmatine Jatrorrhizine	IC ₅₀ (ng/ml)	141 & 148 281 & 163 422 & 1607	<i>P. falciparum</i> D6 and W2 respectively

contd..

Table 2. (contd.)

Plant species	Family	Part used	Type of alkaloid	Compound	Toxicity	Dose efficiency	Plasmodium sp and strain
<i>Galipea longiflora</i>	Rutaceae	Stem bark	Quinoline alkaloids ⁷⁸	2-n-propylquinoline Chimanine B Chimanine D 2-n-pentylquinoline 4-methoxy-2-phenyl-quinoline 2(3,4-methylenedioxy-phenylethyl) quinoline	% mice survival at 0.31 mMol/kg after 14 days post infection	60 40 60 100 60 40	<i>P. vinckeii petteri</i>
<i>Hernandia voronii jumellei</i>	Herandiaceae	Whole plant	Isoquinoline alkaloid ⁷⁹	Harveline A Harveline B Harveline C	IC ₅₀ (nM)	3282 1687	<i>P. falciparum</i> FCM-29
<i>Isopyrum thalictroides</i>	Ranunculaceae	Roots	Bisbenzyliso-quinoline alkaloid ⁸⁰	Penduline Tetrandrine	IC ₅₀ (ng/ml)	17,19.5,12.2, 19.5 34.6, 69.6	<i>P. falciparum</i> Nigerian, F22, FcB1 and W2 respectively
<i>Nectandra salicifolia</i>	Lauraceae	Trunk bark, Root, Leaf/Twig	Bisbenzyliso-quinoline alkaloid ⁸¹	(+)-Costaricine (+)-isoboldine (+)- laurostine {(+)-norboldine} (+)-norpurpureine (+)-boldine (+)-norisocorydine (+)-isocorydine (+)-laurotetanine (1S)-N-methylcooclavine (1S)-norjuziphine (1S)-juziphine (1S)-reticuline (+)-N-methyl Laurotetanine (9S)-sesquiferine-(9S)-O-methyl-flavanantine	IC ₅₀ (μg/ml)	50 & 294 668 & 904 1240 & 1750	<i>P. falciparum</i> D6 and W2 respectively
<i>Nauclea diderrichii</i>	Rubiaceae	Bark	Alkaloid hydrochlorides	-	IC ₅₀ (μg/ml)	5	<i>P. falciparum</i> W2

contd...

Table 2. (*contd.*)

Plant species	Family	Part used	Type of alkaloid	Compound	Toxicity	Dose efficiency	Plasmodium sp and strain
<i>Pachygone dasycarpa</i>	Menispermaceae	Stern bark	Bisbenzylisoquinoline alkaloids ⁸³	(+)-Angchibangkine (+)-O-Methylangchibangkine (+)-12-O-Methyltricordatine	IC ₅₀ (ng/ml) 17.1 & 63.0	306 & 265 326 & 204	<i>P.falciparum</i> D6 and W2
<i>Picralima nitida</i>	Apocyanaceae	Seeds	Indolemonoterpenoids ⁸⁴	Akuammine	ED ₅₀ (ng/ml)	530 & 1.110	<i>P.falciparum</i> D6 and W2 respectively
<i>Picrasma javanica</i>	Simaroubaceae	Bark	Alkaloids ⁸⁵	4-methoxy-1-vinyl-β-carboline 6-hydroxy-4-methoxy-1-vinyl-β-carboline	ID ₅₀ (ng/ml) 3280	2432	<i>P.falciparum</i>
<i>Pogonopus tubulosus</i>	Rubiaceae	Stern bark	Alkaloids ⁸⁶	Tubulosine Psychothrone Cephaeline Tubulosine Psychothrone Cephaeline	IC ₅₀ (μg/ml) 0.027 & 0.011	0.006 & 0.011 0.14 & 0.39	<i>P.falciparum</i> 2087 and TNDO
<i>Polyalthia nitidissima</i>	Annonaceae	N.a.	Bisbenzylisoquinoline alkaloids ⁷¹	Lindoldamine	IC ₅₀ (μM)	0.45 >2	<i>P.bergelei</i> NK 65
<i>Popovia pisocarpa</i>	Annonaceae	N.a.	Bisbenzylisoquinoline alkaloids ⁷¹	O-methyl dauricine Dauricoline Popisonine	IC ₅₀ (μM)	1.96 2.09	<i>P.falciparum</i> FcB1
<i>Psychotria camponutans</i>	Rubiaceae	Stem and roots	Indole alkaloids ⁸⁷	1-Hydroxybenzoisochromanquinone 1-Acetyl-benzoisochromanquinone Benz(G)isoquinoline 5,10-dione	IC ₅₀ (μg/ml)	2.66 6.02	<i>P.falciparum</i> K1
<i>Strychnopsis thouarsii</i>	Menispermaceae	Leaves	Bisbenzylisoquinoline alkaloids ⁸⁸	7-O-dimethyl-tetrandrine	IC ₅₀ (nM)	0.84	<i>P.falciparum</i> FCM-29/Cameroun
<i>Spiroserpnum penduliflorum</i>		Stem and roots				740	

Table 2. (contd.)

Plant species	Family	Part used	Type of alkaloid	Compound	Toxicity	Dose efficiency	Plasmodium sp and strain
<i>Spirospermum penduliflorum</i>	Menispermaceae	N.a.	Bisbenzylisoquinoline alkaloids ⁷¹	Limacine	IC ₅₀ (μ M)	127	<i>P. falciparum</i> FcB1
<i>Stephania erecta</i>	Menispermaceae	Tubers	Bisbenzylisoquinoline alkaloids ⁸⁹	(+)-N-Methyllobine (+)-1,2-Dehydrolobine (+)-2-Norisotetrandrine (+)-Isotetrandrine (+)-2-Northalugosine (+)-Thalugosine (+)-Homooromoline (+)-Stephibaberine (+)-Daphnandrine (+)-2-Norcepharanthine (+)-Cepharanthine (+)-2-Norobaberine (+)-Obaberine	ED ₅₀ (ng/ml)	97.4 & 255.7 306.7 & 256.4 66.1 & 45.3 165.1 & 54.6 68.5 & 125.1 120.6 & 229.7 104.6 & 288.3 130.0 & 310.0 63.0 & 223.2 46.6 & 129.4 140.4 & 294.8 45.9 & 93.7 231.0 & 216.0	<i>P. falciparum</i> D6 and W2 respectively
<i>Stephania pierrei</i>	Menispermaceae	Tubers	Isoquinoline alkaloids ⁹⁰	(-)-Asimilobine (-)-Isolameline (-)-Xylopine (-)-Dicentrine (-)-Nordicentrine (-)-Phanostenine (-)-Casyythicine (-)-Terahydropalmatine (-)-Capurine (-)-Thaicanine (-)-Corydalmine (-)-Xylopinine (-)-Tetrahydrostephbine (+)-Reticuline (+)-Codamine (-)-Delavaine (-)-Salutaridine (-)-Asimilobine-2-O-D-glucoside (-)-Anonamine	ED ₅₀ (ng/ml)	950 & 470 2560 & 1610 440 & 2270 1260 & 2550 470 & 1030 2010 & 2880 2290 & 2260 >10000 & 5020 4340 & 1910 1610 & 550 2840 & 840 >10000 & >10000 2230 & 1940 4050 & 4470 5800 & 4010 >10000 & 10000 >10000 & 10000 >10000 & >10000 1290 & 1900	<i>P. falciparum</i> D6 and W2 respectively

contd..

Table 2. (contd.)

Plant species	Family	Part used	Type of alkaloid	Compound	Toxicity	Dose efficiency	Plasmodium sp and strain
<i>Strychnopsis thouarsii</i>	Menispermaceae	N.a.	Bisbenzyliso-quinoline alkaloids ⁷¹	(-) Roemeroline (+) Magnoflorine (-) N-Methyltetrahydro-palmitine (+) Oblongogine	IC ₅₀ (μM) 3150 & 1780 >10000 & >10000 >10000 & >10000 >10000 & >10000	0.93	<i>P. falciparum</i> FcB1
<i>Strychnos henningssii</i>	Loganeaceae	Stem bark	Indole alkaloids ⁹¹	Holstine Holstine	IC ₅₀ (μM) 31.5 32.7		<i>P. falciparum</i> K1
<i>Strychnos myrtoides</i>	Loganiaceae	Stem bark	Indole alkaloids ⁹²	Strychnobrasiline Malagasharine	IC ₅₀ (μM) 73.08 69.12		<i>P. falciparum</i> FCM-29
<i>Strychnos usambarensis</i>	Loganeaceae	Leaves	Indole alkaloids ⁹¹	Isostrychnopentamine Strychnofoline Strychnopantamine Strychnopantamine methane Sulphonaya	IC ₅₀ (μM) 0.765 13.8 0.164		<i>P. falciparum</i> K1
				Usambarine 18,19-Dihydrousambaridine oxalate	0.140 4.11 1.98 3.02		
		Root bark		5,6-dihydroflavopereirine Usambarinesine 3',4'-Dihydrousanbarensine Nb-methylusambarinesine; Chloride	0.88 0.023 5.345 0.156		
<i>Strychnos usambarensis</i>	Loganeaceae	Leaves	Bisindole monoterpenoalkaloids ⁹³	Usambarensine 3',4'-Dihydrousambarensine Nb-methylusambarensine; Chloride	IC ₅₀ (μg/ml) 0.38 0.01 2.39		<i>P. falciparum</i> K1
				Usambarine 18,19-Dihydrousambarine oxalate	1.85 1.07		

contd..

Table 2. (contd.)

Plant species	Family	Part used	Type of alkaloid	Compound	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
<i>Strychnos variabilis</i>	Loganiaceae	Leaf Leaf + Root bark	Indole alkaloids ⁹¹	Strychnopentamine methanesulphonate Isstrychnopentamine base Akagerine	IC ₅₀ (μM) 22.1 ~92	0.09 0.09 N.T. 6.98 0.020	P. falciparum K1
<i>Toddalia asiatica</i>	Rutaceae	Root bark	Retuline	O-Acetyliserutoline Isoretuline Retulinal/isoretulinal Isostrychnobalaine	IC ₅₀ (μM) ~92	<1	P. falciparum K39
<i>Trichilia patens</i>	Menispermaceae	Wood		Diedehydro isostrychnobalaine monomethane sulphonate 12'-Hydroxyisostrychnobalaine monomethane sulphonate	IC ₅₀ (nM) 36 2.07 1.67 1.58	36 2.07 1.67 1.58	P. falciparum T9-96 and K1
<i>Triphyophyllum peltatum</i>	Dioncophyllaceae	Stem bark	Alkaloid ⁹³	Nitidine Dihydronitidine	IC ₅₀ (μg/ml) 0.045	1.03	P. falciparum K39
<i>Triphyophyllum peltatum</i>	Dioncophyllaceae	Root	Bisbenzylisoquinoline alkaloid ⁹⁴	Phaenthine	IC ₅₀ (nM) 704.87	365.85	P. falciparum T9-96 and K1
<i>Triphyophyllum peltatum</i>	Dioncophyllaceae			Dioncophylline C Dioncophylline B Dioncophylline A	IC ₅₀ (μg/ml) 0.014 & 0.015	<1 <1	P. falciparum and P. berhei
				Naphthylisoquinoline alkaloids ⁹⁵			
				Dioncophylline B Dioncophylline A	IC ₅₀ (ng/ml) 228 & 224	38 & 21	P. berhei (Anka)
							P. falciparum NF 54 respectively

N.A. — Tested but found to be not active; N.T. — Not available; N.a. — Not available; Plants having significantly high efficacies are in bold words; Plants, frequently found in Indian subcontinent and have been scientifically studied are highlighted by (*); Acridone alkaloids from Rutaceae have been collectively derived from *Citrus*, *Glycosmis* and *Severinia*.

Table 3. A composite table of terpenes and quassinoids derived from plants showing their dose related effects *in vivo* for *P. berghei* and *in vitro* for *P. falciparum*. Quassinoids from *Ailanthus*, *Brucea* and *Eurycoma* species are quiet effective than those of others

Plant species	Family	Part used	Type of terpene	Compound	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
N.a.	Simaroubaceae	N.a.	Quassinoïd ⁹⁶	Chapparin Glaucarubol Glaucarubin	IC ₅₀ (μ g/ml)	0.180 0.410 0.055	<i>P. falciparum</i> K1
				Ailanthrone		0.009	
				Holacanthone		0.007	
				Glaucarubinone		0.004	
				Undulatone		0.006	
				6- α -Senecioyloxy-Chaparrinone		0.008	
				Brusatol		0.003	
				Bruceantin		0.008	
				Bruceantinol		0.002	
				Isobrucine A		0.002	
				Simalkalactone D		0.0009	
				Samaderine		0.015	
				Gedunin		1	<i>P. falciparum</i>
N.a.	Meliaceae (<i>Azadirachta indica</i> * and <i>Melia azedarach</i> *)	Bark	Triterpenoid ⁹⁷		IC ₅₀ (μ M)		
							<i>P. falciparum</i> K1
							and T9-96
							respectively
<i>Ailanthus altissima</i>	Simaroubaceae	Woody parts	Quassinoïd ⁹⁸	Ailanthrone	IC ₅₀ (μ M)	0.084 & 0.090	<i>P. falciparum</i> K1
<i>Ambrosia maritima</i>	Asteraceae	N.a.	Sesquiterpene lactone ⁹⁹	Ambrosin	IC ₅₀ (μ g/ml)	0.72	<i>P. falciparum</i>
<i>Achillea millefolium</i> L.	Asteraceae	N.a.	Natural peroxides ¹⁰⁰	α -peroxyachifolid	EC ₅₀ (μ g/ml)	1	<i>P. falciparum</i>
<i>Anthemis nobilis</i> L.	Asteraceae	N.a.		α -peroxyachifolid		5	FCH-5
<i>Aretemisia annua</i> L.	Asteraceae	N.a.		Quinghaosu		0.01	

contd...

Table 3. (contd.)

Plant species	Family	Part used	Type of terpene	Compound	Toxicity	Dose efficiency	Plasmodium sp and strain
<i>Artemisia abrotanum</i> L.	Asteraceae	N.a.		Arteinculiton		5-10	
<i>Artemisia arborescens</i>	Asteraceae	Aerial parts	Sesquiterpenes ¹⁰¹	1(S*)-hydroxy- α -bisaboloxide A acetate	IC ₅₀ (μ M)	3.75	<i>P. falciparum</i> K1
				1(R*),2(R*)-dihydroxy-3,(15)-dehydro-2,3-dihydro- α -bisaboloxide A acetate			
				Arteinculiton	EC ₅₀ (μ g/ml)	5-10	<i>P. falciparum</i> FCH-5
<i>Artemisia maritima</i> L.	Asteraceae	N.a.	Natural peroxide ¹⁰⁰		% inhibition at 10 mg/kg x 4 days	34.1	<i>P. berghei</i> NK 65
<i>Andrographis paniculata</i> *	N.a.	Whole plant	Diterpene ¹⁰²	Neoandrographolide Deoxyandrographolide Andrographolide Andrographiside	% inhibition at 10 mg/kg x 4 days	29.1 60.5	
<i>Bruceae javanica</i>	Simaroubaceae	Fruits	Quassinooids ⁹⁸	Bruceantin	IC ₅₀ (μ M)	0.013 & 0.008	<i>P. falciparum</i> K1 and T9-96 respectively
<i>Bruceae javanica</i>	Simaroubaceae	Fruits	Quassinooid ¹⁰³	Bruceantin	IC ₅₀ (μ g/ml)	0.005 0.011	<i>P. falciparum</i> Wellcome, RFCR 3 and PKIG 6 respectively
<i>Bruceae javanica</i>	Simaroubaceae	Fruits	Quassinooid ¹⁰⁴	Bruceine A Bruceine B hydrate Bruceine C	ID ₅₀ (μ g/ml)	13.94 18.95	<i>P. falciparum</i>
<i>Bruceae javanica</i> L.	Simaroubaceae	Fruits	Quassinooids ¹⁰⁵	Bruceantin Bruceaninol Bruceine A Bruceine B Bruceine C Dehydrobruceine A Brusatol	IC ₅₀ (μ g/ml)	0.0008 0.002 0.011 0.003 0.005 0.011 0.046	<i>P. falciparum</i> K1

contd..

Table 3. (contd.)

Plant species	Family	Part used	Type of terpene	Compound	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
<i>Caesalpinia bonducilla*</i>	Caesalpinaeace	N.a.	Diterpene ⁶³	Bruceine D Yadanziocide A Yadanziocide C Yadanziocide F Yadanziocide I	Effective dose	1.6 mg/kg	<i>P. berghei</i>
<i>Castela nichoisoni</i>	Simaroubaceae	Woody parts	Quassinoïd ⁹⁸	Chaparrin	IC_{50} (μM)	0.084 & 0.090	<i>P. falciparum</i> K1 and T9-96 respectively
<i>Cephalotaxus harringtonia</i>	Cephalotaxaceae	Seeds	Quassinoïd ⁹⁸	Cephalotoxine	IC_{50} (μM)	0.004 & 0.004	<i>P. falciparum</i> K1 and T9-96 respectively
<i>Cyperus rotundu</i>	Cyperaceae	Tubers	Sesquiterpenes ¹⁰⁶	α -cyperone α -selinene β -selinene β -cyperene humulene	IC_{50} ($\mu g/ml$)	5.50 >50 >50	<i>P. falciparum</i> K1
<i>Cyperus rotundus</i>	Cyperaceae	Tubers	Sesquiterpenes ¹⁰⁷	Patchoulenone Caryophyllene-Oxide 10,12-peroxycalamene 4,7-dimethyl-1-tetralone	EC_{50} (M)	1.08×10^{-4} 3.45×10^{-4} 2.33×10^{-6} 8.62×10^{-5}	<i>P. falciparum</i> K1
<i>Eupatorium rufescens</i>	Asteraceae	Leaves	Bisabolane type sesquiterpene ¹⁰⁸	Zingiberene-3, 6- α -endoperoxide Zingiberene-3, 6- β -endoperoxide	EC_{50} ($\mu g/ml$)	10	<i>P. falciparum</i>
<i>Eurycoma longifolia</i>	Simaroubaceae	Roots	Quassinoïds ¹⁰⁹	Eurycomanol	IC_{50} ($\mu g/ml$)	3.81 3.53 2.48 4.89	<i>P. falciparum</i> Gombak A, Gombak C, ST 9, ST 12,

contd...

Table 3. (contd.)

Plant species	Family	Pa. used	Type of terpene	Compound	Toxicity	Dose efficiency	Plasmodium sp and strain
					2.38 1.59 2.14 1.23 2.42	ST85, ST 148, ST 168, ST 179 and ST 197 respectively	
				Eurycomanol 2-O- β -D-glucopyranoside	2.25 0.389 0.99		
					3.49 0.68		
					1.15		
					1.187		
					1.37		
					1.20		
					2.34		
					0.504		
					1.190		
					2.34		
					0.733		
					1.03		
					1.16		
					1.63		
					0.985		
<i>Eurycoma longifolia</i>	Simaroubaceae	Roots	Quassinoïd glycoside ¹⁰ Aglcone	Eurycomanol 2-O- β -D-lycoperanoside Eurycomanol	IC ₅₀ (μ g/ml)	1.500 1.544	<i>P. falciparum</i> Gombak A
<i>Eurycoma longifolia</i> Jack	Simaroubaceae	Roots	Quassinoïd ¹¹	Eurycomalactone Eurycomanone Eurycomanone 6-hydroxy-5,6-dehydro-eurycomalactone	IC ₅₀ (μ g/ml)	0.21 0.11 0.28 1.15	<i>P. falciparum</i> K1

cond...

Table 3. (contd.)

Plant species	Family	Part used	Type of terpene	Compound	Toxicity	Dose efficiency	Plasmodium sp and strain
<i>Margaritaria discoidea</i>	Euphorbiaceae	Root bark	Sesquiterpene ¹⁰⁶	Securinine	IC ₅₀ ($\mu\text{g/ml}$)	5.35	<i>P. falciparum</i> K1
<i>Nardostachys chinensis</i>	Valerianaceae	N.a.	Natural peroxide ¹⁰⁰	Narducinon	EC ₅₀ ($\mu\text{g/ml}$)	1.4	<i>P. falciparum</i> FCH-5
<i>Batalin lobata</i>	Asteraceae	Leaves	Sesquiterpene lactones ¹¹²	Neurolenin A Neurolenin B Neurolenin C/D(1:3) Neurolenin C/D(3:2)	IC ₅₀ ($\mu\text{g/ml}$)	0.336 0.263 0.2794	<i>P. falciparum</i> NF54
<i>Parthenium hysterophorus</i>	Asteraceae	N.a.	Sesquiterpene pseudoguan-olide ¹¹³	Parthenin	IC ₅₀ ($\mu\text{g/ml}$)	1.289	<i>P. falciparum</i> K1
<i>Picrolema pseudocoffea</i>	Simaroubaceae	Roots	Quassinoïd ¹¹⁴	Sergeolidie	50% inhibition	0.002 to 0.006	<i>P. falciparum</i> FUP
<i>Rosa rugosa</i> Then.	N.a.	N.a.	Natural peroxide ¹⁰⁰	Rugasol A	ED ₅₀ (mg/kg/day)	0.2	<i>P. berghhei</i> NK 65
<i>Senecio selloii</i>	Asteraceae	Leaves	Bisabolane type sesquiterpene ¹⁰⁸	Zingiberene 3,6- α -endoperoxide	EC ₅₀ ($\mu\text{g/ml}$)	1	<i>P. falciparum</i> FCH-5
<i>Simaba cedron</i>	Simaroubaceae	Stem bark	Quassinoïd ¹¹⁵	Cedronin	IC ₅₀ ($\mu\text{g/ml}$) ED ₅₀ (mg/kg/day)	0.23 0.25 1.8 respectively	<i>P. falciparum</i> FCC-2 and FZR-8 <i>P. vinkei pterei</i> , 279
<i>Simaba guianensis</i>	Simaroubaceae	Bark	Quassinoïd ³⁰	Simalilactone D Gutolactone	IC ₅₀ (ng/ml)	1.6 & 1.5 4.0 & 4.1	<i>P. falciparum</i> W2 and D6 respectively
<i>Simarouba amara</i>	Simaroubaceae	Fruits	Quassinoïd ¹¹⁶	Ailanthonine 2'-Acetylglaucarubinone	IC ₅₀ ($\mu\text{g/ml}$) &	9 & 1.25 8 & 2.19	<i>P. falciparum</i> K1 <i>P. berghlei</i> , N

contd...

Table 3. (contd.)

Plant species	Family	Part used	Type of terpene	Compound	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
<i>U. lucida</i> sp <i>lucida</i> Benth.	Annonaceae	Root bark Stem bark Leaves	Benzopyranyl sesquiterpene ¹¹⁷	Lucidene Glaucauributrone	ED ₅₀ (mg/kg/day) IC ₅₀ (μ g/ml)	7 & 1.70 4 & 0.86 50	<i>P. falciparum</i> K1
<i>U. pandensis</i> Verdc.	Annonaceae	Root bark Stem bark Leaves	Indolese squiterpenoids ¹¹⁷	3-Farnesylindole (6',7'-Dihydro-8,9'-dihydroxy)-3-farnesylindole (8,9'-dihydroxy)-3-farnesylindole	IC ₅₀ (μ g/ml)	16.7 50.0	<i>P. falciparum</i> K1
<i>U. tanzaniame</i> Verdc.	Annonaceae	Root bark Stem bark Leaves	Benzopyranyl sesquiterpene ¹¹⁷	Tanzanene IC ₅₀ (μ g/ml)	2.86 50	<i>P. falciparum</i> K1	
<i>Vernonia brasiliiana</i>	Asteraceae	Leaves	Triterpene ¹¹⁸	Lupeol β -amyrin	Reduction in parasitaemia & 0% at 15 mg/kg 1% at 25 μ g/ml Germanicol	45% at 25 μ g/ml & N.T. 15% at 25 μ g/ml & N.T.	<i>P. falciparum</i> BH2 26/86 and <i>P. berghei</i>
<i>Xanthium strumarium</i>	Asteraceae	N.a.	Sesquiterpene lactone ¹¹⁹	Tomentosin 8-epi-xanthanin-1 β -5 β .epoxide 8-epi-xanthanin	IC ₅₀ (μ g/ml)	7.8 7.8 125 31	<i>P. falciparum</i> K1
<i>Zanthoxylum gelleiti</i>	Rutaceae	Root bark	Sesquiterpene ¹⁰⁶	N-isobutyldeca-2,4-dienamide Fagamide Lupeol Sesamin 4,7,8-trimethoxyfuro [2,3-b]-quinoline	IC ₅₀ (μ g/ml)	5.37 12.34 >50 >50 >50	<i>P. falciparum</i> K1

N.A. — Tested, but found to be not active; N.T. — Not tested; N.a. — Not available; Plants having significantly high efficacies are in bold words; Plants, frequently found in Indian subcontinent and have been scientifically studied are highlighted by (*); Tetraterpenoids from Meliaceae have been collectively derived from *Azadirachta indica* and *Melia azaderach*.

Table 4. A composite table of aromatic and miscellaneous compounds derived randomly from plants showing their dose related effects *in vivo* for *P. berhei* and *in vitro* for *P. falciparum*. *Diosma* and *Melia* are much effective than others

Plant species	Family	Part used	Type of compounds	Compound	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
N.a.	Meliaceae (<i>Azadirachta indica</i> *)		Limoids ¹²⁰	Khayanthone	IC ₅₀ (μ g/ml)	90	<i>P. falciparum</i> K1
Cedrela odorata		Leaves	Meldenin	Nimbinin		inactive at 50	
		Leaves	Vilasinin 1,3, diacetate		0.77		
		Stem bark	1,1- β -acetoxykhivorin		50		
			3-desacetylkhivorin		50		
Guarea multiflora		Leaves	Gedunin		0.72		
		Stem bark	11- β -acetoxycgedunin		3.11		
		Stem wood	Dihydrogedunin		2.63		
		Fruits	Nimbin		50		
		Leaves	Saliannin		1.74		
Melia azaderach [*])		Stem bark	Carapolide A				
			Carapolide E				
			Rohitukamixture				
			Guarea B		50		
			Evodulone		18.27		
			Desacetyldehydronomilin				
			Limonin				
			Prieurianin				
			Rohitukin				
			Bussein mixture				
			Chukrassin mixture				
			Entandrophragmin				
			6-hydroxycarpin				
			Dehydrocarapin				
			Mexicanolide				
Citrus aurantium [*]	Rutaceae	N.a.	Limoid ¹²¹	Nomilin	IC ₅₀ (μ M)	84.1	<i>P. falciparum</i> FCM
				Limonin		>100	SU ₁
Daphnia	Ranunculaceae	Bark	Coumarin ¹²²	Daphnetin	IC ₅₀ (μ M)	25.40	<i>P. falciparum</i>
Diosma pilosa	N.a.	N.a.	Coumarin Flavone ¹²¹	5,6,7-trimethoxycoumarin Quercetin	IC ₅₀ (μ M)	1.0 6.4	<i>P. falciparum</i> FCMSU ₁

cond...

Table 4. (contd.)

Plant species	Family	Part used	Type of compounds	Compound	Toxicity	Dose efficiency	Plasmodium sp and strain:
<i>Diospyros montana</i>	Ebenaceae	Stem bark	Bisnaphthoquinoid ¹²³	Diosprin	IC ₅₀ (μ M)	626	<i>P.falciparum</i> K1
<i>Exostema caribaicum</i>	Rubiaceae	Stem bark	Coumarin ⁴⁴	4'-5'-dihydroxy-7-methoxy-4-phenyl-5,2'-oxidocoumarin	IC ₅₀ (μ g/ml)	16.5	<i>P.falciparum</i> FCH-S/ Tansania
<i>Fagaropsis angolensis</i>	N.a.	N.a.	Limnoid ¹²¹	Rutaevin	IC ₅₀ (μ M)	82.2	<i>P.falciparum</i> FCM SU ₁
<i>Glycirrhiza glabra</i>	Fabaceae	Roots	Chalcone ¹²⁴	Licochalcone A	IC ₅₀ (μ g/ml)	0.6 & 0.6	<i>P.falciparum</i> 3D7 Dd ₂
<i>Haplophyllum tuberculatum</i>	N.a.	N.A.	Lignan ¹²¹	Justicidin A	IC ₅₀ (μ M)	1.9	<i>P.falciparum</i> FCM SU ₁
<i>Hypericum calycinum</i>	Guttiferae	Aerial parts	Phloroglucinol derivatives ¹²⁵	The compound is related to a number of phloroglucinol derivatives isolated from spp of Asteraceae	IC ₅₀ (μ g/ml)	0.88	<i>P.falciparum</i> K1
<i>Lippia multiflora</i>	Verbenaceae	Dried plant material	Essential oil ¹²⁶	N.a.	ID ₅₀ (μ g/ml)	1/12000	<i>P.falciparum</i> FcB1 and F32
<i>Melia azaderach*</i>	Meliaceae	N.a.	Limnoid ¹²¹	Rutin Gedunin	IC ₅₀ (μ M)	>100 0.08	<i>P.falciparum</i> FCMSU ₁
<i>Miletia thonningii</i>	Papilionaceae	N.a.	Flavonoids ¹²¹	Robustic acid Alpinumisoflavone	IC ₅₀ (μ M)	49.0 24.6	<i>P.falciparum</i> FCM SU ₁
<i>Morinda lucida</i>	Rubiaceae	Stem bark	Anthraquinones ¹²⁷	Digitolutein Rubadin 1-methyl ether Dammacanthal	IC ₅₀ (μ g/ml)	12.92 8.10 9.20	<i>P.falciparum</i>

contd..

Table 4. (contd.)

Plant species	Family	Part used	Type of compounds	Compound	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
<i>Peucedanum astratum</i>	Apiaceae	N.a.	Coumarin ^[21]	Ostruthin Osthol	IC ₅₀ (μM) %	24 97	<i>P. falciparum</i> FCMSU ₁ <i>P. berghhei</i>
<i>Spathodea campanulata</i>	Bignoniaceae	Stem bark	N.a. ^[28]	Ursolic acid Tomentosolic acid 20-β-hydroxyursolic acid	% suppression	81 42	
<i>Swertia chirata</i>	Gentianaceae	N.a.	Xanthone ^[63]	Scherzerin	Effective dose	320 gm/kg to 1.6 mg/kg	<i>P. berghlei</i>
<i>Tabea tia ochracea</i> spp <i>neochrysanthia</i>	Bignoniaceae	Stem bark	Furanonaphtho-5,8-dihydroxy-2-quinones ^[29]	(1'-hydroxy) derivative 2-acetyl-7-methoxy-8-hydroxy derivative 5-and 8-hydroxy-2-(1'-hydroxy)-ethylnaphtho-(2,3-b)-furan-4,9-dione	IC ₅₀ (M)	8.40 x 10 ⁻⁷	<i>P. berghlei</i>
<i>Tephrosia apollinea</i>	Papilionaceae	N.a.	Flavonoids ^[21]	Tephroglabrin (-)Senniglabrin Senniglabrin (+) Glabratephrin	IC ₅₀ (μM)	1.31 x 10 ⁻⁵ 1.67 x 10 ⁻⁷ & 6.77 x 10 ⁻⁷	<i>P. berghlei</i> and <i>P. falciparum</i> FcB2.
<i>Tetradenia riparia</i>	Lamiaceae	Leaves and stem	Essential oil ^[30]	N.a.	IC ₅₀ (μg/ml)	31.4 30.7 32.9 9.0	<i>P. falciparum</i> FCMSU ₁
<i>Uvaria faulknerae</i> Verdc.	Annonaceae	Root bark Stem bark Leaves	Benzylated dihydrochalcones ^[17]	Uvaretin Chamuaritin	IC ₅₀ (μg/ml)	27.5 & 50.3 3.49 45.52	<i>P. falciparum</i> D10 and FAc8 respectively
<i>U. kirkii</i> Hook and <i>U.</i> sp (Pande)	Annonaceae	Root bark Stem bark	Benzylated dihydrochalcones	Uvaretin Diuvaretin		3.49 4.20	<i>P. falciparum</i> K1

contd..

Table 4. (contd.)

Plant species	Family	Part used	Type of compounds	Compound	Toxicity	Dose efficiency	<i>Plasmodium</i> sp and strain
<i>U. leptoclada</i> Oliv.	Annonaceae	Root bark Stem bark	Benzylated dihydrochalcones ¹¹⁷	Uvaretin Triuvaretin	IC ₅₀ (µg/ml)	3.49 46.02	<i>P.falciparum</i> K1
		Leaves		Isotriuvaretin Chamvuaretin			20.85
<i>U. lucida</i> Benth.	Annonaceae	Root bark Stem bark	Benzylated dihydrochalcones	Uvaretin Diuvaretin			5.32
		Leaves		Chamvuaretin			3.49 4.20
<i>U. pandensis</i> Verdc.	Annonaceae	Root bark Stem bark Leaves	Cyclohexene epoxides	(+)-Pandoxide (+)-Seneponoxide (-)-Pipoxide 7-Hydroxy-4',5,6, 8-tetramethoxy-flavanone	>25 25 83.5 50		
<i>Uvaria scheffleri</i> Diels	Annonaceae	Root bark Stem bark Leaves	Chalcone	Glutonol	>50		
<i>Uvaria</i> sp (Pande)	Annonaceae	Root bark Stem bark	Benzylated dihydrochalcones	Uvaretin Diuvaretin		3.49 4.20	
		Leaves		Guaiol			>50
<i>U. tarzaniæ</i> Verde.	Annonaceae	Root bark Stem bark	Benzylated dihydrochalcones	Uvaretin Isotriuvaretin Chamvuaretin		3.49 20.85 5.32	

N.A. — Tested, but found to be not active; N.T. — Not tested; N.a. — Not available; Plants having significantly high efficacies are in bold words; Plants, frequently found in Indian subcontinent and have been scientifically studied are highlighted by (*); Limnoids from Meliaceae have been collectively derived from *Azadirachta indica*, *Cedrela odorata*, *Guarea multiflora* and *Melia azaderach*.

significant antiplasmodial activity as recorded in terms of IC_{50} , EC_{50} , MED_{50} , per cent inhibition ED_{50} etc. Reviews of antimalarial agents from plants in the early 1990's do not show any significant presence of antimalarial active principles among the top 30 extensively investigated medicinal plants¹³¹. However, a compilation of 87 plants which are found effective against *P. falciparum* and *P. yoelli* have only one plant, namely *Azadirachta indica* common with the earlier mentioned top 30 plants¹³². In most reviews of plants used as antimalarials, ethnobotanical listings have no scientific support¹³³. Some studies have been conducted against *P. berghei* and cannot be applied to *P. falciparum* in individual studies¹³⁴. Of these numerous plants that have been forwarded to be candidates for antimalarial activity, only few have served the rigors of complete scientific and accountable evaluation. Crude extracts were the simplest of available medications and are still promoted by WHO policies as emerging alternate systems of medicine to reach the large populations not covered by formal medical care in remote areas. The Indian systems of Ayurveda and Siddha, Unani and Homeopathic have also extensively listed such plants and requires greater scientific support.

The extensive compilation of antimalarial plants brings out the more effective crude extracts in this review as shown in Table 1. Table 1 shows the best three dose efficacies of *Uapaca nitida* (IC_{50} 0.00130 $\mu\text{g/ml}$), *Brucea javanica* (IC_{50} 0.006 $\mu\text{g/ml}$) and *Bridelia cathartica* (ID_{50} 0.005 $\mu\text{g/ml}$). Of

these *Brucea javanica* has been studied most extensively and its quassinoids were found to be effective at IC_{50} of 0.0009 $\mu\text{g/ml}$ against *P. falciparum* K1. The plants of the family Simaroubaceae were also found to be the most effective at IC_{50} of 0.0009 $\mu\text{g/ml}$ (Table 3). Alkaloids from Rutaceae, Ancistrocladaceae, Menispermaceae and Apocynaceae show the most effective IC_{50} . The family Dioncophyllaceae shows the most effective IC_{50} at 0.014 and 0.015 $\mu\text{g/ml}$ against *P. falciparum* NF 54 and *P. berghei* Anka respectively, while *Alstonia angustifolia* shows ED_{50} of 2.92 $\mu\text{g/ml}$ (Table 2). Ursolic acid from *Spathodea campanulata* (Bignoniaceae) produced the highest suppression *in vivo* of 97% at 60 mg/kg/day. The other effective plants are *Melia azaderach* from Meliaceae at ID_{50} of 0.08 $\mu\text{g/ml}$ and *Glycirrhiza glabra* at IC_{50} of 0.6 $\mu\text{g/ml}$ (Table 4).

While these plants are comparable to *Artemisia annua* at IC_{50} of 0.01 $\mu\text{g/ml}$ from which artemisinin is commercially exploited the most extensively studied plants are of the family Simaroubaceae, namely *Brucea javanica* which appears frequently in research studies. *Eurycoma longifolia* also seems to be popular for research purposes with IC_{50} of 0.11 $\mu\text{g/ml}$. *Alstonia, brucea, Simarouba, Eurycoma* etc. are examples of some plants which have been studied frequently against different *Plasmodium* strains by different methods and without conclusive evidences even after two decades of scientific evaluation. Deriving cytotoxic/antiplasmodial activity ratios in these extracts is a desirable

parameter for showing selective antiplasmodial activity and can be attempted for these promising plants¹¹⁵

The isolation and elucidation of the chemical structure of different active components in the medicinal plants is of major value because it identifies a new lead compound. Such lead compounds can be developed further for chemical synthesis of candidate antimalarial drugs. Tables 2, 3 and 4 have listed the class of compounds which need to be further characterised pari-pasu along with its antiplasmodial activity which requires team work drawn from various disciplines ranging from Ethnobotany, Phytochemistry, Pure chemistry, Biological testing and their use in alternate system of medicine and eventually scientific and clinical evaluations. In the present competitive world, the pursuit of products specially aimed at tropical diseases is still not considered to be sufficiently profitable to feature among the research priorities of the pharmaceutical industry.

The century that started by relying on the bark of a tree to treat malaria is still in the search of newer natural products. After such extensive chemical characterization the only successful lead compound was a quinoline alkaloid from *Cinchona*. The newest structural characterization of the sesquiterpene peroxides belonging to a whole new family of compounds derived from the Chinese herbal remedy artemisinin is currently under investigation. Some of its derivatives, such as artemether, artesunate, and dihydroartemisinin, are already in use in various commercial formulations. Further advances of

research methodologies in direct screening for bioactive molecules from plant extract would avoid the tedious and slow methods of these earlier studies and also keep pace against multidrug resistant falciparum malaria.

ACKNOWLEDGEMENTS

We wish to acknowledge Dr. S. Annadurai, Environmental Information System (ENVIS); Ministry of Environment and Forests for help in accessing materials and Mr. Basant, staff for Tropical Soil, Biology and Fertility Project (TSBF South Asian Pacific Programme) for help with the manuscript.

REFERENCES

1. Wright, C.W. and J.D. Phillipson (1990). Natural products and the development of selective antiprotozoal drugs. *Phytother. Res.*, **4**: 127-139.
2. Klayman, D.L. (1985). Quinghaosu (artemisinin): An antimalarial drug from China. *Science*, **228**: 1049-1054.
3. Connelly, M.P.F., E. Fabiano, H. Patel, S.M. Kinyanjui, E.K. Mberu and W.M. Watkins (1996). Antimalarial activity in crude extracts of Malawian medicinal plants. *Ann. Trop. Med. Parasitol.*, **90**(6): 597-602.
4. Meshnick, S.R. (1997). Why does quinine still works after 350 years of use? *Parasitol. Today*, **13**: 89-91.
5. Smith, D.C. (1976). Quinine and fever. The development of the effective dosage. *J. Hist. Med.*, July: 343-367.
6. Greenwood, D. (1992). The quinine connection. *J. Antimicrob. Chemother.*, **30**: 417-427.
7. Anon. (1979). Quinghaosu Antimalarial Coordinating Research Group—Antimalarial studies on quinghaosu. *Chin. Med. J.*, **92**: 811-816.

8. Greenwood, D. (1995). Conflicts of interests: The genesis of synthetic antimalarial agents in peace and war. *J. Amer. Med. Assoc.*, **275**: 230-233.
9. Davidson, G. (1982). Who doesn't want to eradicate malaria? *New Scientist*, **96**: 731-736.
10. Olliaro, P.L. and P.I. Trigg (1995). Status of antimalarial drugs under development. *Bull. WHO*, **73**(5): 565-571.
11. Panisko, D.M. and J.S. Keystone (1990). Treatment of malaria — 1990. *Drugs*, **39**: 160-189.
12. Harinasuta, T., S. Migasena, D. Boonang (1962). In *UNESCO First Regional Symposium on Scientific Knowledge of Tropical Parasites*, Nov 5-9 (University of Singapore): 148-153.
13. Gu, H.M., D.C. Warhurst and W. Peters (1983). Rapid action of Qinghaosu and related drugs on incorporation of (³H) isoleucine by *Plasmodium falciparum* *in vitro*. *Biochem. Pharmacol.*, **32**(17): 2463-2466.
14. Meshnick, S.R., T.E. Taylor and S. Kamchonwongpaisan (1996). Artemisinin and the antimalarial endoperoxides: From herbal remedy to targeted chemotherapy. *Microbiol. Rev.*, **60**(2): 301-315.
15. Choudhuri, A.D. (1996). *Malaria. Indian Med. J.*, **90**: 157-164.
16. Olliaro, P., J. Cattani and D. With (1996). Malaria the submerged disease. *J. Amer. Med. Assoc.*, **275**(3): 230-233.
17. Dutta, G.P. (1995). Challenges of drug resistance reversal in malaria. *J. Parasit. Dis.*, **19**: 5-8.
18. Sharma, V.P. (1995). Return of parasitic diseases. *J. Parasit. Dis.*, **19**: 1-3.
19. Gessler, M.C., M. Tanner, J. Chollet, M.H.H. Nkunya and M. Heinrich (1995). Tanzanian medicinal plants used traditionally for the treatment of malaria I: *in vivo* antimalarial and *in vitro* cytotoxic activities. *Phytother. Res.*, **9**: 504-508.
20. Gessler, M.C., M.H.H. Nkunya, L.B. Mwasumbi, M. Heinrich and M. Tanner (1994). Screening Tanzanian medicinal plants for antimalarial activity. *Acta Trop.*, **56**: 65-77.
21. Wennen, H., M.H.H. Nkunya, D.I. Bray, L.B. Mwasumbi, L.S. Kinabo and V.A.E.B. Kilimali (1990). Antimalarial activity of Tanzanian medicinal plants. *Planta Med.*, **56**: 168-170.
22. Mishra, P., N.L. Pal, P.Y. Guru, J.C. Katiyar and J.S. Tandon (1991). Antimalarial activity of traditional plants against erythrocytic stages of *Plasmodium berghei*. *Intl. J. Pharmacog.*, **1**: 19-23.
23. Leaman, D.J., J.T. Arnason, R. Yusuf, H. Sangat-Roemantyo, H. Soedjito, C.K. Angerhofer and J.M. Pezzuto (1995). Malaria remedies of the Kenyah of Apokayan, east Kalimantan, Indonesia Borneo: A quantitative assessment of local consensus as an indicator of biological efficacy. *J. Ethnopharmacol.*, **49**: 1-16.
24. Grzybek, J., V. Wongpanich, E. Mata-Greenwood, C.K. Angerhofer, J.M. Pezzuto and G.A. Cordell (1997). Biological evaluation of selected plants from Poland. *Intl. J. Pharmacog.*, **35**(1): 1-5.
25. Francois, G., G. Timperman, R.D. Haller, S. Bar, M.A. Isahakia, S.A. Robertson, C. Zhao, N.J. DeSouza, L.A. Assi, J. Holenz and G. Bringman (1997). Growth inhibition of asexual erythrocytic forms of *Plasmodium falciparum* and *P. berghei* *in vitro* by naphthylisoquinoline alkaloid - containing extracts of *Ancistrocladus* and *Triphyophyllum* species. *Intl. J. Pharmacog.*, **35**(1): 55-59.
26. Gbeassor, M., A.Y. Kedjagni, K. Koumaglo, C. DeSouza, K. Agbo, K. Aklikokou and K.A. Amegbo (1990). *In vitro* antimalarial activity of six medicinal plants. *Phytotherapy Res.*, **4**: 115-117.
27. Zafar, M.M., M.E. Hamdard and A. Hameed (1990). Screening of *Artemisia absinthium* for antimalarial effects on *P. berghei* in mice: A preliminary report. *J. Ethnopharmacol.*, **30**: 223-226.
28. Valecha, N., S. Biswas, V. Badoni, K.S. Bhandari and O.P. Sati (1994). Antimalarial activity of *Artemisia japonica*, *Artemisia maritima* and *Artemisia nilagarica*. *Indian J. Pharmacol.*, **26**: 144-146.

29. Badam, L., R.P. Deolankar, S.R. Rojatkar, B.A. Nagsampgi and U.V. Wagh (1988). *In vitro* antimalarial activity of medicinal plants of India. *Indian J. Med. Res.*, **87**: 379-383.
30. Cabral, J.A. (1993). A new antimalarial quassinoid from *Simaba guianensis*. *J. Natl. Prod.*, **56**(11): 1954-1961.
31. Gakunju, D.M.N., E.K. Mberu, S.F. Dossaji, A.I. Gray, R.D. Waigh, P.G. Waterman and W.M. Watkind (1995). Potent antimalarial activity of the alkaloid Nitidine, isolated from a Kenyan herbal remedy. *Antimicrob. Agents. Chemother.*, **39**: 2606-2609.
32. Badam, L., R.P. Doelankar, M.M. Kulkarni, B.A. Nagsampgi and U.V. Wagh (1987). *In vitro* antimalarial activity of Neem (*Azadirachta indica* A. Juss) leaf and seed extracts. *Indian J. Malariaol.*, **24**: 111-117.
33. Abatan, M.O. and M.J. Makinde (1986). Screening *Azadirachta indica* and *Pisum sativum* for possible antimalarial activities. *J. Ethnopharmacol.*, **17**: 85-93.
34. Obih, P.O. and J.M. Makinde (1985). Effect of *Azadirachta indica* on *Plasmodium berghei* in mice. *African J. Med. Sci.*, **14**: 51-54.
35. Brandao, M.G.L., A.U. Krettli, L.S.R. Soares, C.G.C. Nery and H.C. Marinuzzi (1997). Antimalarial activity of extracts and fractions from *Bidens pilosa* and other *Bidens* species (Asteraceae) correlated with the presence of acetylene and flavonoid compounds. *J. Ethnopharmacol.*, **57**(2): 131-138.
36. Jurg, A., T. Tomas and J. Pividal (1991). Antimalarial activity of some plant remedies in use in Marracuene, southern Mozambique. *J. Ethnopharmacol.*, **33**: 79-83.
37. Anderson, M.M., G.C. Kirby, M.J. O'Neill, J.D. Phillipson and D.C. Warhurst (1990). *In vitro* cytotoxicity and antiplasmoidal tests for selection of potential antimalarials from *Brucea javanica* fruits. *Planta Med.*, **56**: 649.
38. Connelly, M.P.E., E. Fabino, I.H. Patel, S.M. Kinyanjui, E.K. Mberu and W.M. Watkins (1996). Antimalarial activity in crude extracts of Malawian medicinal plants. *Ann. Trop. Med. Parasitol.*, **90**(6): 597-602.
39. Gasquet, M., F. Delmas, P. Timon-David, A. Keita, M. Guindo, N. Koita, D. Diallo and O. Douumbo (1993). Evaluation in *in vitro* and *in vivo* of a traditional antimalarial, "Malaria 5". *Fitoterapia*, **LXIV**: 423-426.
40. Gbeassor, M., Y. Kossou, K. Amegbo, C. DeSouza, K. Koumaglo and A. Demke (1989). Antimalarial effects of eight African medicinal plants. *J. Ethnopharmacol.*, **25**: 115-118.
41. Presber, W., B. Hegenscheid, H. Hernandez-Alvarez, D. Herrmann and C. Brendel (1992). Inhibition of the growth of *Plasmodium falciparum* and *P. berghei* *in vitro* by an extract of *Cochlospermum angolense* (Welw). *Acta Tropica*, **50**: 331-338.
42. Benoit, F.A., Valentin, Y. Pelissier, C. Marion, Z. Dakuyo, M. Mallie and J.M. Bastide (1995). Antimalarial activity *in vitro* of *Cochlospermum tinctorium* tubercle extracts. *Trans. R. Soc. Trop. Med. Hyg.*, **89**: 217-218.
43. Sharma, S.K. S. Satyanarayana, R.N.S. Yadav and L.P. Dutta (1993). Screening of *Coptis teeta* Wall for antimalarial effect: A preliminary report. *Indian J. Malariaol.*, **30**: 179-181.
44. Noster, S. and L.J. Kraus (1990). *In vitro* antimalarial activity of *Coutarea latifolia* and *Exostema caribaeum* extracts of *Plasmodium falciparum*. *Planta Med.*, **56**: 63-65.
45. Franssen, F.F.J., L.J.J.W. Smeijster, I. Berger and B.E.M. Aldana (1997). *In vivo* and *in vitro* antiplasmoidal activities of some plants traditionally used in Guatemala against malaria. *Antimicrob. Agents Chemother.*, **41**(7): 1500-1503.
46. Omulokoli, E., B. Khan and S.C. Chhabra (1997). Antiplasmoidal activity of four Kenyan medicinal plants. *J. Ethnopharmacol.*, **56**(2): 133-137.
47. Agbaje, E.O. and A.O. Onabanjo (1991). The effects of extracts of *Enantia chlorantha* in malaria. *Ann. Trop. Med. Parasitol.*, **85**(6): 585-590.

48. Ratsimamanga-Urverg, S., P. Rasoanaivo, A. Rakoto-Ratsimamanga, J. Le Bras, O. Ramiliarisoa, J. Savel and J.P. Coulaud (1991). Antimalarial activity and cytotoxicity of *Evodia fatraina* stem bark extracts. *J. Ethnopharmacol.*, **33**: 231-236.
49. Valsaraj, R., P. Pushpagandhan, U. Nyaman, U.V. Smitt, A. Adsersen and L. Gudiksen (1995). New antimalarial drugs from Indian medicinal plants. In *International Seminar on Recent Trends in Pharmaceutical Sciences*, Ootacamund, 18-20 Feb (Abstract).
50. Ratsimamanga-Urverg, S., P. Rasoanaivo, R. Millijaona, J. Rakotoarimanga, H. Rafatiro, B. Robijaona and A. Rakoto-Ratsimamanga (1994). *In vitro* antimalarial activity, chloroquine potentiating effect and cytotoxicity of alkaloids of *Hernandia voyronii* Jum. (Hernandiaceae). *Phyther. Res.*, **8**: 18-21.
51. Obih, P.O., J.M. Makinde and O.J. Laoye (1985). Investigations of various extracts of *Morinda lucida* for antimalarial actions on *Plasmodium berghei* *berghei* in mice. *African J. Med. Sci.*, **14**: 45-49.
52. Makinde, J.M., S.O. Awe and L.A. Salako (1994). Seasonal variation in the antimalarial activity of *Morinda lucida* on *Plasmodium berghei* *berghei* in mice. *Fitoterapia*, **LXV**: 124-130.
53. Iwu, M.M. and D.L. Klayman (1992). Evaluation of the *in vitro* antimalarial activity of *Picralima nitida* extracts. *J. Ethnopharmacol.*, **36**: 133-135.
54. Francois, G., A.L. Assi, J. Holenz and G. Bringmann (1996). Constituents of *Picralima nitida* display pronounced inhibitory activities against asexual erythrocytic forms of *Plasmodium falciparum* *in vitro*. *J. Ethnopharmacol.*, **54**: 113-117.
55. Amorim, C.Z., C.A. Flores, B.E. Gomes, A.D. Morques and R.S.B. Cordeiro (1988). Screening for antimalarial activity in the genus *Potomorphe*. *J. Ethnopharmacol.*, **24**: 101-106.
56. Makinde, J.M., E.K. Adesogan and O.O.G. Amusan (1987). The schizontocidal activity of *Spathodea campanulata* leaf extract on *Plasmodium berghei* *berghei* in mice. *Phytotherapy Res.*, **11**: 65-68.
57. Kirby, G.C., N.B. Khumalo-Ngwenya, B.A. Grawehr, T.W. Fison, D.C. Warhurst and J.D. Phillipson (1993). Antimalarial activity of 'Mhekara' (*Upacanitida* Mill-Arg.), a Tanzanian tree. *J. Ethnopharmacol.*, **40**: 47-51.
58. Francois, G., G. Timpeuman, J. Holenz, A.L. Assi, T. Gender, L. Maes, J. Dubois, M. Hanocq and G. Bringmann (1996). Naphthylisoquinoline alkaloids exhibit strong growth-inhibiting activities against *Plasmodium falciparum* and *P. berghei* *in vitro*-structure activity relationships of Dioncophylline C. *Ann. Trop. Med. Parasitol.*, **90**(2): 115-123.
59. Marshall, S.J., P.F. Russel, C.W. Wright, M.M. Anderson, J.D. Phillipson, G.C. Kirby, D.C. Warhurst and P.L. Schiff (1994). *In vitro* antiplasmodial antiamoebic and cytotoxic activities of a series of Bisbenzylisoquinoline alkaloids. *Antimicrob. Agents Chemother.*, **38**(1): 96-103.
60. Basco, L.K., S. Mitaku, A.L. Skaltsounis, N. Ravelomanantsoa, F. Tillequin, M. Koch and J. Le Bras (1994). *In vitro* activities of Furoquinoline and acridone alkaloids against *Plasmodium falciparum*. *Antimicrob. Agents Chemother.*, **38**(5): 1169-1171.
61. Wright, C.W., D. Allen, Y. Cai, J.D. Phillipson, I.M. Said, G.C. Kirby and D.C. Warhurst (1992). *In vitro* antiamoebic and antiplasmodial activities of alkaloids isolated from *Strychnos usambarensis*. *Phyther. Res.*, **6**: 121-124.
62. Wright, C.W., D. Allen, J.D. Phillipson, G.C. Kirby, D.C. Warhurst, G. Massoit and L.L. Men Oliver (1993). *Alstonia* species: Are they effective in malaria treatment? *J. Ethnopharmacol.*, **40**: 41-45.
63. Goyal, H., S. Sukumar and K.K. Purushothaman (1981). Antimalarials from Indian medicinal plants. *J. Res. Ayur. Siddha*, **1**: 286-295.
64. Francois, G., G. Bringmann, C. Dochez, C. Schneider, G. Timperman and Ake L. Assi (1995).

- Activities of extracts and Naphthylisoquinoline alkaloids from *Triphyophyllum peltatum*, *Ancistrocladus abbreviatus* and *Ancistrocladus barteri* against *Plasmodium berghei* (Anka strain) *in vitro*. *J. Ethnopharmacol.*, **46**: 115-120.
65. Bringmann, G., D. Koppler, B. Wiesen, G. Francois, A.S. Shankara Narayana, M.R. Almeida, H. Schneider and U. Zimmermann (1996). Ancistroheynine A the first 7,8'-coupled Naphthylisoquinoline alkaloid from *Ancistrocladus heynae*. *Phytochem.*, **43**(6): 1405-1410..
 66. Francois, G., B. Kanyinda, C. Dochez, M. Wery and M. Vanhaelen (1992). Activity of Cocsoline, a Bisbenzylisoquinoline alkaloid from *Anisocycla cymosa* against *Plasmodium falciparum*. *Planta Med.*, **58**(7): 634-635.
 67. Kitagawa, I., K. Minagawa, Rv-5 Zhang, K. Hori, M. Doc, M. Inove, T. Ishida, K. Kimura, J. Uji and H. Shibuya (1993). Dehatrine, an antimalarial Bisbenzylisoquinoline alkaloid from the Indonesian medicinal plant *Beilschmiedia madang*, isolated as a mixture of the rotational isomers. *Chem. Pharm. Bull.*, **41**(5): 997-999.
 68. Karle, J.M., I.L. Karle, L. Cerena and W.K. Milhous (1992). Stereochemical evaluation of the relative activities of the *Cinchona* alkaloids against *Plasmodium falciparum*. *Antimicrob. Agents Chemother.*, **36**(7): 1538-1544.
 69. Druille, P., O. Brandicourt, T. Chongsuphabajaisiddhi and J. Berthe (1988). Activity of a combination of three *Cinchona* bark alkaloids against *Plasmodium falciparum* *in vitro*. *Antimicrob. Agents Chemother.*, **32**(2): 250-254.
 70. Fujioka, H., Y. Nishiyama, H. Furukawa and N. Kumada (1989). *In vitro* and *in vivo* activities of Atalaphilline and related acridone alkaloids against rodent malaria. *Antimicrob. Agents Chemother.*, **33**(1): 6-9.
 71. Frappier, F., A. Jossang, J. Soudon, F. Calvo, P. Rasoanaivo, S. Ratsimamanga-Urverg, J. Saez, J. Schrevel and P. Grellier (1996). Bisbenzylisoquinolines as modulators of chloroquine resistance in *Plasmodium falciparum* and multidrug resistance in tumor cells. *Antimicrob. Agents Chemother.*, **40**(6): 1476-1481.
 72. Likhitwitayawuid, K., C.K. Angerhofer, H. Chai, J.M. Pezzuto, G.A. Cordell and N. Ruangrungsi (1993). Cytotoxic and antimalarial alkaloids from the bulbs of *Crium amabile*. *J. Nat. Prod.*, **56**(8): 1331-1338.
 73. Kirby, G.C., A. Paine, D.C. Warhurst, B.K. Noameuse and J.D. Phillipson (1995). *In vitro* and *in vivo* antimalarial activity of Cryptolepine, a plant derived Indole-quinoline. *Phytother. Res.*, **9**(5): 359-363.
 74. Wright, C.W., J.D. Phillipson, S.O. Awe, G.C. Kirby, D.C. Warhurst, J. Léclercq and L. Angenot (1996). Antimalarial activity of Cyptolepine and some other Anhydronium bases. *Phytother Res.*, **10**(4): 361-363.
 75. Grellier, P., L. Ramiaramanana, V. MiMeroux, E. Deharo, J. Schrerel, F. Frappice, F. Trigalo, B. Bodo and J.L. Pousset (1996). Antimalarial activity of cryptolepine and isocryptolepine, alkaloids isolated from *Cryptolepis sanguinolenta*. *Phytother. Res.*, **10**(4): 317-321.
 76. Lin, L-ze, Hui-L Shich, C.K. Angerhofer, J.M. Pezzuto, G.A. Cordell, L. Zue, M.E. Johnson and N. Ruangrungsi (1993). Cytotoxic and antimalarial Bisbenzylisoquinolise alkaloids from *Cyclea barbata*. *J. Nat. Prod.*, **56**(1): 22-29.
 77. Vennerstrom, J.L. and D.L. Klayman (1988). Protoberberine alkaloids as antimalarials. *J. Med. Chem.*, **31**(6): 1084-1087.
 78. Gantier, J.C., A. Founet, M.H. Munos and R. Hocquemillen (1996). The effect of some 2-substituted Quinolines isolated from *Galipea longifolia* on *Plasmodium vinckeii petteri* infected mice. *Planta Med.*, **62**: 285-286.
 79. Ratsimamanga-Urverg, S., P. Rasoanaivo, H. Rafatiro, B. Robijaona and A. Rakoto-Ratsimamanga (1994). *In vitro* antiplasmodial activity and chloroquine-potentiating action of three new isoquinoline alkaloid dimers isolated from

- Hernandia voyronii* Jumelle. *Ann. Trop. Med. Parasitol.*, **38**(3): 271-277.
80. Valentin, A., F. Benoit Vical, C. Moulis, E. Stanislas, M. Mallie, I. Fouraste and J.M. Bastide (1997). *In vitro* antimalarial activity of penduline, a Bis-benzylisoquinoline from *Isopyrum thalictroides*. *Antimicrob. Agents Chemother.*, **41**(10): 2305-2307.
81. Bohlike, M., H. Guinaudeau, C.K. Angerhofer, V. Wongpanich, D.D. Soejarto and N.R. Farnsworth (1996). Costraicine, a new antiplasmodial Bis-benzylisoquinoline alkaloid from *Nectandra salicifolia* Trunk bark. *J. Nat. Prod.*, **59**: 576-580.
82. Lamidi, M., E. Ollivier, M. Gasquet, R. Faure, L. Nze-Ekekang and G. Balansard (1996). In *Structural and Antimalarial Activities of Saponins from Nauclea diderrichii bark in "Saponins used in traditional and modern medicine"*. Eds. Waller and Yamasaki (Plenum Press, New York): 383-399.
83. Guinandeau, H., M. Bohlke, L-ze Lin, C.K. Angerhofer, C.A. Cordell and N. Ruangrungsi (1997). (+)-Angchibangkine, a new type of Bis-benzylisoquinoline alkaloid, and other dimers from *Pachygone dasycarpa*. *J. Nat. Prod.*, **60**: 258-260.
84. Kapadia, G.J., C.K. Angerhofer and R. Ansaa-Asamoah (1993). Akuammicine: An antimalarial Indole monoterperene alkaloid of *Picralima nitida* seeds. *Planta Med.*, **59**(6): 565-566.
85. Pavanand, K., K. Yongvanitchit, T. Decha-tinongse, W. Nutakul, Y. Jewvachdamrongkul and J. Bansiddhi (1988). *In vitro* antimalarial activity of a Thai medicinal plant *Picrasma javanica*. *Phytother. Res.*, **2**(1): 33-36.
86. Souvain, M., C. Moretti, J.A. Bravo, J. Callapa, V. Munoz, E. Ruiz, B. Richard and I.L. Men-Olivier (1996). Antimalarial activity of alkaloids from *Pogonopus tubulosus*. *Phytother. Res.*, **10**(3): 193-201.
87. Solis, P.N., C. Langat, M.P. Gupta, G.C. Kirby, D.C. Warhurst and J.D. Phillipson (1995). Bioactive compounds from *Psychotria camponutans*. *Planta Med.*, **61**: 62-65.
88. Ratsimamanga-Urverg, S., P. Rasoanaivo, L. Ramiaranana, R. Milijaona, H. Rafatiro, F. Verdier, A. Rakoto-Ratsimamanga and J. Le Bras (1992). *In vitro* antimalarial activity and chloroquine potentiating action of the two bisbenzylisoquinoline enantiomer alkaloids isolated from *Strychnos thouarsii* and *Spriosperrum penduliflorum*. *Planta Med.*, **58**(6): 541-543.
89. Likhitwitayawuid, K., C.K. Angerhofer, H. Chai, C.A. Cordell and J.M. Pezzuto (1993). Cytotoxic and antimalarial alkaloids from the tubers of *Stephania erecta*. *J. Nat. Prod.*, **56**(1): 30-38.
90. Likhitwitayawuid, K., C.K. Angerhofer, H. Chai, J.M. Pezzuto and C.A. Cordell (1993). Cytotoxic and antimalarial alkaloids from the tubers of *Stephania pierrei*. *J. Nat. Prod.*, **56**(9): 1468-1478.
91. Wright, C.W., D. Allen, Y. Cai, Z. Chen, J.D. Phillipson, G.C. Kirby, D.C. Warhurst, M. Tits and L. Angenot (1994). Selective antiprotozoal activity of some *Strychnos* alkaloids. *Phytother. Res.*, **8**: 149-152.
92. Rasonanaivo, P., S. Ratsimamanga-Urverg, R. Milijaona, H. Rafatiro, A. Rakoto-Ratsimamanga, C. Galeffi and M. Nicoletti (1994). *In vivo* and *in vitro* CQ-potentiating action of *Strychnos myrtoides* alkaloids against CQ-resistant strains of *Plasmodium* malaria. *Planta Med.*, **60**: 13-16.
93. Wright, C.W., D.H. Bray, M.J. O'Neil, D.C., Warhurst, J.D. Phillipson, J.Q. Leclercq and L. Angenot (1991). Antiamoebic and antiplasmodial activities of alkaloids isolated from *Strychnos usambarensis*. *Planta Med.*, **57**: 337-340.
94. Ekong, R., I.J. Partridge, M.M. Anderson, G.C. Kirby, D.C. Warhurst, P.F. Russel and J.D. Phillipson (1991). *Plasmodium falciparum*: Effects of phaenthine, a naturally-occurring bisbenzylisoquinoline alkaloid, on chloroquine-resistant and sensitive parasites *in vitro*, and its influence on chloroquine activity. *Ann. Trop. Med. Parasitol.*, **85**(2): 205-213.

95. Francois, G., G. Timperman, W. Eling, L.A. Assi, J. Holenz and G. Bringmann (1997). Naphthalisoquinoline alkaloids against malaria: Evaluation of the curative potentials of Dioncophylline C and Dioncopeltine A against *Plasmodium berghei* *in vivo*. *Antimicrob. Agents Chemother.*, **41**(11): 2533-2539.
96. O'Neill, M.J., D.H. Bray, P. Boardman, J.D. Phillipson, D.C. Warhurst, W. Peters and M. Suffness (1986). Plants as sources of antimalarial drugs: *in vitro* antimalarial activities of some quassinoids. *Antimicrob. Agents Chemother.*, **30**: 101-104.
97. Khalid, S.A. (1989). Isolation and characterization of an antimalarial agents of the neem tree *Azadirachta indica*. *J. Nat. Prod.*, **52**(5): 922-927.
98. Ekong, R.M., G.C. Kirby, G. Patel, J.D. Phillipson and D.C. Warhurst (1990). Comparison of *in vivo* activities of quassinoids with activity against *Plasmodium falciparum*, Anisomycin and some other inhibitors of Eukaryotic protein synthesis. *Biochem. Pharmacol.*, **40**: 297-301.
99. Francois, G., M.K.N. Guessan, C. Dochez, M. Wery and L. Triest (1993). Ambrosin a sesquiterpene lactone from *Ambrosia maritima* inhibits the growth of *Plasmodium falciparum* *in vitro*. *Planta Med.*, **59**(Suppl.): 667.
100. Rucker, G., R.D. Walter, D. Manns and R. Mayer (1991). Antimalarial activity of some natural peroxides. *Planta Med.*, **57**: 295-296.
101. Cubucku, B., D.H. Bray, D.C. Warhurst, A.H. Mericli, N. Ozhetay and G. Sariyar (1990). *In vitro* antiplasmodial activity of crude extracts and compounds from *Artemisia abrotanum*. *Phytother. Res.*, **4**(5): 203-204.
102. Mishra, P., N.L. Pal, P.Y. Guni, J.C. Katiyar, V. Srivastava and J.S. Tandon (1992). Antimalarial activity of *Andrographis paniculata* (Kalmegh) against *Plasmodium berghei* NK 65 in *Mastomys natalensis*. *Intl. J. Pharmacog.*, **30**(4): 263-274.
103. Guru, P.Y., D.C. Warhurst and A. Harris (1983). Antimalarial activity of bruceantin *in vitro*. *Ann. Trop. Med. Parasitol.*, **77**(4): 433-435.
104. Pavanand, K., W. Nutakul, T. Dechatiwongse, K. Joshihira, K. Yong Vanitchit, J.P. Scorill, J.L. Fillippen-Anderson, R. Gilardi, C. George, P. Kanchanapee and H.K. Webster (1986). *In vitro* antimalarial activity of *Brucea javanica* against multi-drug resistant *Plasmodium falciparum*. *Planta Med.*, **2**: 108-111.
105. O'Neill, M.J., D.H. Bray, P. Boardman, K.L. Chan and J.D. Phillipson (1987). Plants as sources of antimalarial drugs, Pt. 4. Activity of *Brucea javanica* fruits against chloroquine-resistant *Plasmodium falciparum* *in vitro* and against *Plasmodium berghei* *in vivo*. *J. Nat. Prod.*, **50**(1): 41-48.
106. Weenen, H., M.H.H. Nkunya, D.H. Bray, L.B. Mwasumbi, L.S. Kinabo, V.A.E.B. Kilimali and J.B.P.A. Wijnbey (1990). Antimalarial compounds containing an-unsaturated carbonyl moiety from Tanzanian medicinal plants. *Planta Med.*, **56**(4): 371-373.
107. Thebtaranonth, C., Y. Thebtaranonth, S. Wanauppathamul and Y. Yutharong (1995). Antimalarial sesquiterpenes from tubes of *Cyperus rotundus*: Structure of 10,12-peroxy-calemenene, a sesquiterpene endoperoxide. *Phytochem.*, **40**(1): 125-128.
108. Rucker, G., E.P. Schenkel, D. Manns, R. Mayer, K. Heiden and B.M. Heinzmann (1996). Sesquiterpene peroxides from *Senecio selloi* and *Eupatorium rufescens*. *Planta Med.*, **62**(6): 565-566.
109. Ang, H.H., K.L. Chan and J.W. Mak (1995). *In vitro* antimalarial activity of quassinoids from *Eurycoma longifolia* against Malaysian chloroquine-resistant *Plasmodium falciparum* isolates. *Planta Med.*, **61**: 171-178.
110. Chan, K.L., S.P. Lee, T.W. Sam and B.H. Han (1989). A quassinoid glycoside from the roots of *Eurycoma longifolia*. *Phytochem.*, **28**(10): 2857-2859.

111. Chan, K.L., M.J. O'Neill, J.D. Phillipson and D.C. Warhurst (1986). Plants as sources of antimalarial drugs. Pt. 3. *Planta Med.*, **52**(2): 105-107.
112. Francois, G., C.M. Passreiter, H.J. Woerdenbag and M.V. Looveren(1996). Antiplasmodial activities and cytotoxic effects of aqueous extracts and sesquiterpene lactones from *Neurolaena lobata*. *Planta Med.*, **62**: 126-129.
113. Hooper, M., G.C. Kirby, M.M. Kulkarni, S.N. Kulkarni, B.A. Nagasampagi, M.J. O'Neill, J.D. Phillipson, S.R. Rojatkar and D.C. Warhurst (1990). Antimalarial activity of parthenin and its derivatives. *European J. Med. Chem.*, **25**: 717-723.
114. Fandeur, T., C. Moretti and J. Polonsky (1985). *In vitro* and *in vivo* assessment of the antimalarial activity of Sergeolid. *Planta Med.*, **51**(1): 20-23.
115. Moretti, C., E. Deharo, M. Sauvain, C. Jardel, P.T. David and M. Gasquet(1994). Antimalarial activity of Cedronin. *J. Ethnopharmacol.*, **43**: 57-61.
116. O'Neill, M.J., D.H. Bray, P. Boardman, J.D. Phillipson, D.C. Warhurst, M.P. Gupta, M. Correya and P. Solis(1988). Plants as a sources of antimalarial drugs. Pt. 6. Activities of *Simarouba amara* Fruits. *J. Ethnopharmacol.*, **22**(2):183-190.
117. Nkunya, M.H.H., H. Weenen, D.H. Bray, Q.A. Mgani and L.B. Mwasumbi(1991). Antimalarial activity of Tanzanian plants and their active constituents: The genus *Uvaria*. *Planta Med.*, **57**: 341-343.
118. Almeida Alves, T.M., T.T. Nagem, L.H. De Carvalho, A.U. Krettli and C.L. Zani (1997). Antiplasmodial triotepene from *Vernonia brasiliiana*. *Planta Med.*, **63**(6): 554-555.
119. Joshi, S.P., S.R. Rojatkan and B.A. Nagasampagi (1997). Antimalarial activity of *Xanthium strumarium*. *J. Med. Aromatic Plants Sci.*, **19**(2): 366-368.
120. Bray, D.H., D.C. Warhurst, J.D. Connelly, M.J. O'Neill and J.D. Phillipson (1990). Plants as source of antimalarial drug. Pt. 7. Activity of some species of Meliaceae plants and their constituent Limoids. *Phytother. Res.*, **4**(1): 29-35.
121. Khalid, S.A., A. Farouk, T.G. Geary and J.B. Jensen(1986). Potential antimalarial candidates from African plants: An *in vitro* approach using *Plasmodium falciparum*. *J. Ethnopharmacol.*, **15**: 201-209.
122. Yang, Y-Zi, A. Raniz, Z-Hua Pan, Zhi-N Zhang, Xic-B Lin and S.R. Meshnik (1992). Daphnetin: A novel antimalarial agent with *in vitro* and *in vivo* activity. *American J. Trop. Med. Hyg.*, **46**(1): 15-20.
123. Hazra, B., R. Ghosh, A. Banerjee, G.C. Kirby, D.C. Warhurst and J.D. Phillipson (1995). *In vitro* antiplasmodial effect of Disopyrin, a plant-derived naphthoquinoid and a novel series of derivatives. *Phytother. Res.*, **9**: 72-74.
124. Chen, M., T.G. Theander, S.B. Christensen, L. Hviid, L. Zhai and A. Kharazmi (1994). Licochalcone A, a new antimalarial agent, inhibits *in vitro* growth of the human malaria parasite *Plasmodium falciparum* and protects mice from *P. yoelli* infection. *Antimicrob. Agents Chemother.*, **38**(7): 1470-1475.
125. Decosterd, L.A.; E. Hoffmann, R. Kyburz, D. Bray and K. Hostettmann(1991). A new phloroglucinol derivative from *Hypericum calycinum* with antifungal and *in vitro* antimalarial activity. *Planta Med.*, **57**: 548-551.
126. Valentin, A., Y. Pelissier, F. Bonoit, C. Marion, D. Kone, M. Mallie, J.M. Bastide and J.M. Bessiere (1985). Composition and antimalarial activity *in vitro* of volatile components of *Lippia multiflora*. *Phytochem.*, **40**: 1439-1442.
127. Koumaglo, K., M. Gbersor, O. Nikabu, C. De Souza and W. Werner (1992). Effects of three compounds extrected from *Morinda lucida* on *Plasmodium falciparum*. *Planta Med.*, **58**(6): 533-534.
128. Amusan, O.O.G., E.K. Adesogan and J.M. Makinde(1996). Antimalarial active principles of *Spathodea campanuta* stem bark. *Phytother. Res.*, **10**(8): 692-693.

129. Perez, H., F. Diaz and J.D. Medine (1997). Chemical investigation and *in vitro* antimalarial activity of *Tabebuia obhracea* sp *neochrysanthia*. *Intl. J. Pharmacol.*, **35**(4): 227-231.
130. Campbell, W.E., D.W. Grammon, P. Smith, M. Abrahams and T.D. Purves (1997). Composition and antimalarial activity *in vitro* of the essential oil of *Tetrandenia riparia*. *Planta Med.*, **63**(2): 270-272.
131. Vohora, S.B. (1990). Research on Indian medicinal plants. *Indian Drugs*, **26**: 526-532.
132. Guru, P.Y., S.N. Singh, R.K. Chatterjee, B.N. Dhawan and V.P. Kamboj (1996). Traditional remedies in the management of parasitic diseases. In *Proceedings of the National Academy of Sciences, India*, Section B — Biological sciences. Eds. V.P. Sharma and V.P. Kamboj (National Academy of Sciences, Allahabad, India): 245-273.
133. Aminuddin, R.D. Girach and A.S. Khan (1993). Treatment of malaria through herbal drugs from Orissa, India. *Fitoterapia*, **LXIV**(6): 545-548.
134. Chawla, A.S. and M. Kumar (1991). Antimalarial agents from plants. *Indian Drugs*, **29**(3): 57-60.

Changing Scenario of Malaria : A Study at Calcutta

B.R. HAZRA, R. SINHA CHOWDHURY, S.K. SAHA^a, M.B. GHOSH and A.K. MAZUMDER

Sixty cases of *P. falciparum* and 165 cases of *P. vivax* were studied clinically along with species identification of parasite after examination of the blood slide by experts at Calcutta. It was observed that malaria had been changing its clinical profile. The classic paroxysm is evident only in 40% cases of *P. falciparum* and 47.27% of *P. vivax* malaria, but the difference between the two groups is not statistically significant. On the other hand continuous or remittent type of fever has been observed in 40% and 27.27% cases of *P. falciparum* and *P. vivax* respectively, while absence of classic paroxysms of fever, in association with splenomegaly when present, poses a diagnostic difficulty with enteric fever. Association of jaundice in 40% and 9.09% cases with *P. falciparum* and *P. vivax* respectively along with hepatomegaly in 80% and 63.63% in them in conjunction with nausea and/or vomiting leads to clinical mimicry with infective hepatitis. Splenomegaly which has been described as cardinal feature of malaria was observed in 40% cases with *P. falciparum* and only in 18.18% cases of *P. vivax* malaria and this is a clear deviation from earlier description and this difference between the two groups is highly significant at 99% level of confidence. Co-existent enteric fever was observed in 3.33% of falciparum and 2.6% of vivax malaria, though this difference is not statistically significant. Acute respiratory distress was observed in 6.6% of *P. falciparum* malaria only. Oliguria with impaired renal function was noted in 5% cases of *P. falciparum* malaria. The present study has also noted convulsion or coma in 8.33%, purpura with disseminated intravascular coagulation in 3.33% and black water fever in 3.33% cases in falciparum malaria which were not observed in cases with vivax malaria and these differences are statistically significant. However, stupor with bilateral extensor planter response was observed in two cases (1.3%) of vivax malaria.

Keywords: Calcutta, *P. falciparum*, *P. vivax*, Urban malaria

Department of Medicine, Medical College, Calcutta-700 073, India.

^aDepartment of Medical Entomology, School of Tropical Medicine, Calcutta-700 073, India.

INTRODUCTION

Malaria is the commonest vector-borne parasitic disease in the world, being endemic in 103 countries around the globe with population at risk of more than 2.5 billion and causing 1 to 3 million deaths annually¹⁻³. There has been a major resurgence of malaria in India associated with developing resistance of anopheline mosquito to insecticides and increasing prevalence of chloroquine resistance in *Plasmodium falciparum* malaria⁴. In spite of phenomenal progress in medical science, malaria still continues to be one of the major killers in tropical countries⁵. Along with changing character of the vector, malaria specially falciparum has also shown a changing profile of clinical presentation and the accompanying acute and chronic complications and its response to treatment⁶. With this idea in background, we have analysed the changing clinical profile of malaria as observed in Calcutta.

MATERIALS AND METHODS

Sixty cases of *P. falciparum* malaria and 165 cases of *P. vivax* malaria diagnosed from O.P.D. and indoor admissions of Medical College and School of Tropical Medicine, Calcutta, were randomly selected during the period from June 1994 to May 1997, for the present study. A thorough history mentioning the age, sex, fever with its type, range, chill, rigor, sweating, headache, nausea and/or vomiting, dizziness, arthralgia, myalgia, cough and cold, acute respiratory distress, oliguria with impairment of renal function, delirium, convulsion, coma and history of

passing red or black urine were meticulously noted and recorded. The presence of anaemia, jaundice, skin rashes including haemorrhagic manifestations, splenomegaly, hepatomegaly and other positive findings in respiratory, cardiovascular or nervous system were also recorded. The cases were diagnosed for malaria by demonstration of malaria parasite by thick and thin film after proper staining along with other necessary investigation. Cases clinically thought to be malaria positive but without demonstration of malaria parasite in the peripheral blood were excluded from the study. The clinical features of falciparum and vivax malaria were tabulated separately and compared. All cases were initially treated with chloroquine with the WHO recommended dose. Response to treatment was noted and recorded clinically in each case. Those cases which did not respond to the above regime clinically or where the condition specially the level of consciousness in *P. falciparum* cases were deteriorating, were treated with quinine 600 mg thrice daily for 7 days orally or I/V in cases in coma (or artemisinin in selected cases) but with change to oral medication as soon as the level of consciousness permitted.

RESULTS

It is evident from the Table 1, all the cases of both *P. vivax* and *P. falciparum* were febrile but 36 cases (60%) of *P. falciparum* had intermittent temperature compared to 120 cases (72.73%) of vivax. It is also noted that 24 (40%) cases of *P. falciparum* and 45 (27.27%) cases of *P. vivax* had continued or remittent fever. Chill and rigor were ob-

served in 48 (80%) and 24 (40%) cases of *P. falciparum* and 150 (90.90%) and 78 (47.27%) cases of *P. vivax* respectively. Headache was associated in 80% cases of *P. vivax* and 100% cases of *P. falciparum*. Dizziness was more common in *P. falciparum* (60% cases) than in *P. vivax* (38.18% cases). Cough and cold was present in 32 (53.33%) cases with *P. falciparum* and 75 (45.45%) cases with *P. vivax*. Coma or convulsion was observed in 5 (8.33%) cases of *P. falciparum* and none with *P. vivax*. Stupor with bilateral extensor planter response and sluggish pupillary response were found in two cases which proved to be vivax only.

Jaundice was remarkably common in *P. falciparum* in 24 (40%) as opposed to 15 (9.09%) of *P. vivax* cases. Splenomegaly was recorded in 24 (40%) cases of *P. falciparum* as compared to 30 cases (18.18%) of *P. vivax* cases. Hepatomegaly was present in 48 (80%) cases of *P. falciparum* and 105 (63.63%) cases of *P. vivax*. Only two cases (3.33%) of *P. falciparum* had purpuric spots with evidence of disseminated intravascular coagulation, while black water fever was also observed in only two cases of *P. falciparum* (3.33%). Amongst falciparum cases 3 (5%) had oliguria with renal impairment, 4 (6.6%) had acute respiratory distress. Enteric fever was associated with 2 (3.33%) cases of *P. falciparum* and 4 (2.6%) cases of *P. vivax* malaria. All the cases of *P. vivax* responded to the standard chloroquine regime but 55 cases (91.66%) of *P. falciparum* malaria clinically responded to chloroquine therapy, the remaining cases needed quinine oral or I/V, or artemisinin in cases complicated with ischaemic heart disease with atrio-ventricu-

lar conduction defect where quinine was avoided.

DISCUSSION

Fever was encountered in all patients with either *P. falciparum* or *P. vivax* malaria. But typical paroxysm at the time of diagnosis was present in 40% cases with *P. falciparum* malaria and 47.27% of *P. vivax* malaria though the difference was not statistically significant. This finding, however, indicates that more than 50% of the cases do not develop typical paroxysm at the time of aetiological diagnosis, and this is a deviation from the frequent description of common classical paroxysm in text book. Periodicity however with alternate day fever was more commonly encountered with 60% although this is not statistically significant. A sizable proportion, of *P. falciparum* (40%) cases had continued or remittent temperature and the percentage with *P. vivax* being 27.27% (Table 1). This type of temperature raises confusion with the common enteric fever in tropical countries like ours, causing a clinical diagnostic dilemma, specially with an associated splenomegaly which may be common in both the conditions. This is why co-prescription with ciprofloxacin and chloroquine are frequently seen in clinical practice. Moreover the present series has encountered co-existing enteric fever in 3.3% cases of falciparum malaria and 2.6% of vivax malaria. It is worth mentioning that nine cases of cerebral malaria with co-existent enteric fever has been reported by Singh⁷. Positive widal test in 15.2% cases of cerebral malaria in Loni areas in Ahmednagar district of western Maharashtra has also been reported dur-

Table 1. Relative incidence of symptoms and signs of *P. falciparum* and *P. vivax* cases

Systems	Symptoms and signs	No. of cases (%)		Statistical significance between the two groups
		Group A <i>Pf</i> (n = 60)	Group B <i>Pv</i> (n = 165)	
General	Fever	60 (100)	165 (100)	
	Intermittent fever	36 (60)	120 (72.73)	NS
	Continued or remittent	24 (40)	54 (27.27)	NS
	High rise of temperature	20 (33.33)	60 (36.36)	NS
	Low grade fever	40 (66.66)	105 (63.63)	NS
	Typical paroxysm	24 (40)	78 (47.27)	NS
	Chill	48 (80)	150 (90.90)	*
	Rigor	24 (40)	78 (47.27)	NS
	Associated enteric fever	2 (3.33)	4 (2.6)	NS
	Sweating	48 (80)	90 (54.54)	**
	Headache	60 (100)	132 (80)	**
	Dizziness	36 (60)	63 (38.18)	**
Gastro-intestinal	Arthralgia	32 (53.33)	105 (63.63)	NS
	Nausea and/or vomiting	36 (60)	75 (45.45)	*
	Abdominal pain/Diarrhoea	6 (10)	15 (9.09)	NS
	Jaundice	24 (40)	15 (9.09)	**
	Splenomegaly	24 (40)	30 (18.18)	**
Respiratory	Hepatomegaly	48 (80)	105 (63.63)	*
	Cough and cold	32 (53.33)	75 (45.45)	NS
	Acute respiratory distress	4 (6.6)	0 (0)	**
Neurology	Convulsion/Coma	5 (8.33)	9 (0)	**
	Stupor with neurological sign		2 (1.3)	
Haematology	Anaemia	48 (80)	75 (45.54)	**
	Purpuric spots in legs with DIC	2 (3.33)	0 (0)	*
Renal	Oliguria with impairment of renal function	3 (5)	0 (0)	*
	Black urine	2 (3.33)	0 (0)	*
	Response to chloroquine	55 (91.66)	165 (100)	**

*Significant at 95% level of confidence; ** Significant at 99% level of confidence; NS — Not significant;
Pf — *P. falciparum*; *Pv* — *P. vivax*.

ing January 1993 to December 1994 by Khubnani *et al.*⁸ In our series chill was present in 80 and 90.90% cases of *P. falciparum* and *P. vivax* malaria respectively, but rigor was found in less than 50% in both groups and the difference is statistically significant. It becomes evident that sensation of chill with fever has a strong association with both types of malaria.

The next important clinical feature is headache which was found in 80% cases with *P. vivax* and 100% cases with *P. falciparum* but this has no diagnostic value, being non-specifically present in any febrile condition. Another important clinical feature was associated with cough and cold, mimicking respiratory tract infection which was encountered in 53.3% of *P. falciparum* and 45.45% of *P. vivax* malaria and this interferes with clinical diagnosis and even after aetiologically, diagnosis of malaria becomes established. The question remains about the pathogenesis of such respiratory symptoms in almost 50% cases of malaria. It is also not clear whether there is associated respiratory tract infection and hence other antibiotic needs to be added along with treatment of malaria. Convulsion and coma were not encountered in *P. vivax* malaria but it was seen in 8.33% in *P. falciparum* cases and this has statistical significance of 99% level of confidence and it appears that alteration in level of consciousness is a strong clinical pointer to the probable clinical diagnosis of *P. falciparum* malaria. However, we had the experience of *P. vivax* malaria presenting with stupor and bilateral extensor planter response with sluggish pupillary reaction in two cases (1.3%).

This could be due to co-existent falciparum infection which was probably missed or it could be due to heavy parasitaemia which was not studied in our case. Then again it justifies thorough clinical and ancillary investigation to differentiate from intracranial infections.

Jaundice was found in 40% cases with *P. falciparum* and 0.09% of *P. vivax* cases and the difference in the two groups is statistically significant at 99% level of confidence, and this in association with hepatomegaly in 80% cases with *P. falciparum* and 63.63% of *P. vivax* specially in association with nausea or vomiting brings the possibility of infective hepatitis as the differential diagnosis which needs to be excluded prior to institution of antimalarial therapy, with the help of appropriate liver function tests. Splenomegaly, however, was obtained in only 18.18% cases of *P. vivax* and 40% cases of *P. falciparum* in contradiction to the common description of splenomegaly in 85 to 100% of all malaria cases^{9,10} and the difference in two groups in statistically significant at 99% level of confidence. Also this is in agreement with the description of the 'small spleen' in malaria by Chauhan *et al.*¹¹, who were unable to elicit splenomegaly during an acute attack of malaria specially in cases who had already suffered from earlier malaria disease. In general splenomegaly appears after two or three episodes. Greater number of splenomegaly in falciparum cases raised the suspicion of quicker rate of enlargement of spleen. Hepatomegaly was more frequent than splenomegaly in all cases of malaria. This could be explained by the pre-

existing causes of hepatomegaly like amoebiasis etc. which were not excluded in all the cases. Detection of purpuric spots vasculitis due to disseminated intravascular coagulation passage of black urine in 3.33% cases of *P. falciparum* indicate that they are rare accompaniments of *P. falciparum* malaria which are amenable to antimalarial therapy after early diagnosis. In two cases of black water fever, there was history of intake of primaquine without prior G-6-PD screening test.

Acute respiratory distress was seen in 6.6% of falciparum malaria. Oliguria with renal impairment was noted in 5% cases of *P. falciparum* malaria only as compared to 50% patients of complicated falciparum malaria reported with renal dysfunction by Nand *et al.*¹² in Rohtak. Jaundice was present in 40% of *P. falciparum* and 9.09% of *P. vivax* malaria as compared to its presence in 100% cases of complicated falciparum malaria¹².

The present study has also revealed that all cases of *P. vivax* responded to the schedule chloroquine dose but 8.34% of *P. falciparum* cases needed therapy other than chloroquine to have clinical cure of their ailment indicating either severe falciparum infection or perhaps the evolving chloroquine resistance in the studied group, which was not proved before switching to alternative therapy. It is note worthy to mention that clinicians often feel shaky whenever predicted clinical response is not obtained in falciparum cases and switch over to other antimalarials. We also did not think it is ethical to deny our patient the effect of alternative antimalarials whenever the clinical response was not a text

book picture. Costly alternative antimalarials were rarely required, only in individualised cases depending on status of other vital organs.

REFERENCES

- WHO(1992). Commission on health and environment. Our planet, our health (World Health Organisation, Geneva): 96.
- Epstein P.R., D.J. Rogers and R. Sloff (1993). Satellite imaging and vector-borne diseases. *Lancet*, **341**: 1404-1406.
- Gupta, R. (1996). Correlation of rainfall with upsurge of malaria in Rajasthan. *J. Assoc. Phys. India*, **44**: 385-387.
- Chodan Kar, C.M. and K.P. Deodhar (1995). Malaria — Still a master killer. *J. Assoc. Phys. India*, **43**(4): 261-262.
- Misra, N.P. (1996). Unusual complications of malaria. *J. Assoc. Phys. India*, **44**(7): 445-446.
- Mehta, S.R., V. Joshi and A.I. Lazar (1996). Unusual acute and chronic complication of malaria. *J. Assoc. Phys. India*, **44**(7): 451-453.
- Singh, P.S. (1995). Co-existence of enteric fever with malaria. *J. Assoc. Phys. India*, **43**: 71.
- Khubnani, H., D. Phalke, A.H. Khubnani and R.C. Jain (1995). Co-existence of anti-salmonella agglutinin in falciparum malaria. *J. Assoc. Phys. India*, **43**: 585-586.
- Marshal, H.A.H. (1986). Splenomegaly in malaria. *Indian J. Malariol.*, **23**: 1-8.
- Harinasuta, T. and D. Bunnag (1988). Clinical features of malaria. In *Principles and Practice of Malaria*. Eds. W.H. Warnsdorfer and Sir I. McGregor, I: 709-734.
- Chauhan, R., V. Kapoor, P.A. Vohra (1996). The 'small spleen' in malaria. *J. Assoc. Phys. India*, **44**(7): 483-485.
- Nand, Nitya, H.K. Agarwal, Pankaj Kumar and N. Budhiraja (1997). Hepatic and renal dysfunction in falciparum malaria. *J. Assoc. Phys. India*, **45**(7): 553-554.

Short Note

Indian Journal of Malariaology
Vol. 35, June 1998, pp. 117-122.

Factors Influencing the Larvicidal Activity of Bacterial Toxin

LAOJANA CHOWANADISAI

Keywords: Bacteria, Factors, Larvicidal activity, Toxin

Many species of mosquito play the important role as being the vectors carried diseases to man, which remain the public health problems in Thailand¹. Control measures for those vectors providing effectiveness and cause less harmful effects to people and environment have to be critically selected. Mosquito control by using biological control agents has been accepted as the most safe larval control among the available control measures². Current bacterial larvicides for controlling mosquito larvae and related species has gained more interest during the past few decades. However, there are many factors concerning the virulence of bac-

terial toxin which can be summarized as follows.

Bacterial toxin

The bacterial toxin can actually be divided into five major groups which consisted of delta endotoxin, beta exotoxin, alpha exotoxin, gamma exotoxin and louse factor^{3,4}. Exotoxin is the water soluble toxic protein which is gradually produced and released during bacterial growth. It can be inactivated by unappropriate temperature. Endotoxin is solubilized in alkaline solution but stable to heat and chemicals.

Biological Control Section, National Institute of Health, Department of Medical Sciences, Soi Bumrasnaradura, Tiwanon Road, Nonthaburi-11000, Thailand.

Some exotoxin particularly a water soluble, thermostable exotoxin or thuringiensis, at high dosage had adverse effects on birds and mammals while at low dosage had a broad spectrum effects on invertebrates since they could interfere the biosynthesis of RNA and some inhibited the function of RNA polymerase⁵. Thus, the bacterial strains to be used for commercial productions must be those that do not produce beta exotoxin.

The toxin produced by bacteria is encoded by the gene which results in the variation on gene type of bacterial toxin. Normally, the structure of toxin consists of primary and tertiary structure. Toxin of primary structure are encoded by *cry* gene and *cyt* gene such as *cry I*, *cry II*, *cry III* and *cry IV*. Gene products can express their specific biological activity against different groups of insect. For example, products of *cry I* gene are toxic to lepidopterans while toxin encoded by *cry IV* are active toward dipterans⁶.

Bacterial toxins are glycoprotein⁷. The N- and O-glycosylation can occur at multiple sites of the primary structure which glycosylated moieties are believed to play an important role in toxicity to insects⁸.

Influence of media on virulence of bacterial toxin

The delta endotoxin of *B. thuringiensis* are packaged into parasporal inclusions. The structure of parasporal inclusions are different among subspecies. It is believed that conditions used for cultivation of bacteria

influences the structure of parasporal inclusion⁶ for example it was reported that among the six media compositions proposed for production of *B. thuringiensis*, basal medium containing 0.2% yeast extract, 0.1% K₂HPO₄ and 0.1% KH₂PO₄ with 1% greengram and 1% cane sugar provided the highest potency of toxin⁹.

Formulation of bacterial larvicide products

As mode of action of bacterial toxin is through oral ingestion, so formulations of the bacterial larvicide are the tools to convey toxin to insect larvae. Formulation can support and increase the ease of handling, provide long shelf life and protect the toxin protein from UV light. Moreover, it can maximize contact of target larvae to bacterial toxin and prolong residual activity¹⁰.

The study on efficacy of aqueous formulation and slow release formulation of *B. sphaericus* against *Cx. quinquefasciatus* indicated that the slow release in briquet formulation provided the best larval reduction for three weeks while reduction of the other suspension and pellet formulations were only three days¹¹. Since depth of water showed remarkable influence on persistence of bacterial larvicides in the breeding sites, once application, the bacterial cells would gradually sink down. Upon the behaviour of larval feeding, any formulation that could bring the bacterial toxin directly to larvae and remained lethal dose at the feeding zone, would be considered as important factor rather than

the dosage at the time of application.

Effect of larval instar

Most of the previous studies agreed that susceptibility of mosquito larvae decreased with increasing instar¹³⁻¹⁵ but later study¹⁶ reported that larval instar was not the reason since it was indicated that each larval instar of *Ae. aegypti* was susceptible to *B. sphaericus* at nearly the same level.

Effect of food on larvicidal activity

Food also influenced the activity of bacterial larvicide. It was observed in the laboratory that the larval mortality decreased with the increasing availability of foods¹⁷. The consumption rate was different among mosquito species¹⁸. Thus, concentration of bacterial larvicide when applied, was not considered as important factor as compared to the time consuming for toxin accumulation and proceeding lethal dose¹⁷.

Temperature

The relation between temperature and mortality of mosquito larvae has been remarkably observed. As the temperature decreased about 10°C, the increase in 5-6 fold of LC₅₀ value could be observed¹⁶. This decrease in temperature might have resulted in increased rate of ingestion as well as rate of release and uptake of bacterial toxin in larval gut¹⁴⁻¹⁶.

Effect of pH

pH had a great effect on the activity of

bacterial toxin¹⁹ because insecticidal activity was dependent upon the solubilization and ingestion of protoxin under alkaline environment of larval midgut²⁰. It was reported that each bacterial toxin could be solubilized at specific pH⁶. However, the activity of endotoxin could be suppressed if pH was reversed to low alkalinity²¹.

Effect of sewage affluent

The activity of microflora as well as solids suspending in the water were found affecting the effectiveness of bacterial larvicide. In the presence of microflora, larval mortality became very low as compared to those observed in the tap water although the same concentration was performed¹⁹. By treating microflora with autoclave, the mortality remained lower than those in tap water. It could be explained that the degree of pollution affected the persistence of bacterial toxin which agreed to the above report²². With increasing degree of pollution, larval reduction became short. However, the persistence and recycling potential of pathogenic bacteria depended upon the degree of water pollution because bacteria used the cadavers as medium for growth and complete the life-cycle then the later bacterial generation would be released to the surroundings after decomposition of the cadavers which occurred rapidly in the sewer waters²³. Contrary to the above mentions, it was reported that *B. sphaericus* was found more effective against mosquito larvae in polluted water than in clean water²⁴. It was believed that not only *B. sphaericus* caused mortality to larvae but also some certain chemicals in those water might be toxic to larvae.

Influence of soil constituents and silt particle on toxin

It was proposed that persistence of *B. thuringiensis israelensis* in nature was so low because bacterial toxin was probably adsorbed to silt particle²⁵. However, this conclusion was supported by the studies reported by Van Essen and Hembree²⁶ that in the presence of clay particle, the persistence sharply dropped as compared to the absence of clay particle.

Effect of sunlight to bacterial toxin

Sunlight has lesser degree of influence on the activity of bacterial toxin. The light intensity of 7.3 lux for normal laboratory would not have any affect on the activity of bacterial toxin. Only six hours exposure to 22,000 lux of direct sunlight inhibited the activity of pathogenic bacteria which could be due to the occurrence of damage on protein composition^{19,27}.

Effects of bioassay procedure on mortality

Result from toxicity tests using individual and grouped larvae were different. It was reported that the concentration of bacterial larvicide required to provide median lethal concentration to larvae testing individually was rather high about 2-folds as compared to 25 grouped larvae even though exposure times were the same. Moreover, volume also affected the mortality. Under the conditions of larval number per volume of bacterial suspension such as one larva per 1 ml, one larva

per 6 ml and 25 larvae per 150 ml, it was indicated that the former condition required 300 µg/ml to provide LC₅₀ while only 70 and 30 µg/ml were enough to induce LC₅₀ to the two latter conditions²⁸.

Recycling potential

It has been suspected that the bacterial larvicide can survive and grow in the natural environment or not. Although bacterial larvicides were generally the spore-crystal complex and after larval feeding, the spores could germinate and complete its life cycle within the cadavers but unfortunately cadavers were not suitable as sources of essential nutrients so toxin produced became irregular^{25,29}.

Resistance to bacterial toxin

Resistance to certain chemicals among insect population has caused big problem for control programme of target species. It has not been doubtful whether resistance to bacterial toxin can be risen among the insect larvae. Resistance to *B. thuringiensis israelensis* in the population of *Ae. aegypti* was observed. Results indicated that after 15 generations of selection, no resistance was noticed³⁰. But resistant ratio to bacterial larvicide among the chemical-resistant strains remarkably varied³¹.

ACKNOWLEDGEMENTS

The author wish to express her sincere gratitude to Dr. Jariya Chanpaisaeng, Dr. Tipvadee Attathom of Department of Entomology, Faculty of Agriculture, Kasetsart

University, Thailand and Dr. Chusak Prasittisuk of World Health Organization, Southeast Asian Region for their encouragement and criticism of the manuscript.

REFERENCES

1. Anon. (1991). *Annual Epidemiological Surveillance Report* (Division of Epidemiology, Ministry of Public Health, Bangkok).
2. Yap, H.H. (1985). Biological control of mosquitoes, especially malaria vector, *Anopheles* species. *Southeast Asian J. Trop. Med. Pub. Hlth.*, **16**: 163.
3. Lysenko, O. and M. Kuvcera (1971). In *Microbial Control of Insects and Mites*. Edited by H.D. Burgess and N.W. Hussey (Academic Press, London): 205-226.
4. Attathom, T. (1992). *Insect Pathology* (Department of Entomology, Faculty of Agriculture, Kasetsart University, Bangkok).
5. Sebesta, K., J. Farkas and K. Horska (1981). In *Microbial Control of Pests and Plant Diseases 1970-1980*. Edited by H.D. Burgess (Academic Press, London) : 249-281.
6. Gill, S.S., E.A. Cowles and P.V. Pietrantonio (1992). The mode of action of *Bacillus thuringiensis* endotoxin. *Ann. Rev. Entomol.*, **37**: 615.
7. Pfannenstiel, M.A., G. Muthukumar, G.A. Couche and K.W. Nickerson (1987). Amino sugars in the glycoprotein toxin from *Bacillus thuringiensis* sub spp *israelensis*. *J. Bacteriol.*, **169**: 796.
8. Muthukumar, G. and K.W. Nickerson (1987). The glycoprotein toxin of *Bacillus thuringiensis* sub spp *israelensis* indicates a lectinlike receptor in the larval mosquito gut. *Appl. Environ. Microbiol.*, **53**: 2650.
9. Mummigatti, S.G. and A.N. Raghunathan (1990). Influence of media composition on the production of (α -endotoxin by *Bacillus thuringiensis* var. *thuringiensis*. *J. Inverte. Pathol.*, **55**: 147.
10. Lacey, L.A. (1984). Production and formulation of *Bacillus sphaericus*. *Mosq. News*, **44**: 153.
11. Lacey, L.A., M.J. Urbina and C.M. Heitzman (1984). Sustained release formulation of *Bacillus sphaericus* and *Bacillus thuringiensis* (H-14) for control of container-breeding *Culex quinquefasciatus*. *Mosq. News*, **44**: 26.
12. Davidson, E.W., M. Urbina, J. Payne, M.S. Mulla, H. Darwazeh, H.T. Dulmage and J.A. Correa (1984). Fate of *Bacillus sphaericus* 1593 and 2362 spores used as larvicides in the aquatic environment. *Appl. Environ. Microbiol.*, **47**: 125.
13. Ramoska, W.A. and J. Burgess (1978). Field application of a bacterial insecticide. *Mosq. News*, **38**: 57.
14. Wraight, S.P., D. Molloy, H. Jamnback and P. McCoy (1981). Effects of temperature and instar on the efficacy of *Bacillus thuringiensis* var. *israelensis* and *Bacillus sphaericus* strain 1593 against *Aedes stimulans* larvae. *J. Inverte. Pathol.*, **38**: 78.
15. Lacey, L.A. and S.L. Oldacre (1983). The effect of temperature, larval age and species of mosquito on the activity of an isolate of *Bacillus thuringiensis* var. *darmstadiensis* toxin for mosquito larvae. *Mosq. News*, **43**: 176.
16. Wraight, S.P., D.P. Molloy and S. Singer (1987). Studies on the culicine mosquito host range of *Bacillus sphaericus* and *Bacillus thuringiensis* var. *israelensis* with notes on the effects of temperature and instar on bacterial efficacy. *J. Inverte. Pathol.*, **49**: 291.
17. Ramoska, W.A. and C. Pacey (1979). Food availability and period of exposure as factors of *Bacillus sphaericus* efficacy on mosquito larvae. *Entomol. Soc. Amer.*, **72**: 523.
18. Ramoska, W.A. and T.L. Hopkins (1981). Effects of mosquito larval feeding behaviour *Bacillus sphaericus* efficacy. *J. Inverte. Pathol.*, **37**: 269.
19. Mulligan III, F.S., C.H. Schaefer and W.H. Wilder (1980). Efficacy and persistence of *Bacillus*

- sphaericus* and *B. thuringiensis* H-14 against mosquitoes under laboratory and field conditions. *Ent. Soc. Amer.*, **73**: 684.
20. Lahkim-Tsror, L., C. Pascar-Gluzman, J. Margalit and Z. Barak (1983). Larvicidal activity of *Bacillus thuringiensis* sub spp *israelensis*, serovar H-14 in *Aedes aegypti*: Histopathological studies. *J. Inverte. Pathol.*, **41**: 104.
 21. Gringorten, J.L., R.E. Milne, P.G. Fast, S.S. Sohi and K. Van Frankenhuyzen (1992). Digestion of *Bacillus thuringiensis* var. *israelensis* spores by larvae of *Aedes aegypti*. *J. Inverte. Pathol.*, **59**: 186.
 22. Mulla, M.S., H.A. Darwazeh, E.W. Davidson and H.T. Dulmage (1984). Efficacy and persistence of the microbial agent *Bacillus sphaericus* against mosquito larvae in organically enriched habitats. *Mosq. News.*, **44**: 166.
 23. Des Rochers, B. and R. Garcia (1984). Evidence for persistence and recycling of *Bacillus sphaericus*. *Mosq. News.*, **44**: 160.
 24. Chowanadisai, L. and B. Phanthumachinda (1987). Small-scale field trial of *Bacillus sphaericus* 1593 against *Culex quinquefasciatus*. *Mosq. Born. Dis. Bull.*, **4**: 1.
 25. Khawaled, K., T. Cohen and A. Zaritsky (1992). Digestion of *Bacillus thuringiensis* var. *israelensis* spores by larvae of *Aedes aegypti*. *J. Inverte. Pathol.*, **59**: 186.
 26. Van Essen, F.W. and S.C. Hembree (1982). Simulated field studies with four formulations of *Bacillus thuringiensis* var. *israelensis* against mosquitoes : Residual activity and effect of soil constituents. *Mosq. News.*, **42**: 66.
 27. Pozsgay, M., P. Fast, H. Kaplan and P.R. Carey (1987). The effect of sunlight on the protein crystal from *Bacillus thuringiensis* var. *kurstaki* HD 1 and NRD 12 : A Roman spectroscopic study. *J. Inverte. Pathol.*, **50**: 246.
 28. Misch, D.W., D.F. Burnside and T.L. Cecil (1992). A novel bioassay system for evaluating the toxicity of *Bacillus thuringiensis* *israelensis* against mosquito larvae. *J. Inverte. Pathol.*, **59**: 286.
 29. Aly, C., M.S. Mulla and B.A. Federici (1985). Sporulation and toxin production by *Bacillus thuringiensis* var. *israelensis* in cadavers of mosquito larvae (Diptera : Culicidae). *J. Inverte. Pathol.*, **46**: 251.
 30. Goldman, I.F., J. Arnold and B.C. Carlton (1986). Selection for resistance to *Bacillus thuringiensis* sub spp *israelensis* in field and laboratory population of the mosquito *Aedes aegypti*. *J. Inverte. Pathol.*, **47**: 317.
 31. Sun, C.N., G.P. Georghiou and K. Weiss (1980). Toxicity of *Bacillus thuringiensis* var. *israelensis* to mosquito larvae variously resistant to conventional insecticides. *Mosq. News.*, **40**: 614.

INDIAN JOURNAL OF MALARIOLOGY

Instructions to Authors

Editorial Policy

The 'Indian Journal of Malariology' is devoted to the publication of original research papers which contribute significantly to any field of malariology. Papers of routine and repetitive nature dealing with gross observations may not be included. Articles will be published at the Editor's discretion in the order accepted. Date of acceptance will be the date on which copy is accepted in final form for publication. The authors should also submit names of three experts in the field of research on which the paper has been submitted. If there is no expert in India, experts from outside the country may be suggested. Manuscripts in triplicate along with the undertaking form duly filled by author(s) should be submitted to:

The Editor
Indian Journal of Malariology
20-Madhuvan
Delhi-110 092, India.

Classes of Items Published

In addition to full papers the Journal publishes short note. Review articles are also invited. Book reviews may also be published at the end of the journal.

Format

The matter should be arranged in the following order: Title, Name(s) of the author(s) with address of the Institute/

University (as footnotes and indicated serially in superscript), Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements and References. Authors should provide keywords and a short title to be used as running title, of not more than five words.

Preparation of Copy

Manuscript should be typewritten in English on one side of the paper leaving $1\frac{1}{2}$ inch left-hand margin. The entire matter should be typed double space including references, tables and captions. Abstract, tables, references and legends for illustrations should be typed on separate sheets of paper. Pages are to be numbered consecutively.

Tables should be placed singly on sheets of paper, along with relevant headings and footnotes. Table width should not be more than 80 characters including column space and should be self-explanatory and referred to in the text. Tables should be numbered in arabic numerals (e.g. 1, 2); avoid roman numerals (e.g. I, II). Do not use any horizontal or vertical lines in the body of the table.

Footnotes to the text should be avoided as far as possible parenthetical insertions are preferable.

Illustrations should be sent in triplicate. All illustrations including figures, pho-

We accept manuscript on $3\frac{1}{2}$ " and $5\frac{1}{4}$ " floppies in MS word.

tographs, graphs and maps should be numbered consecutively in the order in which they appear in the text. Captions and legends should be typed separately and must not appear on the face of illustrations. Authors should identify each illustration on the reverse side with author's name, fig. no. and abbreviated captions. Line drawings should be clear, and letters and numerals should be planned for legibility after reduction. Labelling should be neat and accurate. Photographs should be sharp, glossy, black and white prints, preferably mounted and covered with a transparent overlay for protection. Photographs should have allowance for reduction to 1/3 size. The approximate sizes of art work should be : 24 x 21 cm for quarter page, 45 x 24 cm for half page and 57 x 45 for full page.

Data for tables, graphs, etc. should be carefully verified. All statistics, percentages and other calculations should be checked thoroughly before submission of a paper. Once a paper is accepted for publication, data in it would be treated as final.

Nomenclature. Authors of scientific names of insects should be omitted in abstract and title, but should be included at first instance in the body of the text.

Numbers less than one should have a zero set before the decimal point, e.g. 0.1.

Measurements should follow the International System (SI) of units. Kindly see WHO publication *The SI for the Health*

Professional, WHO, Geneva, 1977. Use of the 24-hour time system (e.g. 0830 hrs, not 8:30 A.M.) is preferable.

References should include only published references and papers in press. References to literature cited should be numbered consecutively and placed at the end of the manuscript. In the text they should be indicated above the line as a superscript number. As far as possible mentioning names of author(s) under references should be avoided in the text. For references to a paper accepted for publication, the words 'in press' should appear after the title of the periodical. Citations of unpublished work should be incorporated in the text itself (e.g. R.G. Roy, unpublished data; or S. Pattanayak, personal communication). If the references is to an article published without any authorship in a periodical, in place of author's name the word "Anonymous" (Anon.) should be used. Titles of periodicals cited in the references are to be abbreviated as in the *World List of Scientific Periodicals*. The following style is accepted for this journal:

Research Paper

Sharma, V.P. (1976). Elimination of aziridine residues from chemosterilised mosquitoes. *Nature*, **261**: 135.

Book/Monograph

Rao, T. Ramachandra (1981). *The Anophelines of India* (WQ, Judge Press, Bangalore).

Landau, I. and Y. Boulard (1978). In *Rodent Malaria*, edited by R. Killick-Kendrick and W. Peters (Academic Press Inc., London): 53-84.

Paper presented at Symposium/Conference

Subbarao, S.K. (1981). *Cytoplasmic incompatibility in mosquitoes*. Paper presented at the International symposium on recent developments in the genetics of insect disease vectors. Bellagio, Italy, 20-24 April.

Authors are requested to verify spelling, punctuation, titles and dates of all references. The address of the publisher should be given for books. References are attributable to authors, not to editors in the case of compilations or contributory texts e.g.:

Killick-Kendrick, R. and W. Peters (1978). Ed. *Rodent Malaria*. (Academic Press Inc., London): 406. (**Incorrect**).

Landau, I. and Y. Boulard (1978). In *Rodent Malaria*, edited by R. Killick-Kendrick and W. Peters (Academic Press Inc., London): 53-84. (**Correct**).

Providing correct and complete references is the sole responsibility of the author.

Short notes should be prepared in a manner similar to the research papers and should contain Title, Name(s) of author(s) with Address of Institute/University as footnotes, Acknowledgements and References.

Proofs

Page proofs of the articles will be sent to the authors for correction. Corrected proofs must be returned promptly to the editor or else the article may not be printed in the stated issue, or may be printed as it stands. Only minimal changes, i.e. those that do not substantially alter the page make-up, are permissible at the proof stage and only in exceptional cases. Alterations which are disallowed by the Editor shall be deleted or charged to author.

From 1994 onwards reprint service has been discontinued. All senior authors (first) will be provided with a copy of the Journal free of cost containing their paper.

Check-list

1. Manuscript to be checked as per the format of IJM.
2. Three copies of the manuscript in double space with a covering letter.
3. Short title of the research paper (max. 5 words).
4. Keywords.
5. Undertaking by the author(s).
6. Names of at least three experts on the subject of paper submitted for publication.
7. Set of figures with legends and captions in triplicate on a separate sheet.

Announcement

We prefer submission of manuscripts on electronic media.

- Acceptable medium is $3\frac{1}{2}$ " or $5\frac{1}{4}$ " disk in MSDOS compatible format with file name, software/hardware used.
- The contents on the disk should exactly match with the manuscript and should be submitted with the hard copy (printed copy). The disk would be sent back in case of revision; the same should be returned to editor along with the revised copy of the manuscript. The file on the disk and printout should be identical. 'R' should be marked with red ink with the file name for revised manuscript.
- Package used for graphs should be mentioned.
- Floppies will be sent back to the authors after a final decision on the manuscript only on request.

— Editors

OTHER PUBLICATIONS OF MALARIA RESEARCH CENTRE

- (1) Proceedings of the ICMR/WHO Workshop on *Community Participation for Disease Vector Control* (1986) pp. 256
Edited by V.P. Sharma
- (2) *Seroepidemiology of Human Malaria — A multicentric study* (1989), pp. 206
Edited by V.P. Sharma
- (3) *Indigenous Larvivorous Fishes of India* (1991), pp. 66
A.G.K. Menon
- (4) Proceedings of an Informal Consultative meeting WHO/MRC on *Forest Malaria in Southeast Asia* (1991), pp. 206
Editors V.P. Sharma and A.V. Kondrashin
- (5) *Malaria Patrika* quarterly (Hindi) 1993 onwards.
- (6) Community Participation in Malaria Control (1993), pp. 295
Edited by V.P. Sharma
- (7) Larvivorous Fishes of Inland Ecosystem: Proceedings of the MRC-CICFRI Workshop (1994), pp. 224
Editors V.P. Sharma and Apurba Ghosh

VIDEO FILMS PRODUCED BY MALARIA RESEARCH CENTRE

DOCUMENTARIES

Fighting Malaria (English)
Master Tape No. 2001

Malaria Control in Shahjahanpur
(English)
Master Tape No. 6003

Malaria Control in Shahjahanpur
(Hindi)
Master Tape No. 6001

Defeating the Invincible - Hardwar
(English)
Master Tape No. 6004

**A Seven Point Action Programme for
Malaria Control in Madras** (English)
Master Tape No. 2010

Tackling Malaria in Orissa (English)
Master Tape No. 2011

**Insecticide Impregnated Bednets for
Malaria Control** (Assamese)
Master Tape No. 2008

**Insecticide Impregnated Bednets for
Malaria Control** (English)
Master Tape No. 2006

Man Made Malaria (English)
Master Tape No. 2002

Sirf Ek Muskan (Hindi)
Master Tape No. 2078

Ek Anootha Prayog (Hindi)
Master Tape No. 2003

**Insecticide Impregnated Bednets for
Malaria Control** (Hindi)
Master Tape No. 2061

Malaria Control in Madras (English)
Master Tape No. 2153

Man, Mines and Malaria (English)
Master Tape No. 2018

Mosquito Menace (English)
Master Tape No. 6049

**A Seven Point Action Programme for
Malaria Control in Madras** (Tamil)
Master Tape No. 2208

SCIENTIFIC DISCUSSION

**Synthetic Malaria Vaccine: A Hope
for Future** (English)
Master Tape No. 2121

Malaria Vaccine: A Perspective
(English)
Master Tape No. 2204

Malaria Vaccine : A State of Art
(English)
Master Tape No. 2122

**Malaria Vaccine : Status and Future
Prospect** (English)
Master Tape No. 2211

M-10, A New Environment Friendly Insecticide for Disease Vector Control (English)

Master Tape No. 2212

Global Malaria Control – An Approach Plan (English)

Master Tape No. 2275

Chelating Agent in Severe Malaria

Master Tape No. 2140

TEACHING PROGRAMMES

Life cycle of Malaria Parasite (English)

Master Tape No. 2247

The Microscope (English)

Master Tape No. 2240

How to Make a Blood Smear and Stain for Malaria Parasite (English)

Master Tape No. 6052

How to Treat Uncomplicated Malaria (English)

Master Tape No. 6045

Cerebral Malaria (English)

Master Tape No. 2200

Malaria in Pregnancy (English)

Master Tape No. 6060

Laboratory Diagnosis of Malaria (English)

Master Tape No. 6066

HEALTH EDUCATION

Malaria – Bednets a TV Spot (Hindi)

Master Tape No. 2013

Malaria – Bednets a TV Spot (English)

Master Tape No. 2072

Malaria – Spread the Knowledge

(English)

Master Tape No. 2071

Malaria – Mukti Pavoo (Hindi)

Master Tape No. 2236

Malaria – Arivay Parappivoo (Tamil)

Master Tape No. 2214

Malaria – Gnanava Haradona

(Kannada) *Master Tape No. 2261*

Malaria – Overhead Tanks and Malaria

Control – A TV Spot (Tamil)

Master Tape No. 2282

Cost of each cassette is Rs. 100.00 + postal charges for 2 cassettes Rs 18.00; 3-4 — Rs. 24.00 and for 5 — Rs. 30/-.


These cassettes could be obtained by sending crossed **Demand Draft**, drawn in favour of "**Director, Malaria Research Centre, Delhi**", and send to the **Assistant Director, A.V.P. Unit, Malaria Research Centre, 2, Nanak Enclave, Delhi-110 009**.

INDIAN ANOPHELINES

by

B.N. NAGPAL • V.P. SHARMA

INDIAN ANOPHELINES



B.N. Nagpal • V.P. Sharma

ISBN81-204-0929-9

Size : Crown 4TO

Price: Rs. 750/-

pp. viii, 416 (Hardbound)

1995

Indian Anophelines is the first book of its kind on the fauna of anopheline mosquitoes from India. The book assumes special importance because of the deteriorating malaria situation in India, complicated by vector resistance to insecticides, ecological succession of mosquitoes, invasion of mosquitoes to new areas, as also their disappearance from certain areas. As a result mosquito fauna has undergone major changes and this precise knowledge at the local level in endemic regions is invariably lacking. Often the identification is made difficult due to variations in many appendages. For each anopheline species the book provides names, derivatives, type form availability, resting habits, breeding ecology, biting time, flight range, susceptibility to insecticides, relation to disease, reported distribution in India and the world, and results of vector incrimination studies.

© OXFORD & IBH PUBLISHING CO PVT. LTD.

66, Janpath, New Delhi-110 001.




An exhaustive volume which brings out the state of art and scope of larvivorous fishes in the management of vector-borne diseases.

**Size: Royal 8 Vo
pp. ix, 224 (Hardbound)
1994**

A complete review of the experience on community participation from various areas in the country in relation to vector/malaria control. A commendable document for future management of vector control through community participation.

**Size: Crown 4To
pp. vii, 295 (Hardbound)
1993**



**INDIAN JOURNAL OF MALARIOLOGY
MALARIA RESEARCH CENTRE (ICMR)**

UNDERTAKING BY AUTHORS

We, the undersigned, give an undertaking to the following effect with regard to our article entitled, “ _____

submitted for publication in the Indian Journal of Malariology :—

- 1*. Ethical committee has approved the research as presented in this research paper/this piece of research does not require ethical committee clearance.
2. The article mentioned above has not been submitted for publication in any form to any other journal.
3. We also agree to the authorship of the article in the following sequence :—

Authors' names (in sequence)

Signature of Authors

1. _____
2. _____
3. _____
4. _____
5. _____
6. _____
7. _____
8. _____

IMPORTANT

1. All authors are required to sign independently in the form and in the sequence given above. A photocopy of this form may also be used.
2. No addition/deletion/ or any change in the sequence of the authorship will be permissible at a later stage, without valid reasons. If change is valid, then all the authors involved should attest to the change. The decision however, rests with the Editor.
3. If the authorship is contested at any stage, the article will be either returned or will not be processed for publication till the dispute is dissolved.

* Please write the applicable statement below:

MALARIA RESEARCH CENTRE

PRICED PUBLICATIONS

Indian Journal of Malariology

Volume 18 Nos. 1-2 (1981)

Volume 19 Nos. 1-2 (1982)

Volume 20 Nos. 1-2 (1983)

India Rs. 30.00

Volume 21 Nos. 1-2 (1984)

Foreign US\$ 10.00

Volume 22 Nos. 1-2 (1985)

Volume 23 Nos. 1-2 (1986)

Volume 24 Nos. 1-2 (1987)

Volume 25 Nos. 1-2 (1988)

Volume 26 Nos. 1-4 (1989)

Volume 27 Nos. 1-4 (1990)

Volume 28 Nos. 1-4 (1991)

India Rs. 75.00

Volume 29 Nos. 1-4 (1992)

Foreign US\$ 20.00

Volume 30 Nos. 1-4 (1993)

Volume 31 Nos. 1-4 (1994)

Volume 32 Nos. 1-4 (1995)

Volume 33 Nos. 1-4 (1996)

Volume 34 Nos. 1-4 (1997)

Volume 35 Nos. 1-4 (1998)

India Rs. 150.00

Foreign US\$ 40.00

The Editor
Indian Journal of Malariology
Malaria Research Centre
20-Madhuwan
Delhi-110 092 (India)

Sir,

I enclose herewith a bank draft No.(s) for \$/Rs. (in favour of the Director, ***Malaria Research Centre, Delhi-110 054***) towards subscription for ***Indian Journal of Malariology*** for the year(s)(2/4 Nos.) The journals should be mailed to me/my client at the following address:

.....
.....
.....
.....